Compositions and methods for the suppression of target polynucleotides from lygus

ABSTRACT

Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the  Lygus  genus, they are capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant. The present invention provides various target polynucleotides from specific polypeptide families as disclosed herein, and further provides target polynucleotides set forth in SEQ ID NOS:1-21 or active variants thereof, wherein a decrease in expression of one or more the sequences in the target pest controls the pest (i.e., has insecticidal activity). Further provided are silencing elements which when ingested by the pest decrease the level of the target polypeptide and thereby control the pest. In specific embodiment, the pest is  Lygus Hesperus . Plants, plant part, bacteria and other host cells comprising the silencing elements or an active variant or fragment thereof of the invention are also provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to U.S. Provisional Application No. 61/021,685, filed Jan. 17, 2008 and U.S. Provisional Application No. 61/021,676; filed Jan. 17, 2008; and is a continuation of U.S. application Ser. No. 12/351,379 filed Jan. 9, 2009 which now granted as U.S. Pat. No. 8,809,625, which is incorporated herein by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates generally to methods of molecular biology and gene silencing to control pests.

REFERENCE TO A SEQUENCE LISTING SUBMITTED AS A TEXT FILE VIA EFS-WEB

The official copy of the sequence listing is submitted concurrently with the specification as a text file via EFS-Web, in compliance with the American Standard Code for Information Interchange (ASCII), with a file name of 366630seqlist.txt, a creation date of Dec. 23, 2008, and a size of 50 Kb. The sequence listing filed via EFS-Web is part of the specification and is hereby incorporated in its entirety by reference herein.

BACKGROUND OF THE INVENTION

Insect pests are a serious problem in agriculture. They destroy millions of acres of staple crops such as corn, soybeans, peas, and cotton. Yearly, these pests cause over $100 billion dollars in crop damage in the U.S. alone. In an ongoing seasonal battle, farmers must apply billions of gallons of synthetic pesticides to combat these pests. Other methods employed in the past delivered insecticidal activity by microorganisms or genes derived from microorganisms expressed in transgenic plants. For example, certain species of microorganisms of the genus Bacillus are known to possess pesticidal activity against a broad range of insect pests including Lepidoptera, Diptera, Coleoptera, Hemiptera, and others. In fact, microbial pesticides, particularly those obtained from Bacillus strains, have played an important role in agriculture as alternatives to chemical pest control. Agricultural scientists have developed crop plants with enhanced insect resistance by genetically engineering crop plants to produce insecticidal proteins from Bacillus. For example, corn and cotton plants genetically engineered to produce Cry toxins (see, e.g., Aronson (2002) Cell Mol. Life Sci. 59(3):417-425; Schnepf et al. (1998) Microbiol. Mol. Biol. Rev. 62(3):775-806) are now widely used in American agriculture and have provided the farmer with an alternative to traditional insect-control methods. However, these Bt insecticidal proteins only protect plants from a relatively narrow range of pests. Moreover, these modes of insecticidal activity provided varying levels of specificity and, in some cases, caused significant environmental consequences. Thus, there is an immediate need for alternative methods to control pests.

BRIEF SUMMARY OF THE INVENTION

Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lygus genus, is capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant. The present invention provides various target polynucleotides from specific polypeptide families as disclosed herein, and further provides various target polynucleotides set forth in SEQ ID NOS:1-21 or active variants or fragments thereof, wherein a decrease in expression of one or more the sequences in the target pest controls the pest (i.e., has insecticidal activity). Further provided are silencing elements, which when ingested by the pest, decrease the level of expression of one or more of the target polynucleotides. In specific embodiment, the pest that is controlled is Lygus Hesperus. Plants, plant parts, bacteria and other host cells comprising the silencing elements or an active variant or fragment thereof are also provided.

In another embodiment, a method for controlling a pest from the Lygus genus is provided. The method comprises feeding to a pest from the Lygus genus a composition comprising a silencing element, wherein said silencing element, when ingested by said Lygus, reduces the level of a target sequence in the Lygus and thereby controls the Lygus. Further provided are methods to protect a plant from Lygus. Such methods comprise introducing into the plant or plant part a silencing element of the invention. When the plant expressing the silencing element is ingested by the pest, the level of the target sequence is decreased and the pest is controlled.

DETAILED DESCRIPTION OF THE INVENTION

The present inventions now will be described more fully hereinafter with reference to the accompanying drawings, in which some, but not all embodiments of the inventions are shown. Indeed, these inventions may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so that this disclosure will satisfy applicable legal requirements. Like numbers refer to like elements throughout.

Many modifications and other embodiments of the inventions set forth herein will come to mind to one skilled in the art to which these inventions pertain having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the inventions are not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

I. Overview

Methods and compositions are provided which employ a silencing element that, when ingested by a pest, such as a pest from the Lygus genus, is capable of decreasing the expression of a target sequence in the pest. In specific embodiments, the decrease in expression of the target sequence controls the pest and thereby the methods and compositions are capable of limiting damage to a plant or plant part. In specific embodiments, the present invention provides target polynucleotide which encode a potassium channel polypeptide, a cuticle polypeptide, an endocuticle polypeptide, a chitin binding polypeptide, a chitinase polypeptide, a hormone inducible polypeptide, a translation initiation factor, a voltage dependant channel, an EIF-related polypeptide, a polypeptide having a coiled coil helix domain, a polypeptide having a zinc finger domain, a receptor associated finger polypeptide, a lethal timorous imaginal disc polypeptide, a ribonucleoprotein, a cathepsin protease polypeptide, a polyprotein deformed destructor, and a death associated leucine rich polypeptide. The present invention provides a target polynucleotides set forth in SEQ ID NOS:1-21 or active variants and fragments thereof. Silencing elements designed in view of these target polynucleotides are provided which, when ingested by the pest, decrease the expression of one or more of the target sequences and thereby controls the pest (i.e., has insecticidal activity). These results provide the first report of insecticidal activity of dsRNA against Lygus Hesperus.

As used herein, by “controlling a pest” or “controls a pest” is intended any affect on a pest that results in limiting the damage that the pest causes. Controlling a pest includes, but is not limited to, killing the pest, inhibiting development of the pest, altering fertility or growth of the pest in such a manner that the pest provides less damage to the plant, decreasing the number of offspring produced, producing less fit pests, producing pests more susceptible to predator attack, or deterring the pests from eating the plant.

By “disease resistance” is intended that the plants avoid the disease symptoms that are the outcome of plant-pathogen interactions. That is, pathogens are prevented from causing plant diseases and the associated disease symptoms, or alternatively, the disease symptoms caused by the pathogen is minimized or lessened.

Reducing the level of expression of the target polynucleotide or the polypeptide encoded thereby, in the pest results in the suppression, control, and/or killing the invading pathogenic organism. Reducing the level of expression of the target sequence of the pest will reduce the disease symptoms resulting from pathogen challenge by at least about 2% to at least about 6%, at least about 5% to about 50%, at least about 10% to about 60%, at least about 30% to about 70%, at least about 40% to about 80%, or at least about 50% to about 90% or greater. Hence, the methods of the invention can be utilized to protect plants from disease, particularly those diseases that are caused by pests from the Lygus genus.

Assays that measure the control of a pest are commonly known in the art, as are methods to quantitate disease resistance in plants following pathogen infection. See, for example, U.S. Pat. No. 5,614,395, herein incorporated by reference. Such techniques include, measuring over time, the average lesion diameter, the pathogen biomass, and the overall percentage of decayed plant tissues. See, for example, Thomma et al. (1998) Plant Biology 95:15107-15111, herein incorporated by reference. See, also the examples below.

The invention is drawn to compositions and methods for protecting plants from a plant pest, such as pests from the Hemiptera order, or inducing resistance in a plant to a plant pest, such as pests from the Hemiptera order. The Hemiptera order comprises four suborders, the Sternorrhyncha (e.g. aphids, whiteflies), Auchenorrhyncha (e.g. cicadas, leafhoppers), Coleorrhyncha, and Heteroptera (e.g. true bugs) and about 67,500 species. Accordingly, the compositions and methods are useful in protecting plants against any member of the Hemiptera order including those of the family Cicadellidae, Membracidae, Fulgoridae, Coccidae, Aphididae, Lygaeidae, Pentatomidae, and Miridae.

In specific embodiments, the invention is drawn to compositions and methods for protecting plants from a plant pest, such as pests from the Lygus genus, or inducing resistance in a plant to a plant pest, such as pests from the Lygus genus. The Lygus genus comprises over 40 species of plant feeding insects in the family Miridae. As used herein, the term “Lygus” or “Lygus Bug” is used to refer to any member of the Lygus genus. Accordingly, the compositions and methods are also useful in protecting plants against any Lygus including, for example, Lygus adspersus, Lygus alashanensis, Lygus borealis, Lygus elisus, Lygus gemellatus, Lygus Hesperus, Lygus lineolaris, or Lygus rugulipennis. In particular embodiment, methods control Lygus Hesperus.

In other embodiments, the pest is a plant sap-sucking insect. As used herein, “plant sap-sucking insects” are insects which feed on plants using their sharp mouth parts which can be inserted into a plant to take fluid from the plant vascular system. In one embodiment, these are insects feeding directly on the fluids in the plant vascular system. In the insertion site, plant cells can also be damaged which may or may not be used as a food source by the plant sap-sucking insect. These insects are plant pests because their feeding reduces the vitality of the crop they feed on and they can transmit viral disease. Also, such sap-sucking insects can create a sugar-rich fluid named honeydew that accumulates on lower plant parts and such parts soon become covered by certain black or brown fungi known as sooty molds, hence interfering with photosynthesis.

Included in such plant sap-sucking insects are aphids or Homopteran insects of the Aphididae, and plant sap-sucking insects as used herein include but are not limited to the peach-potato aphid Myzus persicae, the bean aphid Aphis fabae, the pea aphid Acyrthosiphumpisun, the cabbage aphid Brevicoryne brassicae, the grain aphid Sitobion avenae, the rose-grain aphid Metopolophium dirhodum, the Russian wheat aphid Diuraphis noxia (Mordvilko), the English grain aphid Macrosiphum avenae, the greenbug aphid Schizaphis graminum (Rondani), the carrot aphid Cavariella aegopodii, the potato aphid Macrosiphum euphorbiae, the groundnut aphid Aphiscraccivora, the cotton aphid Aphis gossypii, the black citrus aphid Toxoptera aurantii, the brown citrus apid Toxoptera ciidius, the willow aphid Cavariella spp., the corn leaf aphid Rhopalosiphum maidis, the aphid Rhopalosiphum padi, the willow leaf aphids Chaitophorus spp., the black pine aphids Cinara spp., the Sycamore Aphid Drepanosiphum platanoides, the Spruce aphids Elatobium spp., Aphis citricola, Lipaphis as Laodelphax striatellus (small brown planthopper), Nilaparvata lugens (rice brown plant hopper) and Sogatella furcifera (white-backed rice planthopper), and Deltocephalidae (or leafhoppers) such as Flexamia DeLong spp., Nephotettix cincticeps and Nephotettix virescens, Amrasca bigutulla, and the potato leafhopper Empoasca filament. Also included are scales (also named scale insects) such as Aonidiella aurantii (California red scale), Comstockaspis perniciosa (San Jose scale), Unaspis citri (citrus snow scale), Pseudaulacaspis pentagona (white peach scale), Saissetia oleae (brown olive scale), Lepidosaphes beckii (purple scale), Ceroplastes rubens (red wax scale) and Icerya purchasi (cottonycushion scale), besides Tingidae (or lace bugs) and Psyllidae insects, and spittle bugs.

Further included as plant sap-sucking insects are Heteropteran insects and Hemipteran insects of the Auchenorrhyncha that feed from the plants' vascular system, such as sap-sucking insects of the Cicadoidea (such as Cicadas), Cercopoidea (spittlebugs or froghoppers), Membracoidea (leafhoppers and treehoppers), and Fulgoroidea (planthoppers), e.g., the cotton seed sucker bug Dysdercus peruvianus (Heteroptera, Pyrrhocoridae), the apple dimpling bug, Campylomma liebknechti (Hemiptera: Miridae) and the greenmirid, Creontiades dilutus which are cotton sucking insect pests, and the Lygusbugs (Hemiptera: Miridae, e.g., Lygus hesperus).

II. Target Sequences

As used herein, a “target sequence” comprises any sequence in the pest that one desires to decrease the level of expression. In specific embodiments, decreasing the level of the target sequence in the pest controls the pest. For instance the target sequence can be essential for growth and development. While the target sequence can be expressed in any tissue of the pest, in specific embodiments of the invention, the sequences targeted for suppression in the pest are expressed in cells of the gut tissue of the pest, cells in the midgut of the pest, and cells lining the gut lumen or the midgut. Such target sequences can be involved in gut cell metabolism, growth or differentiation.

Non-limiting examples of target sequences of the invention include a polynucleotide set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21. In specific embodiments, the silencing element comprises at least or consists of 15, 20, 22, 25 or greater consecutive nucleotides of any one of SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21. In further embodiments, the silencing element comprises or consists of at least one of the sequences set forth in SEQ ID NO: 22-408. It is recognized that such silencing elements can further comprise one or more thymine residues at the 3′ end. Such residues can aid in stabilization. The element can have, for example, 1, 2, 3, 4, 5, 6 or more thymine residues at its 3′ end. In further embodiments, the silencing element comprises SEQ ID NO: 23 and 24; 26 and 27; 29 and 30; 32 and 33; 35 and 36; 38 and 39; 41 and 42; 44 and 45; 47 and 48; 50 and 51; 53 and 54; 56 and 57; 59 and 60; 62 and 63; 65 and 66; 68 and 69; 71 and 72; 74 and 75; 77 and 78; 80 and 81; 83 and 84; 86 and 87; 89 and 90; 92 and 93; 95 and 96; 98 and 99; 101 and 102; 104 and 105; 107 and 108; 110 and 111; 113 and 114; 116 and 117; 119 and 120; 122 and 123; 125 and 126; 128 and 129; 131 and 132; 134 and 135; 137 and 138; 140 and 141; 143 and 144; 146 and 147; 149 and 150; 152 and 153; 155 and 156; 158 and 159; 161 and 162; 164 and 165; 167 and 168; 170 and 171; 173 and 174; 176 and 177; 179 and 180; 182 and 183; 185 and 186; 188 and 189; 191 and 192; 194 and 195; 197 and 198; 200 and 201; 203 and 204; 206 and 207; 209 and 210; 212 and 213; 215 and 216; 218 and 219; and/or 221 and 222. As exemplified elsewhere herein, decreasing the level of expression of these target sequence in Lygus controls the pest.

In specific embodiments, the target sequence comprises SEQ ID NO:7, 8, 9, 11, 12 or 14. In further embodiments, the silencing element comprises or consists of at least one of the sequences set forth in SEQ ID NOS:283, 284, 285, 289, 290, 291, 292, 293, 294, 304, 305, 306, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347 or 348. In still further embodiments, the silencing element comprises or consists of SEQ ID NOS: 284 and 285, 290 and 291, 293 and 294; 305 and 306; 317 and 318; 320 and 321; 323 and 324; 326 and 327; 329 and 330; 332 and 333; 335 and 336; 338 and 339; 341 and 342; 344 and 345; or 347 and 348. As exemplified elsewhere herein, expression of these sequences controls lygus.

III. Silencing Elements

By “silencing element” is intended a polynucleotide which when ingested by a pest, is capable of reducing or eliminating the level or expression of a target polynucleotide or the polypeptide encoded thereby. The silencing element employed can reduce or eliminate the expression level of the target sequence by influencing the level of the target RNA transcript or, alternatively, by influencing translation and thereby affecting the level of the encoded polypeptide. Methods to assay for functional silencing elements that are capable of reducing or eliminating the level of a sequence of interest are disclosed elsewhere herein. A single polynucleotide employed in the methods of the invention can comprises one or more silencing elements to the same or different target polynucleotides.

In specific embodiments, the target sequence is not a plant endogenous gene. In other embodiments, while the silencing element controls pests, preferably the silencing element has no effect on the normal plant or plant part.

As discussed in further detail below, silencing elements can include, but are not limited to, a sense suppression element, an antisense suppression element, a double stranded RNA, a miRNA, or a hairpin suppression element. Non-limiting examples of silencing elements that can employed to decrease expression of these target Lygus sequences comprise or consists of fragments and variants of the sense or antisense sequence of the sequence set forth in SEQ ID NO:1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 or SEQ ID NOS: 22-408. or fragments and variants of the sense or antisense sequence thereof.

In specific embodiments, the silencing element comprises or consists of at least one of the sequences set forth in SEQ ID NO: 21-408. It is recognized that such silencing elements can further comprise one or more thymine residues at the 3′ end. Such residues can aid in stabilization. The element can have, for example, 1, 2, 3, 4, 5, 6 or more thymine residues at its 3′ end. In further embodiments, the silencing element comprises SEQ ID NO: 23 and 24; 26 and 27; 29 and 30; 32 and 33; 35 and 36; 38 and 39; 41 and 42; 44 and 45; 47 and 48; 50 and 51; 53 and 54; 56 and 57; 59 and 60; 62 and 63; 65 and 66; 68 and 69; 71 and 72; 74 and 75; 77 and 78; 80 and 81; 83 and 84; 86 and 87; 89 and 90; 92 and 93; 95 and 96; 98 and 99; 101 and 102; 104 and 105; 107 and 108; 110 and 111; 113 and 114; 116 and 117; 119 and 120; 122 and 123; 125 and 126; 128 and 129; 131 and 132; 134 and 135; 137 and 138; 140 and 141; 143 and 144; 146 and 147; 149 and 150; 152 and 153; 155 and 156; 158 and 159; 161 and 162; 164 and 165; 167 and 168; 170 and 171; 173 and 174; 176 and 177; 179 and 180; 182 and 183; 185 and 186; 188 and 189; 191 and 192; 194 and 195; 197 and 198; 200 and 201; 203 and 204; 206 and 207; 209 and 210; 212 and 213; 215 and 216; 218 and 219; and/or 221 and 222.

In other embodiments, the silencing element comprises or consists of at least one of the sequences set forth in SEQ ID NOS:283, 284, 285, 289, 290, 291, 292, 293, 294, 304, 305, 306, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347 or 348. In still further embodiments, the silencing element comprises or consists of SEQ ID NOS: 284 and 285, 290 and 291, 293 and 294; 305 and 306; 317 and 318; 320 and 321; 323 and 324; 326 and 327; 329 and 330; 332 and 333; 335 and 336; 338 and 339; 341 and 342; 344 and 345; or 347 and 348. As exemplified elsewhere herein, expression of these sequences controls lygus.

By “reduces” or “reducing” the expression level of a polynucleotide or a polypeptide encoded thereby is intended to mean, the polynucleotide or polypeptide level of the target sequence is statistically lower than the polynucleotide level or polypeptide level of the same target sequence in an appropriate control pest which is not exposed to (i.e., has not ingested) the silencing element. In particular embodiments of the invention, reducing the polynucleotide level and/or the polypeptide level of the target sequence in a pest according to the invention results in less than 95%, less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5% of the polynucleotide level, or the level of the polypeptide encoded thereby, of the same target sequence in an appropriate control pest. Methods to assay for the level of the RNA transcript, the level of the encoded polypeptide, or the activity of the polynucleotide or polypeptide are discussed elsewhere herein.

i. Sense Silencing Elements

As used herein, a “sense silencing element” comprises a polynucleotide designed to express an RNA molecule corresponding to at least a part of a target messenger RNA in the “sense” orientation. Expression of the RNA molecule comprising the sense suppression element reduces or eliminates the level of the target polynucleotide or the polypeptide encoded thereby. The polynucleotide comprising the sense suppression element may correspond to all or part of the sequence of the target polynucleotide, all or part of the 5′ and/or 3′ untranslated region of the target polynucleotide, all or part of the coding sequence of the target polynucleotide, or all or part of both the coding sequence and the untranslated regions of the target polynucleotide.

Typically, a sense suppression element has substantial sequence identity to the target polynucleotide, optimally greater than about 65% sequence identity, more optimally greater than about 85% sequence identity, about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity. See, U.S. Pat. Nos. 5,283,184 and 5,034,323; herein incorporated by reference. The sense suppression element can be any length so long as it does not interfere with intron splicing and allows for the suppression of the targeted sequence. The sense suppression element can be, for example, 15, 20, 22, 25, 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 900 or longer.

ii. Antisense Silencing Elements

As used herein, an “antisense silencing element” comprises a polynucleotide which is designed to express an RNA molecule complementary to all or part of a target messenger RNA.

Expression of the antisense RNA suppression element reduces or eliminates the level of the target polynucleotide. The polynucleotide for use in antisense suppression may correspond to all or part of the complement of the sequence encoding the target polynucleotide, all or part of the complement of the 5′ and/or 3′ untranslated region of the target polynucleotide, all or part of the complement of the coding sequence of the target polynucleotide, or all or part of the complement of both the coding sequence and the untranslated regions of the target polynucleotide. In addition, the antisense suppression element may be fully complementary (i.e., 100% identical to the complement of the target sequence) or partially complementary (i.e., less than 100% identical to the complement of the target sequence) to the target polynucleotide. In specific embodiments, the antisense suppression element comprises at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to the target polynucleotide. Antisense suppression may be used to inhibit the expression of multiple proteins in the same plant. See, for example, U.S. Pat. No. 5,942,657. Furthermore, the antisense suppression element can be complementary to a portion of the target polynucleotide. Generally, sequences of at least 25, 50, 100, 200, 300, 400, 450 nucleotides or greater may be used. Methods for using antisense suppression to inhibit the expression of endogenous genes in plants are described, for example, in Liu et at (2002) Plant Physiol. 129:1732-1743 and U.S. Pat. Nos. 5,759,829 and 5,942,657, each of which is herein incorporated by reference. In specific embodiments, the antisense element comprise or consists of the complement of at least 15, 20, 22, 25 or greater contiguous nucleotides of any one of SEQ ID NO: 1-408.

iii. Double Stranded RNA Silencing Element

A “double stranded RNA silencing element” or “dsRNA” comprises at least one transcript that is capable of forming a dsRNA either before or after ingestion by a pest. Thus, a “dsRNA silencing element” includes a dsRNA, a transcript or polyribonucleotide capable of forming a dsRNA or more than one transcript or polyribonucleotide capable of forming a dsRNA. “Double stranded RNA” or “dsRNA” refers to a polyribonucleotide structure formed either by a single self-complementary RNA molecule or a polyribonucleotide structure formed by the expression of least two distinct RNA strands. The dsRNA molecule(s) employed in the methods and compositions of the invention mediate the reduction of expression of a target sequence, for example, by mediating RNA interference “RNAi” or gene silencing in a sequence-specific manner. In the context of the present invention, the dsRNA is capable of reducing or eliminating the level or expression of a target polynucleotide or the polypeptide encoded thereby in a pest.

The dsRNA can reduce or eliminate the expression level of the target sequence by influencing the level of the target RNA transcript, by influencing translation and thereby affecting the level of the encoded polypeptide, or by influencing expression at the pre-transcriptional level (i.e., via the modulation of chromatin structure, methylation pattern, etc., to alter gene expression). See, for example, Verdel et al. (2004) Science 303:672-676; Pal-Bhadra et al. (2004) Science 303:669-672; Allshire (2002) Science 297:1818-1819; Volpe et al. (2002) Science 297:1833-1837; Jenuwein (2002) Science 297:2215-2218; and Hall et al. (2002) Science 297:2232-2237. Methods to assay for functional iRNA that are capable of reducing or eliminating the level of a sequence of interest are disclosed elsewhere herein. Accordingly, as used herein, the term “dsRNA” is meant to encompass other terms used to describe nucleic acid molecules that are capable of mediating RNA interference or gene silencing, including, for example, short-interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), hairpin RNA, short hairpin RNA (shRNA), post-transcriptional gene silencing RNA (ptgsRNA), and others.

In specific embodiments, at least one strand of the duplex or double-stranded region of the dsRNA shares sufficient sequence identity or sequence complementarity to the target polynucleotide to allow for the dsRNA to reduce the level of expression of the target sequence. As used herein, the strand that is complementary to the target polynucleotide is the “antisense strand” and the strand homologous to the target polynucleotide is the “sense strand.”

In one embodiment, the dsRNA comprises a hairpin RNA. A hairpin RNA comprises an RNA molecule that is capable of folding back onto itself to form a double stranded structure. Multiple structures can be employed as hairpin elements. In specific embodiments, the dsRNA suppression element comprises a hairpin element which comprises in the following order, a first segment, a second segment, and a third segment, where the first and the third segment share sufficient complementarity to allow the transcribed RNA to form a double-stranded stem-loop structure.

The “second segment” of the hairpin comprises a “loop” or a “loop region.” These terms are used synonymously herein and are to be construed broadly to comprise any nucleotide sequence that confers enough flexibility to allow self-pairing to occur between complementary regions of a polynucleotide (i.e., segments 1 and 2 which form the stem of the hairpin). For example, in some embodiments, the loop region may be substantially single stranded and act as a spacer between the self-complementary regions of the hairpin stem-loop. In some embodiments, the loop region can comprise a random or nonsense nucleotide sequence and thus not share sequence identity to a target polynucleotide. In other embodiments, the loop region comprises a sense or an antisense RNA sequence or fragment thereof that shares identity to a target polynucleotide. See, for example, International Patent Publication No. WO 02/00904, herein incorporated by reference. In specific embodiments, the loop region can be optimized to be as short as possible while still providing enough intramolecular flexibility to allow the formation of the base-paired stem region. Accordingly, the loop sequence is generally less than 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 25, 20, 15, 10 nucleotides or less.

The “first” and the “third” segment of the hairpin RNA molecule comprise the base-paired stem of the hairpin structure. The first and the third segments are inverted repeats of one another and share sufficient complementarity to allow the formation of the base-paired stem region. In specific embodiments, the first and the third segments are fully complementary to one another. Alternatively, the first and the third segment may be partially complementary to each other so long as they are capable of hybridizing to one another to form a base-paired stem region. The amount of complementarity between the first and the third segment can be calculated as a percentage of the entire segment. Thus, the first and the third segment of the hairpin RNA generally share at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, up to and including 100% complementarity.

The first and the third segment are at least about 1000, 500, 400, 300, 200, 100, 50, 40, 30, 25, 22, 20, 15 or 10 nucleotides in length. In specific embodiments, the length of the first and/or the third segment is about 10-100 nucleotides, about 10 to about 75 nucleotides, about 10 to about 50 nucleotides, about 10 to about 40 nucleotides, about 10 to about 35 nucleotides, about 10 to about 30 nucleotides, about 10 to about 25 nucleotides, about 10 to about 20 nucleotides. In other embodiments, the length of the first and/or the third segment comprises at least 10-20 nucleotides, 20-35 nucleotides, 30-45 nucleotides, 40-50 nucleotides, 50-100 nucleotides, or 100-300 nucleotides. See, for example, International Publication No. WO 0200904. In specific embodiments, the first and the third segment comprises at least 20 nucleotides having at least 85% complementary to the first segment. In still other embodiments, the first and the third segments which form the stem-loop structure of the hairpin comprises 3′ or 5′ overhang regions having unpaired nucleotide residues.

In specific embodiments, the sequences used in the first, the second, and/or the third segments comprise domains that are designed to have sufficient sequence identity to a target polynucleotide of interest and thereby have the ability to decrease the level of expression of the target polynucleotide. The specificity of the inhibitory RNA transcripts is therefore generally conferred by these domains of the silencing element. Thus, in some embodiments of the invention, the first, second and/or third segment of the silencing element comprise a domain having at least 10, at least 15, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 500, at least 1000, or more than 1000 nucleotides that share sufficient sequence identity to the target polynucleotide to allow for a decrease in expression levels of the target polynucleotide when expressed in an appropriate cell. In other embodiments, the domain is between about 15 to 50 nucleotides, about 20-35 nucleotides, about 25-50 nucleotides, about 20 to 75 nucleotides, about 40-90 nucleotides about 15-100 nucleotides.

In specific embodiments, the domain of the first, the second, and/or the third segment has 100% sequence identity to the target polynucleotide. In other embodiments, the domain of the first, the second and/or the third segment having homology to the target polypeptide have at least 50%, 60%, 70%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or greater sequence identity to a region of the target polynucleotide. The sequence identity of the domains of the first, the second and/or the third segments to the target polynucleotide need only be sufficient to decrease expression of the target polynucleotide of interest. See, for example, Chuang and Meyerowitz (2000) Proc. Natl. Acad. Sci. USA 97:4985-4990; Stoutjesdijk et al. (2002) Plant Physiol. 129:1723-1731; Waterhouse and Helliwell (2003) Nat. Rev. Genet. 4:29-38; Pandolfini et al. BMC Biotechnology 3:7, and U.S. Patent Publication No. 20030175965; each of which is herein incorporated by reference. A transient assay for the efficiency of hpRNA constructs to silence gene expression in vivo has been described by Panstruga et al. (2003) Mol. Biol. Rep. 30:135-140, herein incorporated by reference.

The amount of complementarity shared between the first, second, and/or third segment and the target polynucleotide or the amount of complementarity shared between the first segment and the third segment (i.e., the stem of the hairpin structure) may vary depending on the organism in which gene expression is to be controlled. Some organisms or cell types may require exact pairing or 100% identity, while other organisms or cell types may tolerate some mismatching. In some cells, for example, a single nucleotide mismatch in the targeting sequence abrogates the ability to suppress gene expression. In these cells, the suppression cassettes of the invention can be used to target the suppression of mutant genes, for example, oncogenes whose transcripts comprise point mutations and therefore they can be specifically targeted using the methods and compositions of the invention without altering the expression of the remaining wild-type allele.

Any region of the target polynucleotide can be used to design the domain of the silencing element that shares sufficient sequence identity to allow expression of the hairpin transcript to decrease the level of the target polynucleotide. For instance, the domain can be designed to share sequence identity to the 5′ untranslated region of the target polynucleotide(s), the 3′ untranslated region of the target polynucleotide(s), exonic regions of the target polynucleotide(s), intronic regions of the target polynucleotide(s), and any combination thereof. In specific embodiments a domain of the silencing element shares sufficient homology to at least about 15 consecutive nucleotides from about nucleotides 1-50, 50-100, 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, 450-500, 550-600, 600-650, 650-700, 750-800, 850-900, 950-1000, 1000-1050, 1050-1100, 1100-1200, 1200-1300, 1300-1400, 1400-1500, 1500-1600, 1600-1700, 1700-1800, 1800-1900, 1900-2000 of the target sequence. In some instances to optimize the siRNA sequences employed in the hairpin, the synthetic oligodeoxyribonucleotide/RNAse H method can be used to determine sites on the target mRNA that are in a conformation that is susceptible to RNA silencing. See, for example, Vickers et al. (2003) J. Biol. Chem 278:7108-7118 and Yang et al. (2002) Proc. Natl. Acad. Sci. USA 99:9442-9447, herein incorporated by reference. These studies indicate that there is a significant correlation between the RNase-H-sensitive sites and sites that promote efficient siRNA-directed mRNA degradation.

The hairpin silencing element may also be designed such that the sense sequence or the antisense sequence do not correspond to a target polynucleotide. In this embodiment, the sense and antisense sequence flank a loop sequence that comprises a nucleotide sequence corresponding to all or part of the target polynucleotide. Thus, it is the loop region that determines the specificity of the RNA interference. See, for example, WO 02/00904, herein incorporated by reference.

In specific embodiments, the silencing element comprising the hairpin comprises a sequence selected from the group consisting of a polynucleotide comprising or consist of at least one of the sequences set forth in SEQ ID NO: 22-408. In further embodiments, the hairpin comprises a sequence selected from the group consisting of SEQ ID NO: 23 and 24; 26 and 27; 29 and 30; 32 and 33; 35 and 36; 38 and 39; 41 and 42; 44 and 45; 47 and 48; 50 and 51; 53 and 54; 56 and 57; 59 and 60; 62 and 63; 65 and 66; 68 and 69; 71 and 72; 74 and 75; 77 and 78; 80 and 81; 83 and 84; 86 and 87; 89 and 90; 92 and 93; 95 and 96; 98 and 99; 101 and 102; 104 and 105; 107 and 108; 110 and 111; 113 and 114; 116 and 117; 119 and 120; 122 and 123; 125 and 126; 128 and 129; 131 and 132; 134 and 135; 137 and 138; 140 and 141; 143 and 144; 146 and 147; 149 and 150; 152 and 153; 155 and 156; 158 and 159; 161 and 162; 164 and 165; 167 and 168; 170 and 171; 173 and 174; 176 and 177; 179 and 180; 182 and 183; 185 and 186; 188 and 189; 191 and 192; 194 and 195; 197 and 198; 200 and 201; 203 and 204; 206 and 207; 209 and 210; 212 and 213; 215 and 216; 218 and 219; and/or 221 and 222.

In other embodiments, the hairpin comprises or consist of a sequence selected from the group consisting of at least one of the sequences set forth in SEQ ID NOS: 284 and 285, 290 and 291, 293 and 294; 305 and 306; 317 and 318; 320 and 321; 323 and 324; 326 and 327; 329 and 330; 332 and 333; 335 and 336; 338 and 339; 341 and 342; 344 and 345; or 347 and 348. As exemplified elsewhere herein, expression of these sequences controls lygus.

In addition, transcriptional gene silencing (TGS) may be accomplished through use of a hairpin suppression element where the inverted repeat of the hairpin shares sequence identity with the promoter region of a target polynucleotide to be silenced. See, for example, Aufsatz et al. (2002) PNAS 99 (Suppl. 4):16499-16506 and Mette et al. (2000) EMBO J 19(19):5194-5201.

In other embodiments, the dsRNA can comprise a small RNA (sRNA). sRNAs can comprise both micro RNA (miRNA) and short-interfering RNA (siRNA) (Meister and Tuschl (2004) Nature 431:343-349 and Bonetta et al. (2004) Nature Methods 1:79-86). miRNAs are regulatory agents comprising about 19 ribonucleotides which are highly efficient at inhibiting the expression of target polynucleotides. See, for example Javier et al. (2003) Nature 425: 257-263, herein incorporated by reference. For miRNA interference, the silencing element can be designed to express a dsRNA molecule that forms a hairpin structure containing a 19-nucleotide sequence that is complementary to the target polynucleotide of interest. The miRNA can be synthetically made, or transcribed as a longer RNA which is subsequently cleaved to produce the active miRNA. Specifically, the miRNA can comprise 19 nucleotides of the sequence having homology to a target polynucleotide in sense orientation and 19 nucleotides of a corresponding antisense sequence that is complementary to the sense sequence.

When expressing an miRNA, it is recognized that various forms of an miRNA can be transcribed including, for example, the primary transcript (termed the “pri-miRNA”) which is processed through various nucleolytic steps to a shorter precursor miRNA (termed the “pre-miRNA”); the pre-miRNA; or the final (mature) miRNA is present in a duplex, the two strands being referred to as the miRNA (the strand that will eventually basepair with the target) and miRNA*. The pre-miRNA is a substrate for a form of dicer that removes the miRNA/miRNA* duplex from the precursor, after which, similarly to siRNAs, the duplex can be taken into the RISC complex. It has been demonstrated that miRNAs can be transgenically expressed and be effective through expression of a precursor form, rather than the entire primary form (Parizotto et al. (2004) Genes & Development 18:2237-2242 and Guo et al. (2005) Plant Cell 17:1376-1386).

The methods and compositions of the invention employ silencing elements that when transcribed “form” a dsRNA molecule. Accordingly, the heterologous polynucleotide being expressed need not form the dsRNA by itself, but can interact with other sequences in the plant cell or in the pest gut after ingestion to allow the formation of the dsRNA. For example, a chimeric polynucleotide that can selectively silence the target polynucleotide can be generated by expressing a chimeric construct comprising the target sequence for a miRNA or siRNA to a sequence corresponding to all or part of the gene or genes to be silenced. In this embodiment, the dsRNA is “formed” when the target for the miRNA or siRNA interacts with the miRNA present in the cell. The resulting dsRNA can then reduce the level of expression of the gene or genes to be silenced. See, for example, U.S. Provisional Application No. 60/691,613, filed Jun. 17, 2005, entitled “Methods and Compositions for Gene Silencing, herein incorporated by reference. The construct can be designed to have a target for an endogenous miRNA or alternatively, a target for a heterologous and/or synthetic miRNA can be employed in the construct. If a heterologous and/or synthetic miRNA is employed, it can be introduced into the cell on the same nucleotide construct as the chimeric polynucleotide or on a separate construct. As discussed elsewhere herein, any method can be used to introduce the construct comprising the heterologous miRNA.

IV. Variants and Fragments

By “fragment” is intended a portion of the polynucleotide or a portion of the amino acid sequence and hence protein encoded thereby. Fragments of a polynucleotide may encode protein fragments that retain the biological activity of the native protein. Alternatively, fragments of a polynucleotide that are useful as a silencing element or a suppressor enhancer element do not need to encode fragment or variant proteins that retain biological activity. Thus, fragments of a nucleotide sequence may range from at least about 10, about 15, 20 nucleotides, about 50 nucleotides, about 75 nucleotides, about 100 nucleotides, 200 nucleotides, 300 nucleotides, 400 nucleotides, 500 nucleotides, 600 nucleotides, 700 nucleotides and up to the full-length polynucleotide employed in the invention. Methods to assay for the activity of a desired silencing element are described elsewhere herein.

“Variants” is intended to mean substantially similar sequences. For polynucleotides, a variant comprises a deletion and/or addition of one or more nucleotides at one or more internal sites within the native polynucleotide and/or a substitution of one or more nucleotides at one or more sites in the native polynucleotide. As used herein, a “native” polynucleotide or polypeptide comprises a naturally occurring nucleotide sequence or amino acid sequence, respectively. For polynucleotides, conservative variants include those sequences that, because of the degeneracy of the genetic code, encode the amino acid sequence of one of the polypeptides employed in the invention. Variant polynucleotides also include synthetically derived polynucleotide, such as those generated, for example, by using site-directed mutagenesis, but continue to retain the desired activity. Generally, variants of a particular polynucleotide of the invention (i.e., a silencing element) will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to that particular polynucleotide as determined by sequence alignment programs and parameters described elsewhere herein. A silencing element or suppressor enhancer element of a variant target sequence need not encodes a protein, but rather will have the ability to reduce the level of expression of the target sequence.

Variants of a particular polynucleotide of the invention (i.e., the reference polynucleotide) can also be evaluated by comparison of the percent sequence identity between the polypeptide encoded by a variant polynucleotide and the polypeptide encoded by the reference polynucleotide. Percent sequence identity between any two polypeptides can be calculated using sequence alignment programs and parameters described elsewhere herein. Where any given pair of polynucleotides employed in the invention is evaluated by comparison of the percent sequence identity shared by the two polypeptides they encode, the percent sequence identity between the two encoded polypeptides is at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity.

“Variant” protein is intended to mean a protein derived from the native protein by deletion or addition of one or more amino acids at one or more internal sites in the native protein and/or substitution of one or more amino acids at one or more sites in the native protein. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, as discussed elsewhere herein. Such variants may result from, for example, genetic polymorphism or from human manipulation. Biologically active variants of a native protein will have at least about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to the amino acid sequence for the native protein as determined by sequence alignment programs and parameters described elsewhere herein. A biologically active variant of a protein of the invention may differ from that protein by as few as 1-15 amino acid residues, as few as 1-10, such as 6-10, as few as 5, as few as 4, 3, 2, or even 1 amino acid residue.

The following terms are used to describe the sequence relationships between two or more polynucleotides or polypeptides: (a) “reference sequence”, (b) “comparison window”, (c) “sequence identity”, and, (d) “percentage of sequence identity.”

(a) As used herein, “reference sequence” is a defined sequence used as a basis for sequence comparison. A reference sequence may be a subset or the entirety of a specified sequence; for example, as a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.

(b) As used herein, “comparison window” makes reference to a contiguous and specified segment of a polynucleotide sequence, wherein the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two polynucleotides. Generally, the comparison window is at least 20 contiguous nucleotides in length, and optionally can be 30, 40, 50, 100, or longer. Those of skill in the art understand that to avoid a high similarity to a reference sequence due to inclusion of gaps in the polynucleotide sequence a gap penalty is typically introduced and is subtracted from the number of matches.

Unless otherwise stated, sequence identity/similarity values provided herein refer to the value obtained using GAP Version 10 using the following parameters: % identity and % similarity for a nucleotide sequence using GAP Weight of 50 and Length Weight of 3, and the nwsgapdna.cmp scoring matrix; % identity and % similarity for an amino acid sequence using GAP Weight of 8 and Length Weight of 2, and the BLOSUM62 scoring matrix; or any equivalent program thereof. By “equivalent program” is intended any sequence comparison program that, for any two sequences in question, generates an alignment having identical nucleotide or amino acid residue matches and an identical percent sequence identity when compared to the corresponding alignment generated by GAP Version 10.

(c) As used herein, “sequence identity” or “identity” in the context of two polynucleotides or polypeptide sequences makes reference to the residues in the two sequences that are the same when aligned for maximum correspondence over a specified comparison window. When percentage of sequence identity is used in reference to proteins it is recognized that residue positions which are not identical often differ by conservative amino acid substitutions, where amino acid residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have “sequence similarity” or “similarity”. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated, e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif.).

(d) As used herein, “percentage of sequence identity” means the value determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison, and multiplying the result by 100 to yield the percentage of sequence identity.

V. DNA constructs

The use of the term “polynucleotide” is not intended to limit the present invention to polynucleotides comprising DNA. Those of ordinary skill in the art will recognize that polynucleotides, can comprise ribonucleotides and combinations of ribonucleotides and deoxyribonucleotides. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. The polynucleotides of the invention also encompass all forms of sequences including, but not limited to, single-stranded forms, double-stranded forms, hairpins, stem-and-loop structures, and the like.

The polynucleotide encoding the silencing element employed in the methods and compositions of the invention can be provided in expression cassettes for expression in a plant or organism of interest. It is recognized that multiple silencing elements including multiple identical silencing elements, multiple silencing elements targeting different regions of the target sequence, or multiple silencing elements from different target sequences can be used. In this embodiment, it is recognized that each silencing element can be contained in a single or separate cassette, DNA construct, or vector. As discussed, any means of providing the silencing element is contemplated. A plant or plant cell can be transformed with a single cassette comprising DNA encoding one or more silencing elements or separate cassettes comprising each silencing element can be used to transform a plant or plant cell or host cell. Likewise, a plant transformed with one component can be subsequently transformed with the second component. One or more silencing elements can also be brought together by sexual crossing. That is, a first plant comprising one component is crossed with a second plant comprising the second component. Progeny plants from the cross will comprise both components.

The expression cassette can include 5′ and 3′ regulatory sequences operably linked to the polynucleotide of the invention. “Operably linked” is intended to mean a functional linkage between two or more elements. For example, an operable linkage between a polynucleotide of the invention and a regulatory sequence (i.e., a promoter) is a functional link that allows for expression of the polynucleotide of the invention. Operably linked elements may be contiguous or non-contiguous. When used to refer to the joining of two protein coding regions, by operably linked is intended that the coding regions are in the same reading frame. The cassette may additionally contain at least one additional polynucleotide to be cotransformed into the organism. Alternatively, the additional polypeptide(s) can be provided on multiple expression cassettes. Expression cassettes can be provided with a plurality of restriction sites and/or recombination sites for insertion of the polynucleotide to be under the transcriptional regulation of the regulatory regions. The expression cassette may additionally contain selectable marker genes.

The expression cassette will include in the 5′-3′ direction of transcription, a transcriptional and translational initiation region (i.e., a promoter), a polynucleotide comprising the silencing element employed in the methods and compositions of the invention, and a transcriptional and translational termination region (i.e., termination region) functional in plants. The regulatory regions (i.e., promoters, transcriptional regulatory regions, and translational termination regions) and/or the polynucleotides employed in the invention may be native/analogous to the host cell or to each other. Alternatively, the regulatory regions and/or the polynucleotide employed in the invention may be heterologous to the host cell or to each other. As used herein, “heterologous” in reference to a sequence is a sequence that originates from a foreign species, or, if from the same species, is substantially modified from its native form in composition and/or genomic locus by deliberate human intervention. For example, a promoter operably linked to a heterologous polynucleotide is from a species different from the species from which the polynucleotide was derived, or, if from the same/analogous species, one or both are substantially modified from their original form and/or genomic locus, or the promoter is not the native promoter for the operably linked polynucleotide. As used herein, a chimeric gene comprises a coding sequence operably linked to a transcription initiation region that is heterologous to the coding sequence.

The termination region may be native with the transcriptional initiation region, may be native with the operably linked polynucleotide encoding the silencing element, may be native with the plant host, or may be derived from another source (i.e., foreign or heterologous) to the promoter, the polynucleotide comprising silencing element, the plant host, or any combination thereof. Convenient termination regions are available from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline synthase termination regions. See also Guerineau et al. (1991) Mol. Gen. Genet. 262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev. 5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene 91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al. (1987) Nucleic Acids Res. 15:9627-9639.

Additional sequence modifications are known to enhance gene expression in a cellular host. These include elimination of sequences encoding spurious polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and other such well-characterized sequences that may be deleterious to gene expression. The G-C content of the sequence may be adjusted to levels average for a given cellular host, as calculated by reference to known genes expressed in the host cell. When possible, the sequence is modified to avoid predicted hairpin secondary mRNA structures.

In preparing the expression cassette, the various DNA fragments may be manipulated, so as to provide for the DNA sequences in the proper orientation and, as appropriate, in the proper reading frame. Toward this end, adapters or linkers may be employed to join the DNA fragments or other manipulations may be involved to provide for convenient restriction sites, removal of superfluous DNA, removal of restriction sites, or the like. For this purpose, in vitro mutagenesis, primer repair, restriction, annealing, resubstitutions, e.g., transitions and transversions, may be involved.

A number of promoters can be used in the practice of the invention. The polynucleotide encoding the silencing element can be combined with constitutive, tissue-preferred, or other promoters for expression in plants.

Such constitutive promoters include, for example, the core promoter of the Rsyn7 promoter and other constitutive promoters disclosed in WO 99/43838 and U.S. Pat. No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985) Nature 313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2:163-171); ubiquitin (Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992) Plant Mol. Biol. 18:675-689); pEMU (Last et al. (1991) Theor. Appl. Genet. 81:581-588); MAS (Velten et al. (1984) EMBO J. 3:2723-2730); ALS promoter (U.S. Pat. No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S. Pat. Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680; 5,268,463; 5,608,142; and 6,177,611.

An inducible promoter, for instance, a pathogen-inducible promoter could also be employed. Such promoters include those from pathogenesis-related proteins (PR proteins), which are induced following infection by a pathogen; e.g., PR proteins, SAR proteins, beta-1,3-glucanase, chitinase, etc. See, for example, Redolfi et al. (1983) Neth. J. Plant Pathol. 89:245-254; Uknes et al. (1992) Plant Cell 4:645-656; and Van Loon (1985) Plant Mol. Virol. 4:111-116. See also WO 99/43819, herein incorporated by reference.

Of interest are promoters that are expressed locally at or near the site of pathogen infection. See, for example, Marineau et al. (1987) Plant Mol. Biol. 9:335-342; Matton et al. (1989) Molecular Plant-Microbe Interactions 2:325-331; Somsisch et al. (1986) Proc. Natl. Acad. Sci. USA 83:2427-2430; Somsisch et al. (1988) Mol. Gen. Genet. 2:93-98; and Yang (1996) Proc. Natl. Acad. Sci. USA 93:14972-14977. See also, Chen et al. (1996) Plant J. 10:955-966; Zhang et al. (1994) Proc. Natl. Acad. Sci. USA 91:2507-2511; Warner et al. (1993) Plant J. 3:191-201; Siebertz et al. (1989) Plant Cell 1:961-968; U.S. Pat. No. 5,750,386 (nematode-inducible); and the references cited therein. Of particular interest is the inducible promoter for the maize PRms gene, whose expression is induced by the pathogen Fusarium moniliforme (see, for example, Cordero et al. (1992) Physiol. Mol. Plant Path. 41:189-200).

Additionally, as pathogens find entry into plants through wounds or insect damage, a wound-inducible promoter may be used in the constructions of the invention. Such wound-inducible promoters include potato proteinase inhibitor (pin II) gene (Ryan (1990) Ann. Rev. Phytopath. 28:425-449; Duan et al. (1996) Nature Biotechnology 14:494-498); wun1 and wun2, U.S. Pat. No. 5,428,148; win1 and win2 (Stanford et al. (1989) Mol. Gen. Genet. 215:200-208); systemin (McGurl et al. (1992) Science 225:1570-1573); WIP1 (Rohmeier et al. (1993) Plant Mol. Biol. 22:783-792; Eckelkamp et al. (1993) FEBS Letters 323:73-76); MPI gene (Corderok et al. (1994) Plant J. 6(2):141-150); and the like, herein incorporated by reference.

Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induces gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-la promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena et al. (1991) Proc. Natl. Acad. Sci. USA 88:10421-10425 and McNellis et al. (1998) Plant J. 14(2):247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz et al. (1991) Mol. Gen. Genet. 227:229-237, and U.S. Pat. Nos. 5,814,618 and 5,789,156), herein incorporated by reference.

Tissue-preferred promoters can be utilized to target enhanced expression within a particular plant tissue. Tissue-preferred promoters include Yamamoto et al. (1997) Plant J. 12(2):255-265; Kawamata et al. (1997) Plant Cell Physiol. 38(7):792-803; Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343; Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant Physiol. 112(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535; Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20:181-196; Orozco et al. (1993) Plant Mol Biol. 23(6):1129-1138; Matsuoka et al. (1993) Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant J. 4(3):495-505. Such promoters can be modified, if necessary, for weak expression.

Leaf-preferred promoters are known in the art. See, for example, Yamamoto et al. (1997) Plant J. 12(2):255-265; Kwon et al. (1994) Plant Physiol. 105:357-67; Yamamoto et al. (1994) Plant Cell Physiol. 35(5):773-778; Gotor et al. (1993) Plant J. 3:509-18; Orozco et al. (1993) Plant Mol. Biol. 23(6):1129-1138; and Matsuoka et al. (1993) Proc. Natl. Acad. Sci. USA 90(20):9586-9590.

Root-preferred promoters are known and can be selected from the many available from the literature or isolated de novo from various compatible species. See, for example, Hire et al. (1992) Plant Mol. Biol. 20(2):207-218 (soybean root-specific glutamine synthetase gene); Keller and Baumgartner (1991) Plant Cell 3(10):1051-1061 (root-specific control element in the GRP 1.8 gene of French bean); Sanger et al. (1990) Plant Mol. Biol. 14(3):433-443 (root-specific promoter of the mannopine synthase (MAS) gene of Agrobacterium tumefaciens); and Miao et al. (1991) Plant Cell 3(1):11-22 (full-length cDNA clone encoding cytosolic glutamine synthetase (GS), which is expressed in roots and root nodules of soybean). See also Bogusz et al. (1990) Plant Cell 2(7):633-641, where two root-specific promoters isolated from hemoglobin genes from the nitrogen-fixing nonlegume Parasponia andersonii and the related non-nitrogen-fixing nonlegume Trema tomentosa are described. The promoters of these genes were linked to a β-glucuronidase reporter gene and introduced into both the nonlegume Nicotiana tabacum and the legume Lotus corniculatus, and in both instances root-specific promoter activity was preserved. Leach and Aoyagi (1991) describe their analysis of the promoters of the highly expressed rolC and rolD root-inducing genes of Agrobacterium rhizogenes (see Plant Science (Limerick) 79(1):69-76). They concluded that enhancer and tissue-preferred DNA determinants are dissociated in those promoters. Teeri et al. (1989) used gene fusion to lacZ to show that the Agrobacterium T-DNA gene encoding octopine synthase is especially active in the epidermis of the root tip and that the TR2′ gene is root specific in the intact plant and stimulated by wounding in leaf tissue, an especially desirable combination of characteristics for use with an insecticidal or larvicidal gene (see EMBO J. 8(2):343-350). The TR1′ gene, fused to nptII (neomycin phosphotransferase II) showed similar characteristics. Additional root-preferred promoters include the VfENOD-GRP3 gene promoter (Kuster et al. (1995) Plant Mol. Biol. 29(4):759-772); and rolB promoter (Capana et al. (1994) Plant Mol. Biol. 25(4):681-691. See also U.S. Pat. Nos. 5,837,876; 5,750,386; 5,633,363; 5,459,252; 5,401,836; 5,110,732; and 5,023,179.

In one embodiment of this invention the plant-expressed promoter is a vascular-specific promoter such as a phloem-specific promoter. A “vascular-specific” promoter, as used herein, is a promoter which is at least expressed in vascular cells, or a promoter which is preferentially expressed in vascular cells. Expression of a vascular-specific promoter need not be exclusively in vascular cells, expression in other cell types or tissues is possible. A “phloem-specific promoter” as used herein, is a plant-expressible promoter which is at least expressed in phloem cells, or a promoter which is preferentially expressed in phloem cells.

Expression of a phloem-specific promoter need not be exclusively in phloem cells, expression in other cell types or tissues, e.g., xylem tissue, is possible. In one embodiment of this invention, a phloem-specific promoter is a plant-expressible promoter at least expressed in phloem cells, wherein the expression in non-phloem cells is more limited (or absent) compared to the expression in phloem cells. Examples of suitable vascular-specific or phloem-specific promoters in accordance with this invention include but are not limited to the promoters selected from the group consisting of: the SCSV3, SCSV4, SCSV5, and SCSV7 promoters (Schunmann et al. (2003) Plant Functional Biology 30:453-60; the rolC gene promoter of Agrobacterium rhizogenes (Kiyokawa et al. (1994) Plant Physiology 104:801-02; Pandolfini et al. (2003) Bio Med Central (BMC) Biotechnology 3:7, (www.biomedcentral.com/1472-6750/3/7); Graham et al. (1997) Plant Mol. Biol. 33:729-35; Guivarc'h et al. (1996); Almon et al. (1997) Plant Physiol. 115:1599-607; the rolA gene promoter of Agrobacterium rhizogenes (Dehio et al. (1993) Plant Mol. Biol. 23:1199-210); the promoter of the Agrobacterium tumefaciens T-DNA gene 5 (Korber et al. (1991) EMBO J. 10:3983-91); the rice sucrose synthase RSs1 gene promoter (Shi et al. (1994) J. Exp. Bot. 45:623-31); the CoYMV or Commelina yellow mottle badnavirus promoter (Medberry et al. (1992) Plant Cell 4:185-92; Zhou et al. (1998) Chin. J. Biotechnol. 14:9-16); the CFDV or coconut foliar decay virus promoter (Rohde et al. (1994) Plant Mol. Biol. 27:623-28; Hehn and Rhode (1998) J. Gen. Virol. 79:1495-99); the RTBV or rice tungro bacilliform virus promoter (Yin and Beachy (1995) Plant J. 7:969-80; Yin et al. (1997) Plant J. 12:1179-80); the pea glutamin synthase GS3A gene (Edwards et al. (1990) Proc. Natl. Acad. Sci. USA 87:3459-63; Brears et al. (1991) Plant J. 1:235-44); the inv CD111 and inv CD141 promoters of the potato invertase genes (Hedley et al. (2000) J. Exp. Botany 51:817-21); the promoter isolated from Arabidopsis shown to have phloem-specific expression in tobacco by Kertbundit et al. (1991) Proc. Natl. Acad. Sci. USA 88:5212-16); the VAHOX1 promoter region (Tornero et al. (1996) Plant J. 9:639-48); the pea cell wall invertase gene promoter (Zhang et al. (1996) Plant Physiol. 112:1111-17); the promoter of the endogenous cotton protein related to chitinase of US published patent application 20030106097, an acid invertase gene promoter from carrot (Ramloch-Lorenz et al. (1993) The Plant J. 4:545-54); the promoter of the sulfate transporter geneSultrl; 3 (Yoshimoto et al. (2003) Plant Physiol. 131:1511-17); a promoter of a sucrose synthase gene (Nolte and Koch (1993) Plant Physiol. 101:899-905); and the promoter of a tobacco sucrose transporter gene (Kuhn et al. (1997) Science 275-1298-1300).

Possible promoters also include the Black Cherry promoter for Prunasin Hydrolase (PH DL1.4 PRO) (U.S. Pat. No. 6,797,859), Thioredoxin H promoter from cucumber and rice (Fukuda A et al. (2005). Plant Cell Physiol. 46(11):1779-86), Rice (RSs1) (Shi, T. Wang et al. (1994). J. Exp. Bot. 45(274): 623-631) and maize sucrose synthese −1 promoters (Yang., N-S. et al. (1990) PNAS 87:4144-4148), PP2 promoter from pumpkin Guo, H. et al. (2004) Transgenic Research 13:559-566), At SUC2 promoter (Truernit, E. et al. (1995) Planta 196(3):564-70. At SAM-1 (S-adenosylmethionine synthetase) (Mijnsbrugge K V. et al. (1996) Planr. Cell. Physiol. 37(8): 1108-1115), and the Rice tungro bacilliform virus (RTBV) promoter (Bhattacharyya-Pakrasi et al. (1993) Plant J. 4(1):71-79).

The expression cassette can also comprise a selectable marker gene for the selection of transformed cells. Selectable marker genes are utilized for the selection of transformed cells or tissues. Marker genes include genes encoding antibiotic resistance, such as those encoding neomycin phosphotransferase II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil, imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D). Additional selectable markers include phenotypic markers such as β-galactosidase and fluorescent proteins such as green fluorescent protein (GFP) (Su et al. (2004) Biotechnol Bioeng 85:610-9 and Fetter et al. (2004) Plant Cell 16:215-28), cyan florescent protein (CYP) (Bolte et al. (2004) J. Cell Science 117:943-54 and Kato et al. (2002) Plant Physiol 129:913-42), and yellow florescent protein (PhiYFP™ from Evrogen, see, Bolte et al. (2004) J. Cell Science 117:943-54). For additional selectable markers, see generally, Yarranton (1992) Curr. Opin. Biotech. 3:506-511; Christopherson et al. (1992) Proc. Natl. Acad. Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; Reznikoff (1992) Mol. Microbiol. 6:2419-2422; Barkley et al. (1980) in The Operon, pp. 177-220; Hu et al. (1987) Cell 48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et al. (1988) Cell 52:713-722; Deuschle et al. (1989) Proc. Natl. Acad. Sci. USA 86:5400-5404; Fuerst et al. (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. (1990) Science 248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al. (1993) Proc. Natl. Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mol. Cell. Biol. 10:3343-3356; Zambretti et al. (1992) Proc. Natl. Acad. Sci. USA 89:3952-3956; Baim et al. (1991) Proc. Natl. Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) Nucleic Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 10:143-162; Degenkolb et al. (1991) Antimicrob. Agents Chemother. 35:1591-1595; Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; Bonin (1993) Ph.D. Thesis, University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547-5551; Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919; Hlavka et al. (1985) Handbook of Experimental Pharmacology, Vol. 78 (Springer-Verlag, Berlin); Gill et al. (1988) Nature 334:721-724. Such disclosures are herein incorporated by reference. The above list of selectable marker genes is not meant to be limiting. Any selectable marker gene can be used in the present invention.

VI. Compositions Comprising Silencing Elements

One or more of the polynucleotides comprising the silencing element can be provided as an external composition such as a spray or powder to the plant, plant part, seed, a pest, or an area of cultivation. In another example, a plant is transformed with a DNA construct or expression cassette for expression of at least one silencing element. In either compositions, the silencing element, when ingested by an insect, can reduce the level of a target pest sequence and thereby control the pest (i.e., any pest from the Lygus genus, such as, Lygus hesperus). It is recognized that the composition can comprise a cell (such as plant cell or a bacterial cell), in which a polynucleotide encoding the silencing element is stably incorporated into the genome and operably linked to promoters active in the cell. Compositions comprising a mixture of cells, some cells expressing at least one silencing element are also encompassed. In other embodiments, compositions comprising the silencing elements are not contained in a cell. In such embodiments, the composition can be applied to an area inhabited by a pest. In one embodiment, the composition is applied externally to a plant (i.e., by spraying a field or area of cultivation) to protect the plant from the pest.

The composition of the invention can further be formulated as bait. In this embodiment, the compositions comprise a food substance or an attractant which enhances the attractiveness of the composition to the pest.

The composition comprising the silencing element can be formulated in an agriculturally suitable and/or environmentally acceptable carrier. Such carriers can be any material that the animal, plant or environment to be treated can tolerate. Furthermore, the carrier must be such that the composition remains effective at controlling a pest. Examples of such carriers include water, saline, Ringer's solution, dextrose or other sugar solutions, Hank's solution, and other aqueous physiologically balanced salt solutions, phosphate buffer, bicarbonate buffer and Tris buffer. In addition, the composition may include compounds that increase the half-life of a composition.

It is recognized that the polynucleotides comprising sequences encoding the silencing element can be used to transform organisms to provide for host organism production of these components, and subsequent application of the host organism to the environment of the target pest(s). Such host organisms include baculoviruses, bacteria, and the like. In this manner, the combination of polynucleotides encoding the silencing element may be introduced via a suitable vector into a microbial host, and said host applied to the environment, or to plants or animals.

The term “introduced” in the context of inserting a nucleic acid into a cell, means “transfection” or “transformation” or “transduction” and includes reference to the incorporation of a nucleic acid into a eukaryotic or prokaryotic cell where the nucleic acid may be stably incorporated into the genome of the cell (e.g., chromosome, plasmid, plastid, or mitochondrial DNA), converted into an autonomous replicon, or transiently expressed (e.g., transfected mRNA).

Microorganism hosts that are known to occupy the “phytosphere” (phylloplane, phyllosphere, rhizosphere, and/or rhizoplana) of one or more crops of interest may be selected. These microorganisms are selected so as to be capable of successfully competing in the particular environment with the wild-type microorganisms, provide for stable maintenance and expression of the sequences encoding the silencing element, and desirably, provide for improved protection of the components from environmental degradation and inactivation.

Such microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms such as bacteria, e.g., Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylius, Agrobacterium, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc, and Alcaligenes, fungi, particularly yeast, e.g., Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula, and Aureobasidium. Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobacteria, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus, Clavibacter xyli and Azotobacter vinlandir, and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces rosues, S. odorus, Kluyveromyces veronae, and Aureobasidium pollulans. Of particular interest are the pigmented microorganisms.

A number of ways are available for introducing the polynucleotide comprising the silencing element into the microorganism host under conditions that allow for stable maintenance and expression of such nucleotide encoding sequences. For example, expression cassettes can be constructed which include the nucleotide constructs of interest operably linked with the transcriptional and translational regulatory signals for expression of the nucleotide constructs, and a nucleotide sequence homologous with a sequence in the host organism, whereby integration will occur, and/or a replication system that is functional in the host, whereby integration or stable maintenance will occur.

Transcriptional and translational regulatory signals include, but are not limited to, promoters, transcriptional initiation start sites, operators, activators, enhancers, other regulatory elements, ribosomal binding sites, an initiation codon, termination signals, and the like. See, for example, U.S. Pat. Nos. 5,039,523 and 4,853,331; EPO 0480762A2; Sambrook et al. (2000); Molecular Cloning: A Laboratory Manual (3rd ed.; Cold Spring Harbor Laboratory Press, Plainview, N.Y.); Davis et al. (1980) Advanced Bacterial Genetics (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.; and the references cited therein.

Suitable host cells include the prokaryotes and the lower eukaryotes, such as fungi. Illustrative prokaryotes, both Gram-negative and Gram-positive, include Enterobacteriaceae, such as Escherichia, Erwinia, Shigella, Salmonella, and Proteus; Bacillaceae; Rhizobiceae, such as Rhizobium; Spirillaceae, such as photobacterium, Zymomonas, Serratia, Aeromonas, Vibrio, Desulfovibrio, Spirillum; Lactobacillaceae; Pseudomonadaceae, such as Pseudomonas and Acetobacter; Azotobacteraceae and Nitrobacteraceae. Among eukaryotes are fungi, such as Phycomycetes and Ascomycetes, which includes yeast, such as Saccharomyces and Schizosaccharomyces; and Basidiomycetes yeast, such as Rhodotorula, Aureobasidium, Sporobolomyces, and the like.

Characteristics of particular interest in selecting a host cell for purposes of the invention include ease of introducing the coding sequence into the host, availability of expression systems, efficiency of expression, stability in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; leaf affinity; lack of mammalian toxicity; attractiveness to pests for ingestion; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like.

Host organisms of particular interest include yeast, such as Rhodotorula spp., Aureobasidium spp., Saccharomyces spp., and Sporobolomyces spp., phylloplane organisms such as Pseudomonas spp., Erwinia spp., and Flavobacterium spp., and other such organisms, including Pseudomonas aeruginosa, Pseudomonas fluorescens, Saccharomyces cerevisiae, Bacillus thuringiensis, Escherichia coli, Bacillus subtilis, and the like.

The sequences encoding the silencing elements encompassed by the invention can be introduced into microorganisms that multiply on plants (epiphytes) to deliver these components to potential target pests. Epiphytes, for example, can be gram-positive or gram-negative bacteria.

The silencing element can be fermented in a bacterial host and the resulting bacteria processed and used as a microbial spray in the same manner that Bacillus thuringiensis strains have been used as insecticidal sprays. Any suitable microorganism can be used for this purpose. Pseudomonas has been used to express Bacillus thuringiensis endotoxins as encapsulated proteins and the resulting cells processed and sprayed as an insecticide Gaertner et al. (1993), in Advanced Engineered Pesticides, ed. L. Kim (Marcel Decker, Inc.).

Alternatively, the components of the invention are produced by introducing heterologous genes into a cellular host. Expression of the heterologous sequences results, directly or indirectly, in the intracellular production of the silencing element. These compositions may then be formulated in accordance with conventional techniques for application to the environment hosting a target pest, e.g., soil, water, and foliage of plants. See, for example, EPA 0192319, and the references cited therein.

In the present invention, a transformed microorganism can be formulated with an acceptable carrier into separate or combined compositions that are, for example, a suspension, a solution, an emulsion, a dusting powder, a dispersible granule, a wettable powder, and an emulsifiable concentrate, an aerosol, an impregnated granule, an adjuvant, a coatable paste, and also encapsulations in, for example, polymer substances.

Such compositions disclosed above may be obtained by the addition of a surface-active agent, an inert carrier, a preservative, a humectant, a feeding stimulant, an attractant, an encapsulating agent, a binder, an emulsifier, a dye, a UV protectant, a buffer, a flow agent or fertilizers, micronutrient donors, or other preparations that influence plant growth. One or more agrochemicals including, but not limited to, herbicides, insecticides, fungicides, bactericides, nematicides, molluscicides, acaracides, plant growth regulators, harvest aids, and fertilizers, can be combined with carriers, surfactants or adjuvants customarily employed in the art of formulation or other components to facilitate product handling and application for particular target pests. Suitable carriers and adjuvants can be solid or liquid and correspond to the substances ordinarily employed in formulation technology, e.g., natural or regenerated mineral substances, solvents, dispersants, wetting agents, tackifiers, binders, or fertilizers. The active ingredients of the present invention (i.e., at least one silencing element) are normally applied in the form of compositions and can be applied to the crop area, plant, or seed to be treated. For example, the compositions may be applied to grain in preparation for or during storage in a grain bin or silo, etc. The compositions may be applied simultaneously or in succession with other compounds. Methods of applying an active ingredient or a composition that contains at least one silencing element include, but are not limited to, foliar application, seed coating, and soil application. The number of applications and the rate of application depend on the intensity of infestation by the corresponding pest.

Suitable surface-active agents include, but are not limited to, anionic compounds such as a carboxylate of, for example, a metal; carboxylate of a long chain fatty acid; an N-acylsarcosinate; mono- or di-esters of phosphoric acid with fatty alcohol ethoxylates or salts of such esters; fatty alcohol sulfates such as sodium dodecyl sulfate, sodium octadecyl sulfate, or sodium cetyl sulfate; ethoxylated fatty alcohol sulfates; ethoxylated alkylphenol sulfates; lignin sulfonates; petroleum sulfonates; alkyl aryl sulfonates such as alkyl-benzene sulfonates or lower alkylnaphtalene sulfonates, e.g., butyl-naphthalene sulfonate; salts of sulfonated naphthalene-formaldehyde condensates; salts of sulfonated phenol-formaldehyde condensates; more complex sulfonates such as the amide sulfonates, e.g., the sulfonated condensation product of oleic acid and N-methyl taurine; or the dialkyl sulfosuccinates, e.g., the sodium sulfonate or dioctyl succinate. Non-ionic agents include condensation products of fatty acid esters, fatty alcohols, fatty acid amides or fatty-alkyl- or alkenyl-substituted phenols with ethylene oxide, fatty esters of polyhydric alcohol ethers, e.g., sorbitan fatty acid esters, condensation products of such esters with ethylene oxide, e.g., polyoxyethylene sorbitan fatty acid esters, block copolymers of ethylene oxide and propylene oxide, acetylenic glycols such as 2,4,7,9-tetraethyl-5-decyn-4,7-diol, or ethoxylated acetylenic glycols. Examples of a cationic surface-active agent include, for instance, an aliphatic mono-, di-, or polyamine such as an acetate, naphthenate or oleate; or oxygen-containing amine such as an amine oxide of polyoxyethylene alkylamine; an amide-linked amine prepared by the condensation of a carboxylic acid with a di- or polyamine; or a quaternary ammonium salt.

Examples of inert materials include, but are not limited to, inorganic minerals such as kaolin, phyllosilicates, carbonates, sulfates, phosphates, or botanical materials such as cork, powdered corncobs, peanut hulls, rice hulls, and walnut shells.

The compositions comprising the silencing element can be in a suitable form for direct application or as a concentrate of primary composition that requires dilution with a suitable quantity of water or other dilutant before application.

The compositions (including the transformed microorganisms) can be applied to the environment of an insect pest (such as a pest from the Lygus genus) by, for example, spraying, atomizing, dusting, scattering, coating or pouring, introducing into or on the soil, introducing into irrigation water, by seed treatment or general application or dusting at the time when the pest has begun to appear or before the appearance of pests as a protective measure. For example, the composition(s) and/or transformed microorganism(s) may be mixed with grain to protect the grain during storage. It is generally important to obtain good control of pests in the early stages of plant growth, as this is the time when the plant can be most severely damaged. The compositions can conveniently contain another insecticide if this is thought necessary. In an embodiment of the invention, the composition(s) is applied directly to the soil, at a time of planting, in granular form of a composition of a carrier and dead cells of a Bacillus strain or transformed microorganism of the invention. Another embodiment is a granular form of a composition comprising an agrochemical such as, for example, a herbicide, an insecticide, a fertilizer, in an inert carrier, and dead cells of a Bacillus strain or transformed microorganism of the invention.

VII. Plants, Plant Parts, and Methods of Introducing Sequences into Plants

In one embodiment, the methods of the invention involve introducing a polypeptide or polynucleotide into a plant. “Introducing” is intended to mean presenting to the plant the polynucleotide or polypeptide in such a manner that the sequence gains access to the interior of a cell of the plant. The methods of the invention do not depend on a particular method for introducing a sequence into a plant, only that the polynucleotide or polypeptides gains access to the interior of at least one cell of the plant. Methods for introducing polynucleotide or polypeptides into plants are known in the art including, but not limited to, stable transformation methods, transient transformation methods, and virus-mediated methods.

“Stable transformation” is intended to mean that the nucleotide construct introduced into a plant integrates into the genome of the plant and is capable of being inherited by the progeny thereof. “Transient transformation” is intended to mean that a polynucleotide is introduced into the plant and does not integrate into the genome of the plant or a polypeptide is introduced into a plant.

Transformation protocols as well as protocols for introducing polypeptides or polynucleotide sequences into plants may vary depending on the type of plant or plant cell, i.e., monocot or dicot, targeted for transformation. Suitable methods of introducing polypeptides and polynucleotides into plant cells include microinjection (Crossway et al. (1986) Biotechniques 4:320-334), electroporation (Riggs et al. (1986) Proc. Natl. Acad. Sci. USA 83:5602-5606, Agrobacterium-mediated transformation (U.S. Pat. No. 5,563,055 and U.S. Pat. No. 5,981,840), direct gene transfer (Paszkowski et al. (1984) EMBO J. 3:2717-2722), and ballistic particle acceleration (see, for example, U.S. Pat. No. 4,945,050; U.S. Pat. No. 5,879,918; U.S. Pat. No. 5,886,244; and, U.S. Pat. No. 5,932,782; Tomes et al. (1995) in Plant Cell, Tissue, and Organ Culture: Fundamental Methods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe et al. (1988) Biotechnology 6:923-926); and Lec1 transformation (WO 00/28058). Also see Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987) Particulate Science and Technology 5:27-37 (onion); Christou et al. (1988) Plant Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926 (soybean); Finer and McMullen (1991) In Vitro Cell Dev. Biol. 27P:175-182 (soybean); Singh et al. (1998) Theor. Appl. Genet. 96:319-324 (soybean); Datta et al. (1990) Biotechnology 8:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA 85:4305-4309 (maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); U.S. Pat. Nos. 5,240,855; 5,322,783; and, 5,324,646; Klein et al. (1988) Plant Physiol. 91:440-444 (maize); Fromm et al. (1990) Biotechnology 8:833-839 (maize); Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764; U.S. Pat. No. 5,736,369 (cereals); Bytebier et al. (1987) Proc. Natl. Acad. Sci. USA 84:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen); Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor. Appl. Genet. 84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992) Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 12:250-255 and Christou and Ford (1995) Annals of Botany 75:407-413 (rice); Osjoda et al. (1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium tumefaciens); all of which are herein incorporated by reference.

In specific embodiments, the silencing element sequences of the invention can be provided to a plant using a variety of transient transformation methods. Such transient transformation methods include, but are not limited to, the introduction of the protein or variants and fragments thereof directly into the plant or the introduction of the transcript into the plant. Such methods include, for example, microinjection or particle bombardment. See, for example, Crossway et al. (1986) Mol Gen. Genet. 202:179-185; Nomura et al. (1986) Plant Sci. 44:53-58; Hepler et al. (1994) Proc. Natl. Acad. Sci. 91: 2176-2180 and Hush et al. (1994) The Journal of Cell Science 107:775-784, all of which are herein incorporated by reference. Alternatively, polynucleotides can be transiently transformed into the plant using techniques known in the art. Such techniques include viral vector system and the precipitation of the polynucleotide in a manner that precludes subsequent release of the DNA. Thus, the transcription from the particle-bound DNA can occur, but the frequency with which its released to become integrated into the genome is greatly reduced. Such methods include the use particles coated with polyethylimine (PEI; Sigma #P3143).

In other embodiments, the polynucleotide of the invention may be introduced into plants by contacting plants with a virus or viral nucleic acids. Generally, such methods involve incorporating a nucleotide construct of the invention within a viral DNA or RNA molecule. Further, it is recognized that promoters of the invention also encompass promoters utilized for transcription by viral RNA polymerases. Methods for introducing polynucleotides into plants and expressing a protein encoded therein, involving viral DNA or RNA molecules, are known in the art. See, for example, U.S. Pat. Nos. 5,889,191, 5,889,190, 5,866,785, 5,589,367, 5,316,931, and Porta et al. (1996) Molecular Biotechnology 5:209-221; herein incorporated by reference.

Methods are known in the art for the targeted insertion of a polynucleotide at a specific location in the plant genome. In one embodiment, the insertion of the polynucleotide at a desired genomic location is achieved using a site-specific recombination system. See, for example, WO99/25821, WO99/25854, WO99/25840, WO99/25855, and WO99/25853, all of which are herein incorporated by reference. Briefly, the polynucleotide of the invention can be contained in transfer cassette flanked by two non-recombinogenic recombination sites. The transfer cassette is introduced into a plant having stably incorporated into its genome a target site which is flanked by two non-recombinogenic recombination sites that correspond to the sites of the transfer cassette. An appropriate recombinase is provided and the transfer cassette is integrated at the target site. The polynucleotide of interest is thereby integrated at a specific chromosomal position in the plant genome.

The cells that have been transformed may be grown into plants in accordance with conventional ways. See, for example, McCormick et al. (1986) Plant Cell Reports 5:81-84. These plants may then be grown, and either pollinated with the same transformed strain or different strains, and the resulting progeny having constitutive expression of the desired phenotypic characteristic identified. Two or more generations may be grown to ensure that expression of the desired phenotypic characteristic is stably maintained and inherited and then seeds harvested to ensure expression of the desired phenotypic characteristic has been achieved. In this manner, the present invention provides transformed seed (also referred to as “transgenic seed”) having a polynucleotide of the invention, for example, an expression cassette of the invention, stably incorporated into their genome.

As used herein, the term plant includes plant cells, plant protoplasts, plant cell tissue cultures from which plants can be regenerated, plant calli, plant clumps, and plant cells that are intact in plants or parts of plants such as embryos, pollen, ovules, seeds, leaves, flowers, branches, fruit, kernels, ears, cobs, husks, stalks, roots, root tips, anthers, and the like. Grain is intended to mean the mature seed produced by commercial growers for purposes other than growing or reproducing the species. Progeny, variants, and mutants of the regenerated plants are also included within the scope of the invention, provided that these parts comprise the introduced polynucleotides.

The present invention may be used for transformation of any plant species, including, but not limited to, monocots and dicots. Examples of plant species of interest include, but are not limited to, corn (Zea mays), Brassica sp. (e.g., B. napus, B. rapa, B. juncea), particularly those Brassica species useful as sources of seed oil, alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cereale), sorghum (Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet (Pennisetum glaucum), proso millet (Panicum miliaceum), foxtail millet (Setaria italica), finger millet (Eleusine coracana)), sunflower (Helianthus annuus), safflower (Carthamus tinctorius), wheat (Triticum aestivum), soybean (Glycine max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis hypogaea), cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato (Ipomoea batatus), cassava (Manihot esculenta), coffee (Coffea spp.), coconut (Cocos nucifera), pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa (Theobroma cacao), tea (Camellia sinensis), banana (Musa spp.), avocado (Persea americana), fig (Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia (Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta vulgaris), sugarcane (Saccharum spp.), oats, barley, vegetables, ornamentals, and conifers.

Vegetables include tomatoes (Lycopersicon esculentum), lettuce (e.g., Lactuca sativa), green beans (Phaseolus vulgaris), lima beans (Phaseolus limensis), peas (Lathyrus spp.), and members of the genus Cucumis such as cucumber (C. sativus), cantaloupe (C. cantalupensis), and musk melon (C. melo). Ornamentals include azalea (Rhododendron spp.), hydrangea (Macrophylla hydrangea), hibiscus (Hibiscus rosasanensis), roses (Rosa spp.), tulips (Tulipa spp.), daffodils (Narcissus spp.), petunias (Petunia hybrida), carnation (Dianthus caryophyllus), poinsettia (Euphorbia pulcherrima), and chrysanthemum.

Conifers that may be employed in practicing the present invention include, for example, pines such as loblolly pine (Pinus taeda), slash pine (Pinus elliotii), ponderosa pine (Pinus ponderosa), lodgepole pine (Pinus contorta), and Monterey pine (Pinus radiata); Douglas-fir (Pseudotsuga menziesii); Western hemlock (Tsuga canadensis); Sitka spruce (Picea glauca); redwood (Sequoia sempervirens); true firs such as silver fir (Abies amabilis) and balsam fir (Abies balsamea); and cedars such as Western red cedar (Thuja plicata) and Alaska yellow-cedar (Chamaecyparis nootkatensis). In specific embodiments, plants of the present invention are crop plants (for example, corn, alfalfa, sunflower, Brassica, soybean, cotton, safflower, peanut, sorghum, wheat, millet, tobacco, etc.). In other embodiments, corn and soybean plants are optimal, and in yet other embodiments corn plants are optimal.

Other plants of interest include grain plants that provide seeds of interest, oil-seed plants, and leguminous plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice, sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower, Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea, mungbean, lima bean, fava bean, lentils, chickpea, etc.

VIII. Methods of Use

The methods of the invention comprise methods for controlling a pest (i.e., pest from the Lygus genus, such as, Lygus hesperus) comprising feeding to a pest a composition comprising a silencing element of the invention, wherein said silencing element, when ingested by a pest (i.e., pests from the Lygus genus, such as, Lygus hesperus), reduces the level of a target polynucleotide of the pest and thereby controls the pest. The pest can be fed the silencing element in a variety of ways. For example, in one embodiment, the polynucleotide comprising the silencing element is introduced into a plant. As the Lygus feeds on the plant or part thereof expressing these sequences, the silencing element is delivered to the pest. When the silencing element is delivered to the plant in this manner, it is recognized that the silencing element can be expressed constitutively or alternatively, it may be produced in a stage-specific manner by employing the various inducible or tissue-preferred or developmentally regulated promoters that are discussed elsewhere herein. For example, the silience element could be expressed in aerial plant tissues such as, the leaves, stem, flower, etc. In other embodiments, the silencing element is expressed in a root. In these embodiments, Hemioptera such as grape phylloxera can be targeted.

In another method, a composition comprising at least one silencing element of the invention is applied to a plant. In such embodiments, the silencing element can be formulated in an agronomically suitable and/or environmentally acceptable carrier, which are preferably, suitable for dispersal in fields. In addition, the carrier can also include compounds that increase the half life of the composition. In specific embodiments, the composition comprising the silencing element is formulated in such a manner such that it persists in the environment for a length of time sufficient to allow it to be delivered to a pest. In such embodiments, the composition can be applied to an area inhabited by a pest. In one embodiment, the composition is applied externally to a plant (i.e., by spraying a field) to protect the plant from pests.

In certain embodiments, the constructs of the present invention can be stacked with any combination of polynucleotide sequences of interest in order to create plants with a desired trait. A trait, as used herein, refers to the phenotype derived from a particular sequence or groups of sequences. For example, the polynucleotides of the present invention may be stacked with any other polynucleotides encoding polypeptides having pesticidal and/or insecticidal activity, such as other Bacillus thuringiensis toxic proteins (described in U.S. Pat. Nos. 5,366,892; 5,747,450; 5,737,514; 5,723,756; 5,593,881; and Geiser et al. (1986) Gene 48:109), lectins (Van Damme et al. (1994) Plant Mol. Biol. 24:825, pentin (described in U.S. Pat. No. 5,981,722), and the like. The combinations generated can also include multiple copies of any one of the polynucleotides of interest. The polynucleotides of the present invention can also be stacked with any other gene or combination of genes to produce plants with a variety of desired trait combinations including, but not limited to, traits desirable for animal feed such as high oil genes (e.g., U.S. Pat. No. 6,232,529); balanced amino acids (e.g., hordothionins (U.S. Pat. Nos. 5,990,389; 5,885,801; 5,885,802; and 5,703,409); barley high lysine (Williamson et al. (1987) Eur. J. Biochem. 165:99-106; and WO 98/20122) and high methionine proteins (Pedersen et al. (1986) J. Biol. Chem. 261:6279; Kirihara et al. (1988) Gene 71:359; and Musumura et al. (1989) Plant Mol. Biol. 12:123)); increased digestibility (e.g., modified storage proteins (U.S. application Ser. No. 10/053,410, filed Nov. 7, 2001); and thioredoxins (U.S. application Ser. No. 10/005,429, filed Dec. 3, 2001)); the disclosures of which are herein incorporated by reference.

The polynucleotides of the present invention can also be stacked with traits desirable for disease or herbicide resistance (e.g., fumonisin detoxification genes (U.S. Pat. No. 5,792,931); avirulence and disease resistance genes (Jones et al. (1994) Science 266:789; Martin et al. (1993) Science 262:1432; Mindrinos et al. (1994) Cell 78:1089); acetolactate synthase (ALS) mutants that lead to herbicide resistance such as the S4 and/or Hra mutations; inhibitors of glutamine synthase such as phosphinothricin or basta (e.g., bar gene); and glyphosate resistance (EPSPS gene)); and traits desirable for processing or process products such as high oil (e.g., U.S. Pat. No. 6,232,529); modified oils (e.g., fatty acid desaturase genes (U.S. Pat. No. 5,952,544; WO 94/11516)); modified starches (e.g., ADPG pyrophosphorylases (AGPase), starch synthases (SS), starch branching enzymes (SBE), and starch debranching enzymes (SDBE)); and polymers or bioplastics (e.g., U.S. Pat. No. 5,602,321; beta-ketothiolase, polyhydroxybutyrate synthase, and acetoacetyl-CoA reductase (Schubert et al. (1988) J. Bacteriol. 170:5837-5847) facilitate expression of polyhydroxyalkanoates (PHAs)); the disclosures of which are herein incorporated by reference. One could also combine the polynucleotides of the present invention with polynucleotides providing agronomic traits such as male sterility (e.g., see U.S. Pat. No. 5,583,210), stalk strength, flowering time, or transformation technology traits such as cell cycle regulation or gene targeting (e.g., WO 99/61619, WO 00/17364, and WO 99/25821); the disclosures of which are herein incorporated by reference.

These stacked combinations can be created by any method including, but not limited to, cross-breeding plants by any conventional or TopCross methodology, or genetic transformation. If the sequences are stacked by genetically transforming the plants, the polynucleotide sequences of interest can be combined at any time and in any order. For example, a transgenic plant comprising one or more desired traits can be used as the target to introduce further traits by subsequent transformation. The traits can be introduced simultaneously in a co-transformation protocol with the polynucleotides of interest provided by any combination of transformation cassettes. For example, if two sequences will be introduced, the two sequences can be contained in separate transformation cassettes (trans) or contained on the same transformation cassette (cis). Expression of the sequences can be driven by the same promoter or by different promoters. In certain cases, it may be desirable to introduce a transformation cassette that will suppress the expression of the polynucleotide of interest. This may be combined with any combination of other suppression cassettes or overexpression cassettes to generate the desired combination of traits in the plant. It is further recognized that polynucleotide sequences can be stacked at a desired genomic location using a site-specific recombination system. See, for example, WO99/25821, WO99/25854, WO99/25840, WO99/25855, and WO99/25853, all of which are herein incorporated by reference.

Methods and compositions are further provided which allow for an increase in RNAi produced from the silencing element. In such embodiments, the methods and compositions employ a first polynucleotide comprising a silencing element for a target pest sequence operably linked to a promoter active in the plant cell; and, a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof operably linked to a promoter active in the plant cell. The combined expression of the silencing element with suppressor enhancer element leads to an increased amplification of the inhibitory RNA produced from the silencing element over that achievable with only the expression of the silencing element alone. In addition to the increased amplification of the specific RNAi species itself, the methods and compositions further allow for the production of a diverse population of RNAi species that can enhance the effectiveness of disrupting target gene expression. As such, when the suppressor enhancer element is expressed in a plant cell in combination with the silencing element, the methods and composition can allow for the systemic production of RNAi throughout the plant; the production of greater amounts of RNAi than would be observed with just the silencing element construct alone; and, the improved loading of RNAi into the phloem of the plant, thus providing better control of phloem feeding insects by an RNAi approach. Thus, the various methods and compositions provide improved methods for the delivery of inhibitory RNA to the target organism. See, for example, U.S. Provisional Application No. 61/021,676, entitled “Compositions and Methods for the Suppression of Target Polynucleotides”, filed Jan. 17, 2008 and herein incorporated by reference in its entirety.

As used herein, a “suppressor enhancer element” comprises a polynucleotide comprising the target sequence to be suppressed or an active fragment or variant thereof. It is recognize that the suppressor enhancer element need not be identical to the target sequence, but rather, the suppressor enhancer element can comprise a variant of the target sequence, so long as the suppressor enhancer element has sufficient sequence identity to the target sequence to allow for an increased level of the RNAi produced by the silencing element over that achievable with only the expression of the silencing element. Similarly, the suppressor enhancer element can comprise a fragment of the target sequence, wherein the fragment is of sufficient length to allow for an increased level of the RNAi produced by the silencing element over that achievable with only the expression of the silencing element. Thus, in specific embodiments, the suppressor enhancer element comprises a fragment or a variant of a polynucleotide encoding a potassium channel polypeptide, a cuticle polypeptide, an endocuticle polypeptide, a chitin binding polypeptide, a chitinase polypeptide, a hormone inducible polypeptide, a translation initiation factor, a voltage dependant channel, an EIF-related polypeptide, a polypeptide having a coiled coil helix domain, a polypeptide having a zinc finger domain, a receptor associated finger polypeptide, a lethal timorous imaginal disc polypeptide, a ribonucleoprotein, a cathepsin protease polypeptide, a polyprotein deformed destructor, and a death associated leucine rich polypeptide. In still other embodiments, the suppressor enhancer element comprises a polynucleotide set forth in SEQ ID NO: 1-42 or an active variant or fragment thereof.

It is recognized that multiple suppressor enhancer elements from the same target sequence or from different target sequences, or from different regions of the same target sequence can be employed. For example, the suppressor enhancer elements employed can comprise fragments of the target sequence derived from different region of the target sequence (i.e., from the 3′UTR, coding sequence, intron, and/or 5′UTR). Further, the suppressor enhancer element can be contained in an expression cassette, as described elsewhere herein, and in specific embodiments, the suppressor enhancer element is on the same or on a different DNA vector or construct as the silencing element. The suppressor enhancer element can be operably linked to a promoter as disclosed herein. It is recognized that the suppressor enhancer element can be expressed constitutively or alternatively, it may be produced in a stage-specific manner employing the various inducible or tissue-preferred or developmentally regulated promoters that are discussed elsewhere herein.

In specific embodiments, employing both a silencing element and the suppressor enhancer element allows for the systemic production of RNAi occurs throughout the entire plant. In further embodiments, the plant or plant parts of the invention have improved loading of RNAi into the phloem of the plant over what would be observed with the expression of the silencing element construct alone and, thus provide better control of phloem feeding insects by an RNAi approach. In specific embodiments, the plants, plant parts, and plant cells of the invention can further be characterized as allowing for the production of a diversity of RNAi species that can enhance the effectiveness of disrupting target gene expression.

In specific embodiments, the combined expression of the silencing element and the suppressor enhancer element increases the concentration of the inhibitory RNA in the plant cell, plant, plant part, plant tissue or phloem over the level that is achieved when the silencing element is expressed alone.

As used herein, an “increased level of inhibitory RNA” comprises any statistically significant increase in the level of RNAi produced in a plant having the combined expression when compared to an appropriate control plant. For example, an increase in the level of RNAi in the plant, plant part or the plant cell can comprise at least about a 1%, about a 1%-5%, about a 5% -10%, about a 10%-20%, about a 20%-30%, about a 30%-40%, about a 40%-50%, about a 50%-60%, about 60-70%, about 70%-80%, about a 80%-90%, about a 90%-100% or greater increase in the level of RNAi in the plant, plant part, plant cell, or phloem when compared to an appropriate control. In other embodiments, the increase in the level of RNAi in the plant, plant part, plant cell, or phloem can comprise at least about a 1 fold, about a 1 fold-5 fold, about a 5 fold-10 fold, about a 10 fold-20 fold, about a 20 fold-30 fold, about a 30 fold-40 fold, about a 40 fold-50 fold, about a 50 fold-60 fold, about 60 fold-70 fold, about 70 fold-80 fold, about a 80 fold-90 fold, about a 90 fold-100 fold or greater increase in the level of RNAi in the plant, plant part, plant cell or phloem when compared to an appropriate control. Methods to assay for an increase in the level of RNAi are discussed elsewhere herein.

The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL Example 1 Specific Target Genes and Silencing Elements that Cause Insecticidal Activity Against Lygus Hesperus

Disruption of insect gene function via RNAi can produce specific activity against target insects. This specificity is enhanced by delivery of the dsRNAs via transgenic plants. Identification of gene function in insects via RNAi has been largely limited to injection of dsRNAs. In fact, past experiments have indicated that insects are not capable of systemic RNAi response based on exposure to dsRNAs.

As described below, we have demonstrated acute activity of numerous dsRNA pairs through injection experiments and additionally have demonstrated insect antagonism through ingestion of dsRNAs. This evidence identifies several gene/primer pair combinations with clear insecticidal properties. The use of dsRNAs in transgenic plants also addresses the potential complication of heterologous protein expression and the possible risks of allergic reaction, non-target activity, and environmental- or bioaccumulation. The data presented below represents the first test of disruption of these particular genes resulting in insecticidal activity in whole organisms and the first report of insecticidal activity of dsRNAs against L. Hesperus.

The invention describes specific target genes and the dsRNA sequences causing insecticidal activity against the hemipteran Lygus hesperus through RNA interference of the target gene's expression. Disruption of the genes targeted by the dsRNA sequences may be broadly insecticidal in numerous species. The specific dsRNA sequences display insecticidal activity upon ingestion indicating they can be utilized with a transgenic plant mode of delivery. Table 1 provides the polynucleotide of each target sequence from Lygus hesperus, a brief description of the function of the protein encoded by the target sequence, and a SEQ ID NO. Table 2 provides a summary of the blastx and blastn sequence homology results for each target sequence from Lygus hesperus. Table 3 provides a summary of primers used to suppress the target polynucleotides.

TABLE 1 Target Polynucleotides from Lygus Hesperus. SEQ ID NO: 1 ilh1c.pk005.o10.f potassium plus GCGTCACTTGCGACTCGTGTCTGAGCGGCAACTTCAAGGGAAA 151: GAGGTACAAATGTCTTTCCTGCTACGACTACGATCTGTGCACCAACTGCTACGAGTGTGGCCTCATCACGGGACT 226: CCACTCAGCAGAGCATCCCATGCAGTGCATCATCACCAGACATGACGTCGACCTGTACTTCGGGGGAGACATGAA 301: TGGCGACGGAAGTCAGTCCTACACGTGTCCTCATTGTGGTCTAATGGGGTTCAGTTTGTCGCTGTTGATCGAGCA 376: CGTGAGCGGTGAGCATATCGCGCTGAGCAACGCTGAAGTGATTTGCCCTGTTTGCGCCGCCACGCCAGTCAACCG 451: ACCGAACAACGTTCGCCAGGATTTTTTGGGGCACCTGACGCTGGAGCATCGCTACCCCTCGCGAGAGCTGACCGC 526: CTTCTTCGAAGAGCCCTCGTCCCGACACATGCCGAGTGGCGTCCGCCGGATTCCACCGCCACCAGGGCGCAGCGC 601: TGCCGGGCGTGGACGCCGGGTCGCACGTTCATTTCGGCTCCTCAGGCGCTCTTACTGGACTCACATCCTCCAGAG 676: AAAGTCCGGATCCCATCGCCGAGTTCTTCTCTCAGCTGTCTGgagtcgctcgtcctcaaggtcctgggccgattc SEQ ID NO: 2 ilh1c.pk004.e6.f cuticle protein plus ACCCCCTGATCGCCGGGATCGTTGCCAATCAGTATCACGCTCAGGATGTG 226: CTCGGACAGTACACTTACGGCTACTCCGGAnCCCCATCCGCTAAACAAGAGGTTAAGACTGCTGACGGAATAACG 301: AGAGGATCTTACTCGTACATCGATGGAAACGGGTCTCGTACAGAGCGCTTCTTACGTTGCTGACCCCGTCAACGG 376: GTTCAGAGTCCACGCCACCAACCTGCCCGTGGGACCTGACGGGTCCGTCGCTGCCGCTCCCGTCGCCAGGCTCCT 451: CAGCCCTTTGGCCATCAGCCCTGTGATCAACCTCCACGGCGCTGCTCCCCTCAACCCCGACGGCACCGTCGCTGA 526: CACCCATGAAGTCGCTGTCGCCAAGGCCGCTCACCTCGCTGCCATCAACGAGGCTAGGGCTAGAGGCAAGAGGTC 601: nGCCCCGCTCAACCCCGACGGTACCGTCGCTGACACCCCCGAAGTTGCTGCTGCTAAGTGGGCTCATCTCGCTGA 676: GATCTCCAAAGCTCGTGGAATCCCTCTCGTATACGCTCCCAGATGGTGGGGACCTGGTGCTCCATTGAACGCTGA SEQ ID NO: 3 ilh1c.pk001.e23.f cuticle plus CTACGCTGGCGGCCCCTCCGCCAAGGAAGAGATCAAGACCGCCGACGG 151: AATTACCCGCGGAGGATACTCATACATCGACGCCAACGGTATCGTCCAGAGCGCCTCTTACGTGTCGGATCCCGT 226: CAACGGATTCCGAGTAGCCGCCACTAACCTCCCCGCTGGACCTGCAGTCCCAGCTGGACCTTCAGTGGTTGCTGC 301: TGCTCCAGCTGTCGTTGCTGCTCCTGCTCCAGTTTTGGCTGCTGCCCCTGCTCCAATTGTGGCTTCAGCTCCCGT 376: TTGGGCTGCTCAACCAGCTGTTGTTGCCGCTCCAGCTCCTGTCGCTGTCGCCGAAGGCCCCGCAGTGACCGCCAC 451: CAACGTCCAGGAAGTTGCTGCCGCTGCTGCTGACGTCCCCGTTGCTGCTGATCTCCCCGAGATCATCGCTGCCCG 526: CTCTCTGCCCACCGTGGTTGCCACCAGGGCCGCCATCGCTCACCCCCTTGCCGCAACCTCCTGGTCCGGCATCGT 601: CCACCACCTGAAGAAGCGTTCCCTTGCCGCCGCTACCGTCGTCACTCCCCTTACTAGTTACCCCGGATCTACCGC 676: TCCCTTGGTTCACGCTTCTCCCGTTATTGCGGCTACACCTGTTATCTCCGCTCACTCGGGTTTGATCGCCACTGA 751: CTCTCTTGTAncctcaccacacctcgttggtgcagtangtnctgtcnagcccctccacaccgccntcctcanan SEQ ID NO: 4 ilh1c.pk010.f11.f endo cuticle plus CATTCGGGAGACATTGCAAAACTGGATGCATAGGGGAAGTCTTTA 151: GGACGGATTTACGGCATACAGTACATGTTACTGTAAGACACGGCGCGTGACTGGACAGCAAGCAGAATGGAGGAG 226: GGACAAGTGTACCAATCATCCGACCAAACCAACTACGTTTACGATGAAGTGTTTCCTGCGCTACCTGAATCAGCC 301: AACCCGGCACCTCACAACGACATCAAAATTTGCAACAACAAAATGCGTGTTGGCTCATCTGTCATCACTCAGGTT 376: TTCCGAGTGCCAGCAGACGAGCGCCGCTACGATCACAACAACAGCTTTGGGGAAAAGGAATCCGTGAGGACCTGC 451: TCTGCCATCATGAAGGAAACTGGAGCAGTCATTGAGATCGCCACGAGCAAGGATATGTCTCTGACTTTCTTGGTG 526: ACTGGAAAGACCGACTCAGTGATGGATGCTCGAAGGAAGATACTGAGCAATTTTCAGACCCAAGCTTCATCCAAG 601: CTCTCTATTCCGAAAGAGCATCACAGGTGGATCCTTGGAAAAGCTGGTGGTCGTCTGAAGGATTTGGAAAAATCA 676: ACAGCCACCAAAATCTCCGTCCCTGGCATAAATGAACACTCGGATGAAATCACTGTGACGGGAACTCGTGAAGGG 751: ATCGACAAGGCCATCCATGAAATGCAAGTnatttcggacgaacaatccaagaagn SEQ ID NO: 5 ilh1c.pk011.m15.f cuticle plus AACCCCCTGATCGCCGGGATCGTTGCCAATCAGTATCACGCTCAGGATGTG 226: CTCGGACAGTACACTTACGGCTACTCCGGAnCCCCATCCGCTAAACAAGAGGTTAAGACTGCTGACGGAATAACG 301: AGAGGATCTTACTCGTACATCGATGGAAACGGGTCTCGTACAGAGCGCTTCTTACGTTGCTGACCCCGTCAACGG 376: GTTCAGAGTCCACGCCACCAACCTGCCCGTGGGACCTGACGGGTCCGTCGCTGCCGCTCCCGTCGCCAGGCTCCT 451: CAGCCCTTTGGCCATCAGCCCTGTGATCAACCTCCACGGCGCTGCTCCCCTCAACCCCGACGGCACCGTCGCTGA 526: CACCCATGAAGTCGCTGTCGCCAAGGCCGCTCACCTCGCTGCCATCAACGAGGCTAGGGCTAGAGGCAAGAGGTC 601: nGCCCCGCTCAACCCCGACGGTACCGTCGCTGACACCCCCGAAGTTGCTGCTGCTAAGTGGGCTCATCTCGCTGA 676: GATCTCCAAAGCTCGTGGAATCCCTCTCGTATACGCTCCCAGATGGTGGGGACCTGGTGCTCCATTGAACGCTGA SEQ ID NO: 6 ilh1c.pk005.d21.f chitin binding plus CCAACATGTATCTCTCAGTTGTTGGATTGGTGATGGCTTCCGCTG 151: CTTTCGTCAGCTGCGAGCCATCGAATTTCGCGTGTACTGGCGAGTCGAACTACAAGTATCCTGTGGAGGGCTCGT 226: GCCACAACTACTACCAGTGCGAAAAGGGCTCCACTACGCCTTCAATTCGAGACTGCTCGCTGCCGCTGCTTCGAT 301: TTCGGGATTTCGATCCAGTCAAATTGGAGTGTGACTGGTGCTGGCGGGTAGACTGTTCAGCCAAACCCGCACCCC 376: CACCGACTCCATCGCCGACTCCGGCGCCAACTTCAAGGCCTACTGCTGCGCCGACTACTGGACCAACCTCAGCGC 451: CCACTACTGGACCCACAGCGGCGCCAACCTCAGCGCCCACTGCTGCACCAACCTCAGCTCCCACTGCTGCTCCAA 526: CTCCAGCGCCCACTGCGCCGCCAACTCCAGCGCCCACTGCGGCGCCAACTCCAGCGCCCACTGCAGCACCAACCT 601: CAGCTCCCACTGCTGCTCCAACTCCAGCGCCTACTGCTGCTCCAACTCCAGCGCCTACTGCTGCGCCAACATCAG 676: CGCCCTCTACTGGACCCACTGTCGCCCCAACTCGCAGGCCAnctcaagaacccacaatggcaaaaaaatcttcga SEQ ID NO: 7 ilh1c.pk011.f4.f chitinase plus CAAATAAGAAACATGAAGATAGTACCGTTCTTAGTTCTTCTACTT 151: GTTCAAACGGTTCTTTCCGAAACGACGCCGGCTTCAAACAATCGCCGTATTGTTTGCTACCACACAAGTTGGAGT 226: GCGTATCGTGTCCCAGAGGCAAAATTTACAGCGAAGAACATCAACCCGTACCTTTGCACTCATTTAATATATTCG 301: TTTGCCAATGTATTGGTAAATGAAGCAACCATCGTTCCTGGTGATGCATGGCAGGATATTGATAACCATCAGTTC 376: AGAGATTTTGTTGAGTTGAAAACCACATTCAACGAAAACCTGAAAACGTTACTCGCAATAGGAGGCTACAGAGAA 451: GGGTCGTCGAAGTTCACCCCTATCGCAGCCACCCCCACGAAAAGGGCAGCGTTTGCTCGCAACACGCTCAAGTTT 526: TTGAAAACTTACGGTTTTGACGGGCTCAACATCGATTGGCAGTTCCCTAACGATCAGCATAGAAATGGCAGTGTT 601: GAAGACTATAAGAACTTTGTGTATTTGCTGCAAGATATCGACAAAGTCTTCAGAGAGGAAGCTGCAGCTTCCGGG 676: AAACCTAAAATGATGTTGACCATTTCCGTTCCGGGTAATACGCTGCTAATAGAAAGTGGCTATGATCTACCAAAT 751: CTAGCGAAGTATGTAGAGTTCATGAACGTCCTGAGCTACGATTACCACTTTGCn SEQ ID NO: 8 ilh1c.pk004.l22.f hormone inducible; JH plus TCCAGTTCTTTAACGAGGTAACCATGTACAAGACTATCTTAC 151: CTGAGTTGGGAGCCTTGGATTTGGGTTTGTGCCCGAAGATGTTCCATGGAGAGGCACATAATGGTAAAAATCCTG 226: AACAAGACATCGTGGTTATTGAAGATTTGTGTCCTCAAGGTTACAAAGTGCCGGAAAAGTTGTTTTTGGACGCTG 301: ATCACTTAGTGATGGCCATGAAAAAAATAGGGCAACTTCACGGATTATCTTATAAAATGAAAGTATCGTCTCCAG 376: AGAGGTTGTTCGAATTGAGGAATATGCTGATCCCGAAGGTGATTGACGATTCGAAAGGTCTCAATGATGCTTGTC 451: TGGCCAGGGGTTTCAAACCCTTGGTGGAGTCGAGCCCCAGTTACAGTGTAGTGAATAAAGTTTACAAGAAACTCG 526: TCGTAGCGGATGCCGTGGATGTTGCCTATAGTTTACAGAAGCCTGAAGAACCATTCGCCGTTATCACCCACGGTG 601: ATTTCAATGGTAATAACATATTGTATAAGTATGATGCCAGTGGAAATGTAGTGGATATGAAAATGATAGATTTTG 676: GTTTCGCTTCTTATTTGGATCCTGCTGTTGACATAGCTTTCTTCCTGTACATGAACTCTTCTCCTGAAACTAGGA 751: AGCTGCACTGGGATTCATTCCTGAATGCATACTGGGAGGGAGTCATCTCTGTTGCTGGTGATCCn SEQ ID NO: 9 ilh1c.pk003.d10.f translation initiation factor Plus CGTGTGCTGATCATTCGATATCCCGGAAACGTGTTTACTTTCCTTTATTG 151: TGCATAAATACACTTCCGTGGCGGTTCGCGATGTCGAATACAAAAGTCGCGTCTTCCGGTCAACCTAAGCTCTCC 226: TCCCAAGATCTTTCGACTCTTGACGTGACGGCGCTTACCCCATTGTCGCCAGAAGTCATCAGTAGACAAGCGACC 301: ATCAATATCGGTACTATTGGTCACGTGGCACATGGGAAagtcnactgtngnngaaagagtgtctggtgttcnaa SEQ ID NO: 10 ilh1c.pk010.d2.f translation initiation factor plus TTTTTGGTTTTCATTGAAAATTTCGATAATTTTCCAAAGTTT 151: TATTATGGTTCAAATTCAAAATGTTTTCTACTGATTTTGATTCTCACAGTATAATTTCGACGTGGAAGTGTTAAG 226: GGCTCAGTGATCGATGGCAGGGAAAGCTTTTTGATAACTATTGGTAAGTCCGAGTTTGTAAGATGACCTCTTTTC 301: AAAAGTGTGTAGGATTTGGTCGGATATTTCCTTTAGGGATTCTCAGAAATCACAATGTTGCATCTCGAAGGTGCA 376: TTCACGGCTCTTCCGTTTTGTACAAAAAGAGGAAAACCAGAGAGGAGAGGAAGTTGCCCAAAGCTATTGTTTACT 451: CTCCCAAATCGAAATGGAAACAAGGCGAGCCCGTTGACGTGTGGAAGCGTATGACAGTGGCGGAGGTAGCAAATA 526: CACTGGGTAAAGATGTAGGACACGTTTTAGAAGTTATGTCGTTCATTGACAACACGGAACAGTACAGAAAAGACC 601: GTGATGTCATCGACAACTTCAAAGTTATAGAAGAAATAGTGAAAAAGTCGGGTCATCGATGTAGGATGGCTAGTA 676: AGCCTACAGAAACTGAAGAAAAAAGTTTTAAAGATGTTGGAcgaagannccttcggattacgttgatcccaggcc SEQ ID NO: 11 ilh1c.pk0l1.h12.f voltage dependent channel Plus TGCCCGAGTGCGTGTTTCGTCAAATAGAAACCCGGGTCTTTTCTGT 151: AAGAATTAAATCGCAATGGCTCCTCCTTTCTACGCTGATCTAGGTAAGAACGCCCGCGATGTCTTCGGTAAAGGG 226: TACCATTTCGGACTCCTGAAGCTCGACGTCAAGACCAAGACTAACACGGGCGTCGAATTCAGCATCGGCGGCGTT 301: CAAAACCTCGAAACCAAAAACGTAGTCGGCTCTCTCGAGACCAAGTACAAATTCAAGGAGTATGGCGTTACTTTC 376: ACGGAGAAATGGAACACTGACAACGTACTGGCCACTGAAATCGCCGTTGCTGATTTCTGCGATGGAGCAAAAATG 451: TCCCTTGACACCTCTTTTATCCCTCACAAGGGTGATAAGACCCTGCGATTGAAGGGCGAATTCAAGAATGACACC 526: TGCGCCATGAACCTTGAAAGCGACTTCAAGTCTGGCGGACCTCTCGTCCGAGGTGGCGCTGTCCTCGGCTACGGA 601: GGCTGGCTATGTGGTTACGCCACGGCCTTCGACGTTAGCAAGAGTAAACTCACCGAAAACAAAGTCACCATGGGA 676: TTCATCACAAAAGATTTCATCTTGAACACCGTTATCAATGACGGAAGAGTCTTCTCTGGTTCCATCTACCACAAA 751: GTTAACAGCAAGTTGGAAACTGGAGTCCAGATCTCGTGGGCCTCTGATAACAACAGCACCGACTTCGGCATCGnc SEQ ID NO: 12 ilh1c.pk002.a24.f voltage dependent channel plus aTTCTGCTTGGGTTTTTTATTTAGTTGAAC 151: AGTTTTCCGTGGACTCTTATGACGATAACTTCCTCATTCCAAATCTTCTTCGGGACTATCCATCATTTTAATCAG 226: AAGTAGAAGCCGACTATTCTAAAAACCACCTATGGGGCCTCCATTCTTCGCGGATCTCGGTAAAAACTCGAGAGA 301: CATCTTCAATAAAGGTTATAATTTCGGGCTGCTTAAGTTGGACATAAAAACCAGAACAGAAACCGGAGTTGAGTT 376: CGAAATCGGTGGAGTCCAGAACCTTGAGACGAAAAATGTAGCCGGCTCGCTCGAGACTAAGTACAAATTCAAGGA 451: CTTCGGGATCAGCTTTTCGGAGAAATGGAATACGGATAATGTTCTTCAGCTAGAAGTAGCTGCTGCTGATATCTG 526: CGAAGGAGTCAAAATGTCCTGCATGAGTATCATGACTCCTTCTTCAGATGAGGAGAAAGGTGGCACTGACAAAAT 601: TTTGAGATTCAAGAGTGAATATAAGAATGCTATCATGGCTGTGAACTTGGAGAGCGATTTCAAAGCTGGTGGTCC 676: GACCTTGGGAGTCTCTGGCGTTTTTGGATTAGGTGGATGGTTGCTCGGAGCTATAGCGGCATTAGATACTGAGAC 751: TTCGAAAGTGATGACCTTCTCTTTGGGAATGGGAnTTTTAACCAAAGACTTCATACTAAACACCGCTGTTATCAA 826: CAAGGGAACAGACTTcann SEQ ID NO: 13 ilh1c.pk009.f20.f EIF-related factor plus CGAAAGCAAACAGGACATCATATTTCGCAGGAATAAATTGGAAGA 151: TCCCATCACACGAGAAAGCAAACCGGACGTCATATTTCGCAGGGTGCGAGGTATCCTCAACAAGCTCACTCCTGA 226: GAAATTCGATAAGCTAAGCGATGACCTCTTGAAAGAAGAATTTAATTCTGATGTCATTCTCAAAGGCGTCATTCT 301: ATTGGTGTTTGAAAAAGCACTAGATGAGCCGAAGTACAGTGCTATGTATGCTCAGCTCTGCCGGCGACTTTGTGA 376: AGAGATCCGAAGTGCCGACCAGCCTGAACCCTGCCCTTTTCGCCATTTGCTTCTGTCCAGCTGCAAAGCTCAGTT 451: TGAGAGCCGTTCGAAGCACACTAGCAGCAAGCGGAAATCGCTCGGGAACATAAAGTTCATCGGAGAGCTTTGCAA 526: ACTTGGAATCCTTCAGCGCGACATCTTGTACAGGTGTTTGATCCAACTTCTCGAACACAAGACCAAGACGCCTGA 601: CGAAATGGCCGAAGATCTTGAGTGCGTCTGTCAGATCCTCCGCACTTGCGGCCACATCTTGGACAACGAGGAAGC 676: TCAGAAGCTGATGAATCAACTTTTTGATCGTATGGCGTCCCTCTCCAAGAACGTCAACCTGCCGATCCGGATCCG 751: CTTCATGCTCCGTGACATTATCGAGCTCCGGAGGGATAACTGGGTTc SEQ ID NO: 14 ilh1c.pk002.d9.f coiled coil helix domain ... CTAACTTTCCTnTTCCGCGTTGTTGCGTTCCTGTGAAATTTCACTAA 151: AATTGTGATTATTTTATTGTACTCAGAACTATACCTACTTCGTATTTCGATTTGAATACATTCCAAGGGCTTTCG 226: CATGACTCAAACTTTCTTCTAGAAGTGGTTTGTTGCGACGTGTTGAGTTCAATAGTGTGGTATTCACAACCGGTT 301: TCGCCCATTGGGCCATCAACGAGTATTTTCCAGGTGATGATCTATTGATATGGGGGGCGTAGCCGCTTCAAGTCC 376: TTTGCCAGACGAAGAACCCCGACCTGAAGCTCCAGGCAGCAGGAAGGCAGACGAAGTACCTGCTGAGAGTGGTCA 451: GAACCCCGCAGGACAACCTCACCCAGATGGCGCCAAGGAAGAAGAGAACGGAGATAACGAGGnAAAGGCCTGGCC 526: TTATAAAAGCCGATGGATCTATAAATTGGGATTGCCCATGTTTGGGAGGGATGGCACATGGGCCCTGTGGCGATG 601: AGTTCAGAGCTGCTTTCTCCTGTTTCCACTATTCCACTGCTGAACAAAAAGGCTCCGACTGTTTggnaaccgttc SEQ ID NO: 15 ilh1c.pk003.j7.f zinc finger domain CACAAAAAGCTCCATACAGGTGAACGCCC 151: TTTCAAATGCGCACACTGCGTTCGGACTTTCAGCCGGAAAGAGCACTTAGTACGGCATGCCCACTCTCATACAGG 226: ACAAAAACTCTTCAACTGCGACGTCTGCGGGAAAAGCTTCAGTCGGAAAGACAACGTACGGAAACACCGGAAAAC 301: GCATGAAACGACAGGTCCGTACTCTTGCGAGTTCTGCGGTATGCAGTTCAACGTTCGGCCGTACTATATAATGCA 376: CAAAAACAAGCACAAAGACGGGTCGTGCGTCCTTGAAGTGAAGAAGGTTGATGTTGAGGAGTCTATCACGTACGA 451: AGnTCAGGAAGAGTCTCCAGATGTTCATTCGAACGAATCCAATTCCTTCCAACAGGTAACATCTAGCACATCCAC 526: TTCAATACTGGAAAAAGCGTTGACGCAAGAAGGCTGAACTTTGGACTTCTTGAATTAACTTTAGGCCAAACTATT 601: ACAGAGTTGACAAGTATGGAGTGTGCTCAGAGGATTAGTTGGTGGAAGTAACTAGTCCAGAAGCTATTCAGAATT 676: AAGAACTAGAATTGAATGCAACAGCAATCAGTTTGCCCTTTCAGTTTGTGGTTTGTTTTTCTGTTGGAAACTATC 751: TCTCGGGCATGAATAAGGAGAATGTGTACCAAGTATTTCAGTCTTCCTCTGCTCTGTGATGTAACTCTGTGCTTC 826: TTTCCTATACTCGCGTTGGTAATCAA SEQ ID NO: 16 ilh1c.pk003.o10.f receptor associated finger AAGAATTGTAAATCAATATCAAAATGGAGATGATGAAGTCAGA 151: TGTCGACTGAAAAGAATGTTTGGATTCCAAGAGATCCAAAAGCTCATTAAATATAACGTAAATACTGTGCTGTCC 226: ATGGACTGGCTTGACCGTAATGCCAAAAACTGTCCGAAATGCAACGnnCCCATTCAGAAAATCAGTGGATGTAAC 301: CATATGGTATGCTGGAAATGCAAAACATCTTTTTGCTGGCACTGCCTATGCTTTACGTGCATAGGATAGTAAGGA 376: CGTGAGATGATCCTGTAGTTACAGCTCTCTTGCCACTGACTACCTAGAAATATCGCACTAGTCATAGTCAGCCAC 451: CCTCCTCTACCTCGCCATTATCTCATTTGGGCTGTGACAAACACAAACCTCGTGTATATCTCGTATACATTACTA 526: TGTACCTTGTTTGCGCTGTGACATCTCAGGAACCCCTTGATATGAAAATTTAAGTGGTAAAAAAACTTTTTTACG 601: ATTCCGaaaaaaaaaaaaaaaaaaaacccnactttatgtacaaagttggcattataagaaagcattgatatca lethal tumorous imaginal discs SEQ ID NO: 17 ilh1c.pk004.b8.f GCCTCTCTTCAAGTTTTTGCGGTGTCGGAATGTCAAATTAAATA 151: ATTGTTCCGATCAAATTAATATGTCTAGCATACGATTTCTTAGAAAATTCAGTGGATTTAGAATCAGTGGTTTCC 226: TAGTAGTGGGGCAGTGTGGTGCGCAGAAAATTTGCAGCTTAGGTCATTTGAAATCTCAAGAGAACTCTAGTTTAC 301: TAAGATTTACCGGTGTTAGTACGAGAAATTTCCATTTGGGAGTGCCATCTCTCGCCAAGAAAGACTACTACGAGA 376: TCTTGGGCATCTCTAGAAACGCGTCGGTCAAGGAAGTGAAAAAAGCGTACTATCAGCTGGCCAAGAAATACCATC 451: CAGACACGAATAAAAnnnnTCCGAACGCCGCCAAGAAGTTTCAAGAAGTATCAGAAGCCTATGAGGTACTGAGTG 526: ACGACACCAAGAGGAAACAATATGATCAATGGGGTACGACGTCGGAGCAGATGGGCCGAGAAGGTGCTGGTACAG 601: GTCCAGGTAACATGGGCGGCTTCAACTGGCAGTACCGGGCTTCCGTGGACCCTCAGGAGCTCTTCAGGAAGATCT 676: TTGGAGACGCTGCAGGCGGATTTTCCACCGGATTCGACGATTTCGCTGAGTCTAGATTCGGTCACGGTGCTGCCG 751: AAGAAATTCTAATGAAACTCACCTTCTCTCAAGCCGTGCGGGGAGTGAGCAAAGAAATATACGTTAATGt SEQ ID NO: 18 ilh1c.pk004.d17.f ribonucleoprotein GATGATCACnTTTACGGCTAATACTCGTAGATCTCCAGTTT 151: CGATACAAATTTGAATTCAACGAGATAACCGAATGAAATGACTTGGAAATCAGCTTAAAAGCAGTGAACTCAGCG 226: GTAGAGGGGAAAATGTCTCACTCCGACTCAAGAACAGGGAAAACCTCCAGAAGTACGAATGAGTCGAAATCAGGA 301: GCCTCGGGGCGACAGAAAACTTCAAGAACTGAGCCGAAAACCCCGAAAACTGAGTCAAAAACCTCGAAGTCAGCG 376: TCGAAAACCTCGAAGTCAGAAGGGAAGTCTGTGTTGTCTGAAAGTAGAGATAAAAGTAATAAATTTTCAAAAAGC 451: GAATCTGAGTCGTATCGCAAGTCCGATGCGAGGGGACAGCGGGACGAGGCACCAGGACCGTCAGACAGCAGAACA 526: GGAAAAGACGTCACTGGGGATAGGAAAACTAAGAAACAGAAAAGTGAGAAAGGGGTCGACGGATCTACTGGAGAA 601: TCGAAGAAACTCCCAGTGTCGTCCTCAAGAACGTCGGAAGCGCCGCGGAACATCCGAGATCTCTTGAGGAGGATC 676: AACGAGGAGAACGAATCTCAGCCAACACCTTCTTCTCGTCTGAAAGAnCCCAAGCCGGAGAGGACGAAGAGTAAA 751: GTTCCATCCAAAGCACCGCAGGCGAGTATTCCAGATAGGGACGTGGTACGAGCAAAAGCTGCGGAAncggccttg SEQ ID NO: 19 ilh1c.pk004.k13.f cathepsin; protease GTTCACCAAGGAAGTATCGCACCACATTCTCTGCCAAAC 151: TACAGCAGGATCCCAAACCACCGGAATGAACACCATTTTGGCTCTCGCAAGTCTGTTGGGCTGCTGTCTGGCGGC 226: GTCCGTTCCGGATTCGAAGTGGGATTCTTTCAAGGCCAAATACGGAAAAACGTACGACGACCCAAAAGTCGATAG 301: TGAGAGACGTAACAACTACGGAAAAACGCTAGAGATGATCAAGGCTCACAACGCACTCTATGGACAGGGCCGGGT 376: GTCCTACTACCTGGCAGAGAACCATCTTGCAGACTTGTCGTCCAGTGAACGAATGAAGTTAAGAGGATTCAGAAA 451: ATCCGAAAGTCAATCGGGCGGCAGAATCCACCAGCACACTGGATTGGGCCGACCCGATTCCGTCGATTGGCGAAA 526: CAAAAGCGTTGTGACCAGCGTCAAAAATCAAGGACAATGTGGTAGCTGCTGGGCTTTCAGTGCGACTGCAGCAGT 601: GGAATCGCAATACGCTATCAAAACCGGGCAATTAGTGGATCTCAGCGAGCAGCAGGTAGTGGACTGTGACCGTAA 676: TGGTCACGCTTGCAAGTATGGTGACAACCTTGACGCGTTAGGGTATATCGAGGAAGAAGGTCAGGAGCTTCTTTC 751: CTCTTATCCCTACATTGCTGAGCCAGAGACTTGTCAATACGCAGCAGATAAAGTGAAGGTGAAGATTGCGAGTTT 826: CCnn SEQ ID NO: 20 ilh1c.pk011.a8.f polyprotein deformed destructor GTCTTAAGTGATGAAGATGTTGTGTTAGGTTTACCGGG 151: CGTGCCAGGATACCATGCTATGGAAATGGCAACGTCTGAAGGTTTTCCTTTCACAGCAAGTCGACCACAAGGAAG 226: TTCCAATAAGCGGTGGTTGTTTAACATCAATGAGAATGCCGAGAAGAGATCCTTAATCGCCATGGACCCCTTATT 301: GGTGAAAGTGTTAGAATCGAAGAGGGTTCAGAGAGATCGAGGGTTGATTCCGTGTACCGTTTTTGTAGACTGCTT 376: GAAGGATTCACGAATAGCGAATGAATCTTACCTCACACCCGGTAAGACTAGGATCTTCTCTATCTCACCGGTTGA 451: CTTTACGATTGAGTTTCGGAAGTATTTCCTTGATATCCTAGCGGCGCAACAACAAAGTCGATTCCACCTAGAGCA 526: TATGGTAGGTATGAATGTTCATTCGCTTGAGTGGACTTTACTAGCCCGCCGTATCCAATCTGTGGGTTCTGCAGT 601: GATCTGTGGTGATTACTCGAACTTTGGTCCTGGTTTGGATAGCGAAGTTGTTGCAGCTGTTGGGGACGTTTGGGC 676: TGATTGGTATGAGTTTTACGAGACCGCTCAGGGCGTCTCGGAAGAGGAGAGAAAGCGACGCCgccnaagtaagaa SEQ ID NO: 21 ilh1c.pk011.d10.f death associated leucine rich ... CATGGCGTACGGTGTAACAAGAGTCGTGTTCCGCTGCGAGGAAGCT 151: CAGGAATCCGGAnAATTGGATCTGTCGGAATGTCAACTCATGCAGGTGCCGGACGCGGTCTACCACTTGATGAGG 226: CACACGGAACTGAAGGCGTGTAATCTCTCAAGCAACGTCATCACCAAAATTCCCCCGAAATTCGCGGTCAACTTT 301: TCTCTCATTACAGAGCTGAACCTGGCGCACAACCAGATGAGCAAACTCCCGGACGAGCTCGCCG

TABLE 2 Summary of homology for the target nucleotides. Lygus target sequences: Homology ilh1c.pk005.o10.f blastx: melanogaster; drosophila; modulatory; potassium; channel; isoform; sapiens; homo; rerio; danio; anopheles; musculus; gambiae; pe . . . blastn: melanogaster; drosophila; isoform; full; insert; 85c-85c; bac; gambiae; str; pest; section; anopheles; length ilh1c.pk004.e6.f blastx: drosophila; melanogaster; anopheles; gambiae; pest; cuticle; str; pseudoobscura; a3a; tm-lcp; tm-a3a; larval; cuticular; tenebri . . . blastn: melanogaster; drosophila; length; section; full; bac; 92e-92f ilh1c.pk001.e23.f blastx: drosophila; melanogaster; pseudoobscura; anopheles; gambiae; buzzatii; pest; str; mellifera; predicted; cuticle; apis; a3a; dbuz . . . blastn: musculus; mus; bac; library; mouse; r.norvegicus; roswell; institute; hippocampus; product:hypothetical; female; containing; can . . . ilh1c.pk010.f11.f blastx: glycoprotein; endocuticle; structural; drosophila; anopheles; gambiae; melanogaster; pseudoobscura; pest; str; mori; bombyx; cut . . . blastn: melanogaster; drosophila; cuticle; larval; lcp-14; m.sexta; constituent; asap; sexta; gambiae; bombyx; lcp17; subalbatus; mori; . . . ilh1c.pk011.m15.f blastx: anopheles; gambiae; pest; cuticle; str; melanogaster; drosophila; lm-acp; isoform; tm-lcp; larval; a1a; a3a; tm-a3a; tm-a1a; mel . . . blastn: anopheles; gambiae; melanogaster; drosophila; pest; str; ccp84ab; cuticle; ccp84ad; ccp84ag; full; insert ilh1c.pk005.d21.f blastx: branchiostoma; region-containing; floridae; variable; chitin-binding blastn: cultivar-group; japonica; sativa; oryza; predicted; mucin; insert; full; collagen; norvegicus; discoideum; alpha; dictyostelium; . . . ilh1c.pk011.f4.f blastx: danio; rerio; predicted; melanogaster; anopheles; drosophila; gambiae; chitinase; isoform; acidic; pest; str; paralichthys; oliv . . . blastn: chitinase; predicted; rerio; danio; acidic; transcript; taurus; variant; bos; sapiens; b04; homo; chia; mammalian; chitotriosida . . . ilh1c.pk004.a13.f blastx: carboxylesterase; gossypii; esterase; aphis; carboxylic-ester; hydrolase; persicae; myzus; fe4; lygus; juvenile; polyphemus; ant . . . blastn: carboxylesterase; anisopteromalus; melanogaster; calandrae; drosophila; esterase; mellifera; apis; antheraea; est; malathion-sus . . . ilh1c.pk004.i18.f blastx: esterase; tribolium; castaneum; mellifera; juvenile; carboxylic-ester; carboxylesterase; hormone; hydrolase; apis; persicae; myz . . . blastn: carboxylesterase; esterase; anisopteromalus; m.persicae; calandrae; anopheles; gambiae; pest; est1; str; mellifera; desago; pred . . . ilh1c.pk004.l22.f blastx: anopheles; gambiae; drosophila; melanogaster; pest; str; pseudoobscura; hormone-inducible; juvenile blastn: ilh1c.pk005.k23.f blastx: esterase; tribolium; castaneum; melanogaster; anopheles; drosophila; gambiae; carboxylesterase; pest; athalia; str; juvenile; ro . . . blastn: ilh1c.pk010.g16.f blastx: melanogaster; drosophila; anopheles; gambiae; pest; str; jhi-26; juvenile; yakuba; pseudoobscura; hormone-inducible blastn: ilh1c.pk002.d16.f blastx: vitellogenin; plautia; stali; mellifera; apis; nipponica; pimpla; clavatus; encarsia; gambiae; vitellogenin-1; vitellogenin-3; v . . . blastn: vitellogenin; plautia; aedes; aegypti; stali; vg-b; dictyostelium; discoideum; vga1; vtg; athalia; periplaneta; formosa; rosae; . . . ilh1c.pk001.f1.f blastx: vitellogenin; anopheles; gambiae; pest; str; molitor; encarsia; nigrofuscata; toxorhynchites; graptopsaltria; quinquefasciatus; . . . blastn: vitellogenin; aedes; vg-c; aegypti; polynesiensis; vitellogenin-c; graptopsaltria; nigrofuscata ilh1c.pk005.f15.f blastx: vitellogenin; plautia; stali; anopheles; vitellogenin-2; periplaneta; gambiae; mellifera; americana; apis; pest; str; pimpla; cl . . . blastn: vitellogenin; quinquefasciatus; dictyostelium; phragmatopoma; californica; discoideum; variant; pipiens; cement; oreochromis; cu . . . ilh1c.pk003.d10.f blastx: translation; initiation; eukaryotic; gamma; structural; predicted; x-linked; musculus; gallus; unnamed; leptinotarsa; decemlinea . . . blastn: translation; initiation; eukaryotic; structural; musculus; x-linked; product:eukaryotic; full-length; enriched; mus; library; in . . . ilh1c.pk010.d2.f blastx: melanogaster; drosophila; anopheles; gambiae; initiation; pest; str; translation; mellifera; gallus; apis; predicted; translatio . . . blastn: ilh1c.pk011.g22.f blastx: elongation; translation; eukaryotic; beta; anopheles; gambiae; sapiens; synthetic; rerio; danio; pest; homo; str; construct; gal . . . blastn: anopheles; gambiae; elongation; translation; eukaryotic; full-length; extremity; mosquito; beta; malaria; females; african; sing . . . ilh1c.pk011.h12.f blastx: voltage-dependent; channel; mitochondrial; melanogaster; drosophila; anopheles; porin; anion-selective; anion; gambiae; gallus; . . . blastn: anopheles; gambiae; full-length; extremity; mosquito; malaria; females; african; 5-prime; single; adult; total; read; made; mito . . . ilh1c.pk001.k13.f blastx: mannose-6-phosphate; isomerase; phosphomannose; phosphohexomutase; arabidopsis; schizosaccharomyces; thaliana; cultivar-group; n . . . blastn: predicted; isomerase; glabrata; candida; bar1; related; other; japonicum; pmi40; inp51; vid28; yarrowia; neurospora; mellifera; . . . ilh1c.pk001.k16.f blastx: predicted; cytoplasmic; poly(a)-binding; polyadenylate; structure; strongylocentrotus; crystal; isoform; poly(a; x-ray; purpurat . . . blastn: inducible; cytoplasmic; sapiens; gallus; poly(a; homo; form; finished; pabpc4; aedes; polya; asap; aegypti; predicted; human; tr . . . ilh1c.pk001.l22.f blastx: proteasome; non-atpase; drosophila; musculus; melanogaster; unnamed; isoform; macropain; 26s; mus; prosome; predicted; danio; re . . . blastn: anopheles; gambiae; full-length; extremity; proteasome; non-atpase; mosquito; females; african; malaria; single; macropain; adul . . . ilh1c.pk001.l4.f blastx: blastn: sativa; oryza; glycine-rich; scapularis; rna-binding; japonica; ixodes; cultivar-group; nipponbare; trospa; cultivar; monsanto; . . . ilh1c.pk001.m15.f blastx: glutathione; s-transferase; anopheles; drosophila; melanogaster; gambiae; class-sigma; isoform; pest; allergen; str; gst; bla; s . . . blastn: melanogaster; drosophila; glutathione; isoform; gsts1; aegypti; insert; aedes; full; extremity; glutathione-s-transferase; blatt . . . ilh1c.pk001.m17.f blastx: drosophila; melanogaster; isoform; aegypti; aedes; pseudoobscura; cg118; apis; mellifera; rna-binding; predicted blastn: isoform; melanogaster; drosophila; vig; insert; predicted; full; mrnabp; aedes; asap; conserved; ciona; aegypti; mellifera; i29m . . . ilh1c.pk001.n23.f blastx: predicted; ankyrin; domain; repeat; sapiens; musculus; unnamed; isoform; homo; dictyostelium; mus; discoideum; taurus; bos; schi . . . blastn: domain; strongylocentrotus; repeat; purpuratus; ankyrin; predicted;; ilh1c.pk001.n6.f blastx: melanogaster; drosophila; reticulum-type; sarco(endo)plasmic; isoform; atpase; predicted; calcium; mellifera; anopheles; gambiae . . . blastn: sarco(endo)plasmic; reticulum-type; calcium; atpase; melanogaster; mellifera; predicted; drosophila; xenopus; ca-p60a; isoform; . . . ilh1c.pk001.o17.f blastx: melanogaster; drosophila; dyskerin; musculus; isoform; predicted; gallus; ribonucleoprotein; mus; danio; rerio; anopheles; nucle . . . blastn: melanogaster; drosophila; nop60b; lipolytica; nucleolar; yarrowia; predicted; dyskerin; isoform; clib99; purpuratus; danio; ribo . . . ilh1c.pk001.o4.f blastx: drosophila; dehydrogenase; ubiquinone; melanogaster; subcomplex; nadh; beta; anopheles; musculus; unnamed; gambiae; predicted; 1 . . . blastn: full-length; nigroviridis; dehydrogenase; tetraodon; ubiquinone; subcomplex; nadh; beta; asap; musculus; product:nadh; danio; re . . . ilh1c.pk002.a11.f blastx: melanogaster; drosophila; anopheles; sapiens; gambiae; interacting; homo; pest; str; dna-damage-inducible; gadd45gip1; papilloma . . . blastn: ilh1c.pk002.a24.f blastx: voltage-dependent; channel; drosophila; melanogaster; mitochondrial; anion; isoform; porin; sapiens; familiaris; predicted; homo . . . blastn: nigroviridis; voltage-dependent; full-length; rerio; danio; tetraodon; mitochondrial; channel; anion; tropicalis; xenopus; porin . . . ilh1c.pk002.b12.f blastx: drosophila; melanogaster; aminopeptidase-like; anopheles; pseudoobscura; gambiae; bombyx; leucyl; pest; mori; str; simulans blastn: tropicalis; xenopus; aminopeptidase; leucine; gambiae; str; lap3-prov; finished; pest; anopheles ilh1c.pk003.n7.f blastx: kynurenine; aminotransferase; drosophila; melanogaster; aegypti; isoform; aedes; transaminase; aminotrasferase; anopheles; tropi . . . blastn: melanogaster; drosophila; isoform; anopheles; gambiae; insert; full; single; fk0aaa5bf12; total; kynurenine; nuclear; ciona; ext . . . ilh1c.pk003.p4.f blastx: drosophila; melanogaster; tripeptidyl-peptidase; tripeptidyl; isoform; pseudoobscura; aminopeptidase; peptidase; anopheles; pred . . . blastn: tripeptidyl; peptidase; musculus; product:tripeptidyl; sapiens; full-length; enriched; mus; library; homo; insert; predicted; ri . . . ilh1c.pk004.c13.f blastx: aminomethyltransferase; cleavage; glycine; system; drosophila; melanogaster; t-protein; structure; mitochondrial; crystal; rerio . . . blastn: aminomethyltransferase; mitochondrial; predicted; norvegicus; cleavage; glycine; rattus; system; debaryomyces; gcvt; hansenii; c . . . ilh1c.pk004.i5.f blastx: amino-acid; predicted; synthesis; control; general; 1-like; musculus; gcn1; sapiens; homo; unnamed; mus; canis; mellifera; famil . . . blastn: ilh1c.pk001.d8.f blastx: drosophila; melanogaster; pseudoobscura; isoform; anopheles; gambiae; pest; str; simulans blastn: melanogaster; drosophila; aminopeptidase; sapiens; full-length; homo; full; human; length; leucine; fetal; 25-normalized; cs0df0 . . . ilh1c.pk001.e10.f blastx: e1a-stimulated; cellular; repressor; sapiens; unnamed; musculus; homo; mus; predicted; anopheles; gambiae; danio; rerio; gallus; . . . blastn: product:hypothetical; aminoacyl-transfer; musculus; full-length; synthetases; enriched; containing; library; e1a-stimulated; ins . . . ilh1c.pk001.i10.f blastx: aminopeptidase; musculus; melanogaster; drosophila; unnamed; mus; dictyostelium; membrane-bound; lycopersicon; discoideum; escul . . . blastn: aminopeptidase; musculus; membrane-bound; full-length; enriched; mus; library; insert; product:membrane-bound; riken; full; lyco . . . ilh1c.pk010.p16.f blastx: aminotransferase; phosphoserine; musculus; unnamed; sapiens; mus; isoform; homo; synthetic; construct; mellifera; xenopus; rattu . . . blastn: product:phosphoserine; aminotransferase; full-length; musculus; yersinia; enriched; library; insert; pestis; riken; blastocyst; . . . ilh1c.pk003.k14.f blastx: carboxypeptidase; vitellogenic-like; sapiens; serine; homo; carboxypeptidase-like; predicted; cpvl; vitellogenic; canis; mellife . . . blastn: full-length; 25-normalized; sapiens; placenta; carboxypeptidase; human; homo; cot; aegypti; aedes; troglodytes; vitellogenic; se . . . ilh1c.pk004.a13.f blastx: carboxylesterase; gossypii; esterase; aphis; carboxylic-ester; hydrolase; persicae; myzus; fe4; lygus; juvenile; polyphemus; ant . . . blastn: carboxylesterase; anisopteromalus; melanogaster; calandrae; drosophila; esterase; mellifera; apis; antheraea; est; malathion-sus . . . ilh1c.pk001.b20.f blastx: glycine; decarboxylase; decarboxylating; dehydrogenase; cleavage; melanogaster; system; drosophila; sapiens; mitochondrial; homo . . . blastn: glycine; decarboxylase; melanogaster; drosophila; decarboxylating; mitochondrial; dehydrogenase; cleavage; musculus; product:gly . . . ilh1c.pk004.i18.f blastx: esterase; tribolium; castaneum; mellifera; juvenile; carboxylic-ester; carboxylesterase; hormone; hydrolase; apis; persicae; myz . . . blastn: carboxylesterase; esterase; anisopteromalus; m.persicae; calandrae; anopheles; gambiae; pest; est1; str; mellifera; desago; pred . . . ilh1c.pk004.o2.f blastx: carboxypeptidase; vitellogenic-like; sapiens; vitellogenic; serine; homo; carboxypeptidase-like; cpvl; predicted; canis; pygmaeu . . . blastn: carboxypeptidase; anopheles; gambiae; vitellogenic; carboxypeptidase- like; full-length; vitellogenic-like; extremity; mosquito; . . . ilh1c.pk005.m3.f blastx: proteolipid; vacuolar; drosophila; synthase; melanogaster; anopheles; isoform; gambiae; kda; atp; pest; mellifera; str; c-subuni . . . blastn: anopheles; gambiae; full-length; extremity; mosquito; malaria; african; 5- prime; females; single; total; adult; made; read; vacu . . . ilh1c.pk002.o3.f blastx: ubiquitin-specific; ubiquitin; protease; carboxyl-terminal; thiolesterase; herpesvirus; associated; n-terminal; hydrolase; usp7h . . . blastn: ubiquitin-specific; protease; ubiquitin; predicted; specific; herpesvirus; associated; musculus; hausp; virus-associated; norveg . . . ilh1c.pk003.h22.f blastx: pyrophosphatase; musculus; dutp; deoxyuridine; unnamed; triphosphatase; dutpase; human; nucleotidohydrolase; mus; norvegicus; st . . . blastn: musculus; full-length; enriched; mus; product:dutpase; triphosphatase; library; insert; riken; full; deoxyuridine; days; dutpase . . . ilh1c.pk003.i6.f blastx: inosine-uridine; nucleoside; hydrolase; preferring; cultivar-group; japonica; sativa; xenopus; oryza; schizosaccharomyces; laevi . . . blastn: staphylococcus; aureus; subsp; tropicalis; xenopus; mw2; n315; mu50; finished; strain:mw2; mrsa252; mssa476; col ilh1c.pk004.a13.f blastx: carboxylesterase; gossypii; esterase; aphis; carboxylic-ester; hydrolase; persicae; myzus; fe4; lygus; juvenile; polyphemus; ant . . . blastn: carboxylesterase; anisopteromalus; melanogaster; calandrae; drosophila; esterase; mellifera; apis; antheraea; est; malathion-sus . . . ilh1c.pk003.g17.f blastx: drosophila; melanogaster; acetyltransferase; choline; anopheles; gambiae; isoform; sapiens; danio; rerio; predicted; structure; . . . blastn: ilh1c.pk009.k12.f blastx: drosophila; initiation; melanogaster; translation; eukaryotic; predicted; anopheles; gambiae; taurus; pest; danio; rerio; str; b . . . blastn: melanogaster; drosophila; translation; eukaryotic; initiation; tropicalis; xenopus; 110 kda; rerio; danio; gambiae; eif3s8-prov; . . . ilh1c.pk009.f20.f blastx: eif4g-related; danio; rerio; predicted; nat1b; isoform; xenopus; translation; initiation; eukaryotic; tropicalis; gallus; gamma; . . . blastn: melanogaster; drosophila; eif4g-related; predicted; isoform; xenopus; laevis; nat1; translation; mellifera; 49e-49f; full; eukar . . . ilh1c.pk008.o12.f blastx: translationally; translationally-controlled; controlled; drosophila; tumor; melanogaster; mellifera; predicted; anopheles; tctp; . . . blastn: drosophila; melanogaster; translationally; controlled; anopheles; gambiae; tumor; tctp; lonomia; bombyx; xylostella; african; in . . . ilh1c.pk008.k5.f blastx: elongation; rhodopseudomonas; palustris; translation; bradyrhizobium; melanogaster; gtp-binding; drosophila; tu:small; domain; m . . . blastn: melanogaster; drosophila; elongation; insert; rerio; danio; full; brevipalpis; asap; gambiae; translation; wigglesworthia; marit . . . ilh1c.pk008.c24.f blastx: translation; eukaryotic; initiation; interacting; sapiens; melanogaster; drosophila; homo; predicted; familiaris; isoform; varia . . . blastn: full-length; 25-normalized; sapiens; human; placenta; homo; cot; interacting; translation; eukaryotic; initiation; danio; rerio; . . . ilh1c.pk008.b15.f blastx: melanogaster; musculus; drosophila; predicted; unnamed; anopheles; translation; mus; gambiae; sapiens; pest; riken; rerio; danio . . . blastn: sapiens; melanogaster; drosophila; homo; translation; danio; rerio; et16; fis; length; taurus; bos; spliced; alternatively; tran . . . ilh1c.pk007.p11.f blastx: translation; initiation; eukaryotic; drosophila; melanogaster; anopheles; gambiae; bombyx; eif-5a; pest; spodoptera; danio; reri . . . blastn: initiation; translation; eukaryotic; arabidopsis; thaliana; bombyx; eif5a; mori; rerio; danio; eif-5a; 5a-4; gsltsil10za11; thal . . . ilh1c.pk003.d10.f blastx: translation; initiation; eukaryotic; gamma; structural; predicted; x-linked; musculus; gallus; unnamed; leptinotarsa; decemlinea . . . blastn: translation; initiation; eukaryotic; structural; musculus; x-linked; product: eukaryotic; full-length; enriched; mus; library; in . . . blastn: domain; strongylocentrotus; repeat; purpuratus; ankyrin; predicted; schistosoma; japonicum blastn: sarco(endo)plasmic; reticulum-type; calcium; atpase; melanogaster; mellifera; predicted; drosophila; xenopus; ca-p60a; isoform; . . . ilh1c.pk002.d16.f blastx: vitellogenin; plautia; stali; mellifera; apis; nipponica; pimpla; clavatus; encarsia; gambiae; vitellogenin-1; vitellogenin-3; v . . . blastn: vitellogenin; plautia; aedes; aegypti; stali; vg-b; dictyostelium; discoideum; vga1; vtg; athalia; periplaneta; formosa; rosae; . . . ilh1c.pk002.d9.f blastx: coiled-coil-helix-coiled-coil-helix; containing; predicted; domain; sapiens; musculus; homo; chchd4; anopheles; norvegicus; gamb . . . blastn: coiled-coil-helix-coiled-coil-helix; containing; predicted; domain; gallus; norvegicus; rattus; rerio; danio; chchd4; musculus; . . . ilh1c.pk002.j6.f blastx: transmembrane; predicted; sapiens; tropicalis; homo; xenopus; musculus; gallus; norvegicus; mus; rattus; danio; canis; rerio; te . . . blastn: ilh1c.pk002.k17.f blastx: proteasome; drosophila; regulatory; melanogaster; isoform; musculus; non-atpase; 26s; unnamed; predicted; mus; anopheles; gambia . . . blastn: proteasome; regulatory; melanogaster; drosophila; predicted; 26s; anopheles; transcript; non-atpase; gambiae; isoform; variant; . . . ilh1c.pk002.k5.f blastx: nucleoporin; sapiens; homo; predicted; unnamed; 54 kda; familiaris; p54; variant; isoform; kda; canis; musculus; macaca; apis; fa . . . blastn: nucleoporin; product: nucleoporin; full-length; musculus; enriched; norvegicus; library; insert; riken; rattus; mus; full; macrop . . . ilh1c.pk002.m21.f blastx: rapamycin-insensitive; predicted; companion; sapiens; musculus; mtor; homo; insensitive; pianissimo; rapamycin; mus; rictor; gal . . . blastn: ilh1c.pk002.n11.f blastx: melanogaster; drosophila; 6-phosphofructo-2-kinase; isoform; 2,6- bisphosphatase; fructose-2,6-biphosphatase; predicted; fructose . . . blastn: melanogaster; drosophila; isoform; pfrx; fructose; long; full; form; insert; 6-phosphofructo; str; 2-kinase; pest; 2,6-bisphosph . . . ilh1c.pk003.d10.f blastx: translation; initiation; eukaryotic; gamma; structural; predicted; x-linked; musculus; gallus; unnamed; leptinotarsa; decemlinea . . . blastn: translation; initiation; eukaryotic; structural; musculus; x-linked; product: eukaryotic; full-length; enriched; mus; library; in . . . ilh1c.pk003.d17.f blastx: mitochondrial; translocase; membrane; inner; predicted; import; melanogaster; musculus; drosophila; anopheles; isoform; tim9; ga . . . blastn: nigroviridis; full-length; tetraodon; mitochondrial; translocase; membrane; gallus; tim9a; inner; gambiae; purpuratus; danio; fi . . . ilh1c.pk003.h22.f blastx: pyrophosphatase; musculus; dutp; deoxyuridine; unnamed; triphosphatase; dutpase; human; nucleotidohydrolase; mus; norvegicus; st . . . blastn: musculus; full-length; enriched; mus; product: dutpase; triphosphatase; library; insert; riken; full; deoxyuridine; days; dutpase . . . ilh1c.pk003.j5.f blastx: benzodiazepine; receptor; peripheral-type; benzodiazapine; peripheral; sapiens; musculus; homo; construct; synthetic; unnamed; m . . . blastn: ilh1c.pk003.j7.f blastx: finger; melanogaster; zinc; drosophila; musculus; sapiens; predicted; ozf; pygmaeus; homo; mus; pongo; unnamed; taurus; bos; imp . . . blastn: sapiens; finger; zinc; homo; predicted; highly; gallus; anopheles; fis; rerio; danio; gambiae; pest; str; zscan2; 75a; variant; . . . ilh1c.pk003.l11.f blastx: transmembrane; inducible; musculus; hormone; growth; gallus; unnamed; mus; norvegicus; anopheles; pygmaeus; xenopus; gambiae; ra . . . blastn: transmembrane; product: growth; musculus; inducible; full-length; hormone; enriched; library; insert; riken; mus; full; growth; o . . . ilh1c.pk003.l18.f blastx: ubiquitin; polyubiquitin; musculus; isoform; familiaris; mus; predicted; sapiens; taurus; canis; homo; bos; caballus; schistosom . . . blastn: polyubiquitin; norvegicus; rattus; ubiquitin; taeniopygia; variant; guttata; 7-like; pub; trifallax; ubiquitins; ttu3; sterkiell . . . ilh1c.pk003.o10.f blastx: receptor-associated; finger; androgen; predicted; triad2; ring; musculus; caenorhabditis; hfb30; isoform; unnamed; mus; taurus; . . . blastn: ubiquitin-conjugating; rerio; danio; ariadne; predicted ilh1c.pk004.b8.f blastx: melanogaster; drosophila; lethal(2)tumorous; isoform; imaginal; discs; tid56; mitochondrial; tumorous; l(2)tid; tid58; tid50; br . . . blastn: musculus; full-length; subfamily; anopheles; product: dnaj; member; gambiae; mus; hsp40; enriched; adult; library; alternatively; . . . ilh1c.pk004.d17.f blastx: nucleolar; cerevisiae; assembly; polymerase; laevis; function; suppressor; ac40; srp40p; purpuratus; snornps; ribonucleoprotein; . . . blastn: ilh1c.pk004.e16.f blastx: disrupted; disorder; musculus; drosophila; bipolar; predicted; melanogaster; unnamed; mus; familiaris; isoform; canis; asparagin . . . blastn: musculus; disorder; disrupted; bipolar; full-length; sapiens; enriched; homo; library; mus; predicted; human; insert; asparagine . . . ilh1c.pk004.g2.f blastx: benzodiazepine; receptor; peripheral-type; musculus; mitochondrial; unnamed; mus; peripheral; isoquinoline-binding; pkbs; pbr; t . . . blastn: ilh1c.pk004.k13.f blastx: cathepsin; proteinase; cysteine; l-like; sapiens; scrofa; homo; heterodera; glutinosa; globodera; glycines; pallida; sus; myxine . . . blastn: cysteine; decemlineata; leptinotarsa; proteinase; intestain; digestive; cathepsin; sapiens; h.americanus; preproenzyme; homo; vi . . . ilh1c.pk004.m4.f blastx: unc-51-like; sapiens; kinase; predicted; musculus; homo; isoform; unnamed; gallus; taurus; mus; ulk3; bos; xenopus; mellifera; l . . . blastn: melanogaster; drosophila; musculus; predicted; product: hypothetical; kinase; insert; full; full-length; unc-51-like; containing; . . . ilh1c.pk005.a7.f blastx: cathepsin; caenorhabditis; rerio; danio; elegans; procathepsin; tuberaphis; b-s; rat; olivaceus; fundulus; heteroclitus; paralic . . . blastn: full-length; sapiens; homo; human; 25-normalized; placenta; construct; synthetic; cathepsin; cot; ctsb; jurkat; brain; cells; ce . . . ilh1c.pk005.h9.f blastx: nucleolar; snornp-associated; interacting; small; predicted; ribonucleoproptein-associated; 55-kda; musculus; sapiens; rerio; da . . . blastn: ilh1c.pk005.i1.f blastx: melanogaster; drosophila; adenosine; deaminase; rna-specific; double- stranded; isoform; pre-mrna; editing; purpuratus; that; pre . . . blastn: ilh1c.pk005.i10.f blastx: taurus; precystatin; bos; cystatin; hemorrhage; angiopathy; bovine; unnamed; cerebral; amyloid blastn: ilh1c.pk005.i12.f blastx: polyphosphate; anopheles; multikinase; drosophila; inositol; melanogaster; gambiae; pest; musculus; str; predicted; mus; canis; . . . blastn: melanogaster; drosophila; 21d-21e; insert; section; full; ipk2; bac ilh1c.pk005.i15.f blastx: cytochrome; melanogaster; drosophila; periplaneta; fuliginosa; migratoria; dimidiata; triatoma; locusta; caretta; quadriocellata . . . blastn: mitochondrial; cytochrome; blackburnia; cytb; isolate; gerris; insularis; gracilicornis; jk041; jk042; jk045; migratoria; latiab . . . ilh1c.pk005.i16.f blastx: domain-containing; sapiens; dnaj; homo; novel; subfamily; anopheles; norvegicus; hsp40; predicted; gambiae; gallus; rattus; memb . . . blastn: dnaj-1; drosophila; nigroviridis; full-length; tetraodon; predicted; prokaryotic; norvegicus; simulans; domain; rerio; danio; sh . . . ilh1c.pk005.m3.f blastx: proteolipid; vacuolar; drosophila; synthase; melanogaster; anopheles; isoform; gambiae; kda; atp; pest; mellifera; str; c-subuni . . . blastn: anopheles; gambiae; full-length; extremity; mosquito; malaria; african; 5- prime; females; single; total; adult; made; read; vacu . . . ilh1c.pk005.o17.f blastx: cathepsin; rerio; danio; virgifera; b-like; protease; ventricosus; branchiostoma; olivaceus; paralichthys; parcxpwnx02; lugens; . . . blastn: product: cathepsin; full-length; enriched; musculus; library; insert; riken; full; cathepsin; mus; macrophage; synthetic; constru . . . ilh1c.pk006.c6.f blastx: vesicle-associated; membrane; vamp-associated; protein-associated; predicted; tropicalis; xenopus; associated; rerio; danio; iso . . . blastn: ilh1c.pk006.f2.f blastx: receptor-associated; finger; predicted; isoform; ring; sapiens; androgen; unnamed; homo; xenopus; nigroviridis; triad2; rnf14-pr . . . blastn: ilh1c.pk007.a8.f blastx: membrane-associated; finger; drosophila; melanogaster; ring; gallus; musculus; c3hc4; predicted; anopheles; gambiae; taurus; mus . . . blastn: ciona; full; insert; intestinalis ilh1c.pk007.b21.f blastx: phosphoprotein; golgi-localized; golgi; predicted; calcium-binding; musculus; isoform; familiaris; membrane; mus; gallus; anophe . . . blastn: ilh1c.pk007.g16.f blastx: burkholderia; pseudomallei; membrane; outer; mallei; hep_hag; family; atcc; s13; exported; autotransporter; adhesin blastn: musculus; mus; bac; linkage; group; mouse; zebrafish ilh1c.pk007.j24.f blastx: vitellogenin; plautia; stali; cynthia; mellifera; samia; apis; clavatus; japonica; molitor; encarsia; nigrofuscata; saturnia; an . . . blastn: ilh1c.pk007.o17.f blastx: beta-galactosidase; galactosidase; familiaris; lysosomal; drosophila; anopheles; canis; gambiae; melanogaster; beta; pest; fasci . . . blastn: ilh1c.pk007.p11.f blastx: translation; initiation; eukaryotic; drosophila; melanogaster; anopheles; gambiae; bombyx; eif-5a; pest; spodoptera; danio; reri . . . blastn: initiation; translation; eukaryotic; arabidopsis; thaliana; bombyx; eif5a; mori; rerio; danio; eif-5a; 5a-4; gsltsil10za11; thal . . . ilh1c.pk007.p13.f blastx: finger; predicted; sapiens; zinc; homo; musculus; unnamed; gallus; mus; troglodytes; taurus; human; containing; bos; pan blastn: ilh1c.pk008.c24.f blastx: translation; eukaryotic; initiation; interacting; sapiens; melanogaster; drosophila; homo; predicted; familiaris; isoform; varia . . . blastn: full-length; 25-normalized; sapiens; human; placenta; homo; cot; interacting; translation; eukaryotic; initiation; danio; rerio; . . . ilh1c.pk008.f16.f blastx: carboxypeptidase; melanogaster; drosophila; ochlerotatus; aedes; anopheles; gambiae; aegypti; pest; str; fluid; polynesiensis; c . . . blastn: carboxypeptidase; bombyx; fluid; mf-cpa; mori; molting; cpb-i; ochlerotatus; triseriatus ilh1c.pk008.h14.f blastx: signalosome; cop9; musculus; predicted; isoform; mus; photomorphogenic; complex; xenopus; constitutive; arabidopsis; norvegicus; . . . blastn: predicted; photomorphogenic; constitutive; arabidopsis; norvegicus; thaliana; rattus; cop9; mellifera; cops8_predicted; apis ilh1c.pk008.j3.f blastx: receptor; benzodiazepine; benzodiazapine; peripheral; musculus; peripheral-type; unnamed; synthetic; construct; mus; sapiens; mi . . . blastn: anopheles; gambiae; full-length; extremity; mosquito; african; malaria; females; single; total; adult; read; made; fk0aaa40cb05; . . . ilh1c.pk008.k6.f blastx: predicted; upstream; element; musculus; fuse; isoform; far; anopheles; gambiae; unnamed; mus; taurus; rerio; danio; pest; str; b . . . blastn: musculus; regulatory; splicing; library; full-length; enriched; mus; product: kh-type; insert; kh-type; riken; norvegicus; full; . . . ilh1c.pk009.d7.f blastx: transcriptional; transcription; repressor; potential; isoform; sapiens; ccr4- not; complex; predicted; not4hp; homo; ccr4-associa . . . blastn: melanogaster; drosophila; isoform; mellifera; predicted; apis; homo; not4- n; insert; not4-np; full; sapiens ilh1c.pk009.f20.f blastx: eif4g-related; danio; rerio; predicted; nat1b; isoform; xenopus; translation; initiation; eukaryotic; tropicalis; gallus; gamma; . . . blastn: melanogaster; drosophila; eif4g-related; predicted; isoform; xenopus; laevis; nat1; translation; mellifera; 49e-49f; full; eukar . . . ilh1c.pk010.f11.f blastx: glycoprotein; endocuticle; structural; drosophila; anopheles; gambiae; melanogaster; pseudoobscura; pest; str; mori; bombyx; cut . . . blastn: melanogaster; drosophila; cuticle; larval; lcp-14; m.sexta; constituent; asap; sexta; gambiae; bombyx; lcp17; subalbatus; mori; . . . ilh1c.pk010.i24.f blastx: receptor; benzodiazepine; benzodiazapine; peripheral; peripheral-type; musculus; sapiens; mitochondrial; drosophila; unnamed; co . . . blastn: ilh1c.pk010.m17.f blastx: ntf2-related; drosophila; melanogaster; anopheles; export; gambiae; pest; predicted; musculus; str; nxt1; mus; apis; canis; mell . . . blastn: ntf2-related; export; sapiens; anopheles; predicted; gambiae; ntf2-like; homo; pest; strongylocentrotus; str; nxt1; transcript; . . . ilh1c.pk010.n4.f blastx: receptor; delta; signal; translocon-associated; sapiens; construct; synthetic; homo; rerio; danio; anopheles; predicted; gambiae . . . blastn: sapiens; receptor; synthetic; construct; delta; signal; homo; translocon- associated; 25-normalized; full-length; ssr4; placenta; . . . ilh1c.pk011.a8.f blastx: polyprotein; deformed; wing; destructor; sacbrood; nonstructural; varroa; kakugo; unnamed; venturia; rna-dependent; homo; sapien . . . blastn: deformed; polyprotein; wing; isolate; nonstructural; fis; homo; sapiens; kakugo; varroa; destructor ilh1c.pk011.d10.f blastx: drosophila; melanogaster; death-associated; leucine-rich; containing; cytoplasmic; caenorhabditis; anopheles; leucine; repeat; g . . . blastn: death-associated; leucine-rich; cytoplasmic; small; sclp; predicted; sexta; gambiae; str; manduca; mellifera; pest; apis; anophe . . . ilh1c.pk011.e16.f blastx: mediator; transcription; polymerase; drosophila; predicted; musculus; melanogaster; complex; sapiens; anopheles; mus; soh1; homo . . . blastn: nigroviridis; full-length; tetraodon; melanogaster; drosophila; isoform; med31; full; insert ilh1c.pk009.d7.f blastx: transcriptional; transcription; repressor; potential; isoform; sapiens; ccr4- not; complex; predicted; not4hp; homo; ccr4-associa . . . blastn: melanogaster; drosophila; isoform; mellifera; predicted; apis; homo; not4- n; insert; not4-np; full; sapiens ilh1c.pk003.d10.f blastx: translation; initiation; eukaryotic; gamma; structural; predicted; x-linked; musculus; gallus; unnamed; leptinotarsa; decemlinea . . . blastn: translation; initiation; eukaryotic; structural; musculus; x-linked; product: eukaryotic; full-length; enriched; mus; library; in . . . ilh1c.pk003.f22.f blastx: transcription; upstream; predicted; nucleolar; danio; rerio; isoform; ubf-1; autoantigen; nor-90; ubtf; unnamed; human; polymera . . . blastn: ilh1c.pk004.e16.f blastx: disrupted; disorder; musculus; drosophila; bipolar; predicted; melanogaster; unnamed; mus; familiaris; isoform; canis; asparagin . . . blastn: musculus; disorder; disrupted; bipolar; full-length; sapiens; enriched; homo; library; mus; predicted; human; insert; asparagine . . . ilh1c.pk004.m22.f blastx: spinocerebellar; predicted; ataxin; ataxin-7; ataxia; sapiens; familiaris; gallus; musculus; isoform; homo; canis; norvegicus; r . . . blastn: ilh1c.pk005.l24.f blastx: melanogaster; drosophila; isoform; anopheles; gambiae; caenorhabditis; pest; str; elegans; predicted; f-box; leucine-rich; lrr-r . . . blastn: melanogaster; drosophila; isoform; full; bac; clones; asap; conserved; mellifera; apis; aegypti; predicted; aedes; 99b-99b; sect . . . ilh1c.pk006.c15.f blastx: caenorhabditis; calpain; anopheles; elegans; gambiae; family; gallus; calcium-activated; pest; str; isoform; xenopus; neutral; m . . . blastn: calpain; musculus; ncl-4; sapiens; tract-specific; product: calpain; homo; mus; transcript; full-length; capn9; digestive; enrich . . . ilh1c.pk001.f20.f blastx: caenorhabditis; elegans; predicted; schistosoma; rna-directed; transcriptase; polymerase; containing; polyprotein; rerio; danio; . . . blastn: caenorhabditis; zebrafish; linkage; elegans; group; ch211-12p12; ch211- 260p11; dkey-9p20 ilh1c.pk006.c6.f blastx: vesicle-associated; membrane; vamp-associated; protein-associated; predicted; tropicalis; xenopus; associated; rerio; danio; iso . . . blastn: ilh1c.pk001.h3.f blastx: drosophila; melanogaster; proteinase; sarcophaga; 26, 29 kda; homologue; predicted; anopheles; gambiae; gallus; danio; rerio; pest . . . blastn: anopheles; gambiae; proteinase; sarcophaga; 26, 29 kda; melanogaster; full- length; drosophila; homologue; extremity; mosquito; afr . . . ilh1c.pk007.c6.f blastx: predicted; containing; armadillo; sapiens; repeat; homo; strongylocentrotus; purpuratus; anopheles; novel; gambiae; pest; str; n . . . blastn: musculus; complex; cultivar-group; product: adaptor-related; mus; adaptor-related; japonica; beta; sativa; full-length; oryza; en . . . ilh1c.pk007.m5.f blastx: transcription; polypeptide; general; sapiens; musculus; 63 kda; homo; gallus; iiic; iiic-epsilon; tf3c-epsilon; mus; anopheles; t . . . blastn: ilh1c.pk008.c24.f blastx: translation; eukaryotic; initiation; interacting; sapiens; melanogaster; drosophila; homo; predicted; familiaris; isoform; varia . . . blastn: full-length; 25-normalized; sapiens; human; placenta; homo; cot; interacting; translation; eukaryotic; initiation; danio; rerio; . . . ilh1c.pk008.d5.f blastx: prostaglandin; prostaglandin-endoperoxide; synthase; synthase-2; cyclooxygenase-2; cox-2; taurus; familiaris; tropicalis; caball . . . blastn: prostaglandin; synthase; gallus; rerio; predicted; c.porcellus; danio; cyclooxygenase-2; chicken ilh1c.pk008.f17.f blastx: cathepsin; proteinase; b-like; e.c.3.4.22.1; schistosoma; papain-like; virgifera; lysosomal; isotype; mansoni; triatoma; sm31; d . . . blastn: cathepsin; sapiens; construct; synthetic; homo; 25-normalized; ctsb; full- length; human; pygmaeus; placenta; pongo; cot; cs0di02 . . . ilh1c.pk008.g3.f blastx: pyroglutamyl-peptidase; pyrrolidone-carboxylate; unnamed; musculus; 5- oxoprolyl-peptidase; norvegicus; peptidase; xenopus; sapie . . . blastn: ilh1c.pk002.o12.f blastx: anopheles; gambiae; trypsin; pest; str; protease; trypsin-related; chymotrypsin; aegypti; aedes; chymotrypsin-like; ctenocephali . . . blastn: ilh1c.pk003.d10.f blastx: translation; initiation; eukaryotic; gamma; structural; predicted; x-linked; musculus; gallus; unnamed; leptinotarsa; decemlinea . . . blastn: translation; initiation; eukaryotic; structural; musculus; x-linked; product: eukaryotic; full-length; enriched; mus; library; in . . . ilh1c.pk004.o2.f blastx: carboxypeptidase; vitellogenic-like; sapiens; vitellogenic; serine; homo; carboxypeptidase-like; cpvl; predicted; canis; pygmaeu . . . blastn: carboxypeptidase; anopheles; gambiae; vitellogenic; carboxypeptidase- like; full-length; vitellogenic-like; extremity; mosquito; . . .

TABLE 3 Summary of Top Blast Hit sid database accession# score ilh1c.pk005.o10.f gb AAL28614.1 498 ilh1c.pk004.e6.f gb EAA04403.2 161 ilh1c.pk001.e23.f gb EAA04403.2 160 ilh1c.pk010.f11.f sp Q7M4F2 359 ilh1c.pk011.m15.f sp P83995 300 ilh1c.pk005.d21.f gb AAN62848.1 104 ilh1c.pk011.f4.f gb EAA06494.2 559 ilh1c.pk004.a13.f gb AAT09370.1 634 ilh1c.pk004.i18.f gb AAT09370.1 648 ilh1c.pk004.l22.f gb EAA03540.3 275 ilh1c.pk005.k23.f gb AAT09370.1 377 ilh1c.pk010.g16.f gb EAA08488.2 148 ilh1c.pk002.d16.f dbj BAA22791.1 567 ilh1c.pk001.f1.f dbj BAA22791.1 321 ilh1c.pk005.f15.f gb AAB72001.1 245 ilh1c.pk003.d10.f emb CAF92618.1 196 ilh1c.pk010.d2.f gb AAF56796.2 188 ilh1c.pk010.d2.f gb AAM50998.1 188 ilh1c.pk011.g22.f ref XP_625027.1 437 ilh1c.pk011.h12.f gb AAT01080.1 744 ilh1c.pk001.k13.f ref XP_623842.1 477 ilh1c.pk001.k16.f ref XP_396057.2 508 ilh1c.pk001.k16.f ref XP_623167.1 508 ilh1c.pk001.l22.f ref XP_392692.2 673 ilh1c.pk001.m15.f gb AAV31410.1 583 ilh1c.pk001.m17.f ref XP_392925.2 390 ilh1c.pk001.n23.f ref XP_790997.1 235 ilh1c.pk001.n6.f gb AAD09820.1 384 ilh1c.pk001.o17.f gb AAL90146.1 758 ilh1c.pk001.o17.f gb AAX52682.1 758 ilh1c.pk001.o4.f gb EAA04597.2 302 ilh1c.pk001.o4.f gb EAL32669.1 302 ilh1c.pk002.a11.f gb EAA05241.2 189 ilh1c.pk002.a24.f gb AAT01080.1 436 ilh1c.pk002.b12.f gb EAA01140.2 269 ilh1c.pk003.n7.f ref NP_788640.1 760 ilh1c.pk003.p4.f ref XP_395521.2 340 ilh1c.pk004.c13.f gb EAL33114.1 538 ilh1c.pk004.i5.f ref XP_392968.2 323 ilh1c.pk001.d8.f gb EAA12913.3 565 ilh1c.pk001.e10.f ref NP_001007306.1 255 ilh1c.pk001.i10.f ref XP_635611.1 284 ilh1c.pk010.p16.f ref XP_396126.2 278 ilh1c.pk003.k14.f ref XP_854245.1 403 ilh1c.pk004.a13.f gb AAT09370.1 634 ilh1c.pk001.b20.f gb AAF54512.1 741 ilh1c.pk004.i18.f gb AAT09370.1 648 ilh1c.pk004.o2.f gb AAC41580.1 502 ilh1c.pk004.o2.f ref XP_854245.1 502 ilh1c.pk005.m3.f emb CAA46187.1 706 ilh1c.pk005.m3.f sp P55277 706 ilh1c.pk002.o3.f ref XP_392848.2 561 ilh1c.pk003.h22.f ref XP_393899.1 331 ilh1c.pk003.i6.f gb AAI08879.1 238 ilh1c.pk004.a13.f gb AAT09370.1 634 ilh1c.pk003.g17.f gb EAA14743.2 158 ilh1c.pk009.k12.f ref XP_623580.1 583 ilh1c.pk009.f20.f ref XP_394628.2 332 ilh1c.pk008.o12.f dbj BAD52260.1 711 ilh1c.pk008.k5.f gb EAA09467.2 366 ilh1c.pk008.c24.f ref XP_624438.1 804 ilh1c.pk008.b15.f gb EAA06364.2 466 ilh1c.pk007.p11.f gb ABA54998.1 231 ilh1c.pk003.d10.f emb CAF92618.1 196 ilh1c.pk002.d16.f dbj BAA22791.1 567 ilh1c.pk002.d9.f gb EAA44856.2 233 ilh1c.pk002.j6.f gb AAY24048.1 120 ilh1c.pk002.j6.f ref NP_938017.1 120 ilh1c.pk002.k17.f gb EAA01750.2 528 ilh1c.pk002.k5.f dbj BAA91735.1 239 ilh1c.pk002.k5.f dbj BAD97072.1 239 ilh1c.pk002.k5.f dbj BAE01389.1 239 ilh1c.pk002.k5.f gb AAF67488.1 239 ilh1c.pk002.k5.f gb AAH12559.1 239 ilh1c.pk002.k5.f ref NP_059122.2 239 ilh1c.pk002.m21.f ref XP_425021.1 404 ilh1c.pk002.n11.f gb EAA00451.2 968 ilh1c.pk003.d10.f emb CAF92618.1 196 ilh1c.pk003.d17.f gb EAA06794.2 348 ilh1c.pk003.h22.f ref XP_393899.1 331 ilh1c.pk003.j5.f gb AAK31586.1 153 ilh1c.pk003.j7.f gb AAY51599.1 268 ilh1c.pk003.j7.f ref NP_650534.1 268 ilh1c.pk003.l11.f emb CAG31191.1 245 ilh1c.pk003.l18.f ref NP_066289.2 321 ilh1c.pk003.o10.f ref XP_624683.1 196 ilh1c.pk004.b8.f ref XP_394833.1 546 ilh1c.pk004.d17.f gb AAA35091.1 115 ilh1c.pk004.d17.f gb AAH84355.1 115 ilh1c.pk004.d17.f ref NP_013018.1 115 ilh1c.pk004.e16.f ref XP_397356.2 317 ilh1c.pk004.g2.f gb EAL33487.1 94 ilh1c.pk004.g2.f ref XP_531704.2 94 ilh1c.pk004.k13.f gb AAY45870.1 381 ilh1c.pk004.m4.f ref XP_396911.2 421 ilh1c.pk005.a7.f gb AAB65345.1 257 ilh1c.pk005.h9.f ref XP_787944.1 119 ilh1c.pk005.i1.f gb EAL32477.1 120 ilh1c.pk005.i10.f pir UDBO 105 ilh1c.pk005.i10.f ref NP_776454.1 105 ilh1c.pk005.i12.f gb EAA03479.2 394 ilh1c.pk005.i15.f gb AAG31619.1 827 ilh1c.pk005.i16.f ref XP_395584.2 731 ilh1c.pk005.m3.f emb CAA46187.1 706 ilh1c.pk005.m3.f sp P55277 706 ilh1c.pk005.o17.f gb AAQ83887.1 461 ilh1c.pk006.c6.f gb EAA06671.2 201 ilh1c.pk006.f2.f emb CAF96101.1 180 ilh1c.pk007.a8.f gb EAL28755.1 343 ilh1c.pk007.b21.f ref XP_422806.1 140 ilh1c.pk007.g16.f ref YP_102734.1 129 ilh1c.pk007.j24.f gb AAB72001.1 168 ilh1c.pk007.o17.f ref NP_001015958.1 118 ilh1c.pk007.o17.f ref NP_001030215.1 118 ilh1c.pk007.p11.f gb ABA54998.1 231 ilh1c.pk007.p13.f dbj BAA91976.1 337 ilh1c.pk008.c24.f ref XP_624438.1 804 ilh1c.pk008.f16.f sp P04069 273 ilh1c.pk008.h14.f ref XP_391971.1 401 ilh1c.pk008.j3.f ref XP_397432.2 305 ilh1c.pk008.k6.f gb AAH85379.1 222 ilh1c.pk009.d7.f ref XP_392724.2 1062 ilh1c.pk009.d7.f ref XP_623058.1 1062 ilh1c.pk009.f20.f ref XP_394628.2 332 ilh1c.pk010.f11.f sp Q7M4F2 359 ilh1c.pk010.i24.f ref XP_397432.2 190 ilh1c.pk010.m17.f gb EAA12371.3 392 ilh1c.pk010.n4.f ref XP_624607.1 423 ilh1c.pk011.a8.f gb AAP49008.1 433 ilh1c.pk011.a8.f gb AAP49283.1 433 ilh1c.pk011.d10.f ref XP_623853.1 358 ilh1c.pk011.e16.f ref XP_393244.1 522 ilh1c.pk009.d7.f ref XP_392724.2 1062 ilh1c.pk009.d7.f ref XP_623058.1 1062 ilh1c.pk003.d10.f emb CAF92618.1 196 ilh1c.pk003.f22.f emb CAF92109.1 360 ilh1c.pk004.e16.f ref XP_397356.2 317 ilh1c.pk004.m22.f ref XP_541817.2 200 ilh1c.pk004.m22.f ref XP_848286.1 200 ilh1c.pk005.l24.f gb AAN71350.1 427 ilh1c.pk005.l24.f ref NP_733291.1 427 ilh1c.pk006.c15.f gb EAL38766.1 400 ilh1c.pk001.f20.f gb AAB71256.1 392 ilh1c.pk006.c6.f gb EAA06671.2 201 ilh1c.pk001.h3.f dbj BAA86911.1 967 ilh1c.pk007.c6.f ref XP_507719.1 126 ilh1c.pk007.m5.f ref XP_342400.2 234 ilh1c.pk008.c24.f ref XP_624438.1 804 ilh1c.pk008.d5.f ref XP_422297.1 244 ilh1c.pk008.f17.f gb AAT48984.1 386 ilh1c.pk008.g3.f emb CAG00772.1 267 ilh1c.pk008.g3.f ref XP_786904.1 267 ilh1c.pk002.o12.f gb AAL93243.1 142 ilh1c.pk003.d10.f emb CAF92618.1 196 ilh1c.pk004.o2.f gb AAC41580.1 502 ilh1c.pk004.o2.f ref XP_854245.1 502

TABLE 4 SEQ ID Target region/ est and Target Region Antisense sense/ position of gene Sense primer primer % CG antisense ilh1c.pk5.o1.f  43 AAGAGGTACAAA GAGGUACAAA GGAAAGACAU % CG = 39.1 22/23/24 TGTCTTTCCTG UGUCUUUCC UUGUACCUC  26 AAGTCAGTCCTA GUCAGUCCUA GGACACGUGU % CG = 52.2 25/26/27 CACGTGTCCTC CACGUGUCC AGGACUGAC 353 AACAACGTTCGC CAACGUUCGC AAAAUCCUGG % CG = 39.1 28/29/30 CAGGATTTTTT CAGGAUUUU CGAACGUUG ilh1c.pk4.e6.f  16 AAGACTGCTGAC GACUGCUGAC CGUUAUUCCG % CG = 43.5 31/32/33 GGAATAACGAA GGAAUAACG UCAGCAGUC 332 AACCCCGACGGC CCCCGACGGC AGCGACGGUG % CG = 69.6 34/35/36 ACCGTCGCTGA ACCGUCGCU CCGUCGGGG  56 AAGATCTCCAAA GAUCUCCAAA UCCACGAGCU % CG = 43.5 37/38/39 GCTCGTGGAAT GCUCGUGGA UUGGAGAUC ilh1c.pk1.e23.f  49 AAATTACCCGCG AUUACCCGCG AGUAUCCUCC % CG = 47.8 40/41/42 GAGGATACTCA GAGGAUACU GCGGGUAAU 256 AATTGTGGCTTC UUGUGGCUUC ACGGGAGCUG % CG = 47.8 43/44/45 AGCTCCCGTAT AGCUCCCGU AAGCCACAA 656 AACTCTCTTGTA CUCUCUUGUA UGGUGAGG.U % CG = 43.5 46/47/48 NCCTCACCACA NCCUCACCA ACAAGAGAG ilh1c.pk1.f11.f  37 AAGTCTTTAAGG GUCUUUAAGG UAAAUCCGUC % CG = 39.1 49/50/51 ACGGATTTACG ACGGAUUUA CUUAAAGAC  24 AATGCGTGTTGG UGCGUGUUGG ACAGAUGAGC % CG = 47.8 52/53/54 CTCATCTGTCA CUCAUCUGU CAACACGCA 543 AAGCTGGTGGTC GCUGGUGGUC CCUUCAGACG % CG = 52.2 55/56/57 GTCTGAAGGAT GUCUGAAGG ACCACCAGC 613 AACACTCGGATG CACUCGGAUG CAGUGAUUUC % CG = 43.5 58/59/60 AAATCACTGTG AAAUCACUG AUCCGAGUG ilh1c.pk11.m15.f  28 AATCAGTATCAC UCAGUAUCAC AUCCUGAGCG % CG = 43.5 61/62/63 GCTCAGGATGT GCUCAGGAU UGAUACUGA 355 AACACCCATGAA CACCCAUGAA GACAGCGACU % CG = 56.5 64/65/66 GTCGCTGTCGC GUCGCUGUC UCAUGGGUG  57 AAGATCTCCAAA GAUCUCCAAA UCCACGAGCU % CG = 43.5 67/68/69 GCTCGTGGAAT GCUCGUGGA UUGGAGAUC ilh1c.pk5.d21.f  94 AACTACAAGTAT CUACAAGUAU CUCCACAGGA % CG = 47.8 70/71/72 CCTGTGGAGGG CCUGUGGAG UACUUGUAG 219 AAATTGGAGTGT AUUGGAGUGU GCACCAGUCA % CG = 47.8 73/74/75 GACTGGTGCTG GACUGGUGC CACUCCAAU  57 AACATCAGACGC CAUCAGACGC CAGUAGAGGG % CG = 52.2 76/77/78 CCTCTACTGGA CCUCUACUG CGUCUGAUG ilh1c.pk11.f4.f  51 AAACGGTTCTTT ACGGUUCUUU UCGUUUCGGA % CG = 47.8 79/80/81 CCGAAACGACG CCGAAACGA AAGAACCGU 225 AACCATCGTTCC CCAUCGUUCC GCAUCACCAG % CG = 47.8 82/83/84 TGGTGATGCAT UGGUGAUGC GAACGAUGG 545 AAAGTCTTCAGA AGUCUUCAGA AGCUUCCUCU % CG = 47.8 85/86/87 GAGGAAGCTGC GAGGAAGCU CUGAAGACU ilh1c.pk4.l22.f  79 AAGATGTTCCAT GAUGUUCCAU UGCCUCUCCA % CG = 47.8 88/89/90 GGAGAGGCACA GGAGAGGCA UGGAACAUC  22 AAATAGGGCAAC AUAGGGCAAC AUCCGUGAAG % CG = 39.1 91/92/93 TTCACGGATTA UUCACGGAU UUGCCCUAU 469 AAGAACCATTCG GAACCAUUCG UGAUAACGGC % CG = 47.8 94/95/96 CCGTTATCACC CCGUUAUCA GAAUGGUUC 651 AAGCTGCACTGG GCUGCACUGG GAAUGAAUCC % CG = 47.8 97/98/99 GATTCATTCCT GAUUCAUUC CAGUGCAGC ilh1c.pk3.d1.f  88 AATACAAAAGTC UACAAAAGUC GGAAGACGCG % CG = 47.8 100/101/102 GCGTCTTCCGG GCGUCUUCC ACUUUUGUA 132 AAGATCTTTCGA GAUCUUUCGA CGUCAAGAGU % CG = 43.5 103/104/105 CTCTTGACGTG CUCUUGACG CGAAAGAUC  27 AATATCGGTACT UAUCGGUACU GUGACCAAUA % CG = 39.1 106/107/108 ATTGGTCACGT AUUGGUCAC GUACCGAUA ilh1c.pk1.d2.f  96 AATTTCGACGTG UUUCGACGUG UAACACUUCC % CG = 39.1 109/110/111 GAAGTGTTAAG GAAGUGUUA ACGUCGAAA 249 AATGTTGCATCT UGUUGCAUCU GCACCUUCGA % CG = 43.5 112/113/114 CGAAGGTGCAA CGAAGGUGC GAUGCAACA 422 AACACTGGGTAA CACUGGGUAA CCUACAUCUU % CG = 43.5 115/116/117 AGATGTAGGAC AGAUGUAGG UACCCAGUG ilh1c.pk11.h12.f  29 AACCCGGGTCTT CCCGGGUCUU UUUACAGAAA % CG = 43.5 118/119/120 TTCTGTAAAGA UUCUGUAAA AGACCCGGG  22 AAACCTCGAAAC ACCUCGAAAC ACGUUUUUGG % CG = 39.1 121/122/123 CAAAAACGTAG CAAAAACGU UUUCGAGGU 665 AAGTTGGAAACT GUUGGAAACU CUGGACUCCA % CG = 43.5 124/125/126 GGAGTCCAGAT GGAGUCCAG GUUUCCAAC ilh1c.pk2.a24.f  72 AAATCTTCTTCG AUCUUCUUCG GGAUAGUCCC % CG = 39.1 127/128/129 GGACTATCCAT GGACUAUCC GAAGAAGAU  23 AAAACCAGAACA AACCAGAACA UCCGGUUUCU % CG = 43.5 130/131/132 GAAACCGGAGT GAAACCGGA GUUCUGGUU 645 AAGTGATGACCT GUGAUGACCU CCAAAGAGAA % CG = 43.5 133/134/135 TCTCTTTGGGA UCUCUUUGG GGUCAUCAC ilh1c.pk9.f2.f   9 AACAGGACATCA CAGGACAUCA UGCGAAAUAU % CG = 43.5 136/137/138 TATTTCGCAGG UAUUUCGCA GAUGUCCUG  21 AAAAAGCACTAG AAAGCACUAG UCGGCUCAUC % CG = 43.5 139/140/141 ATGAGCCGAAG AUGAGCCGA UAGUGCUUU  43 AAGTTCATCGGA GUUCAUCGGA GCAAAGCUCU % CG = 43.5 142/143/144 GAGCTTTGCAA GAGCUUUGC CCGAUGAAC 596 AACTTTTTGATC CUUUUUGAUC ACGCCAUACG % CG = 43.5 145/146/147 GTATGGCGTCC GUAUGGCGU AUCAAAAAG ilh1c.pk2.d9.f   3 AACTTTCCTNTT CUUUCCUNUU ACAACGCGGA % CG = 43.5 148/149/150 CCGCGTTGTTG CCGCGUUGU A.AGGAAAG 394 AAGAGAACGGAG GAGAACGGAG CCUCGUUAUC % CG = 43.5 151/152/153 ATAACGAGGNA AUAACGAGG UCCGUUCUC  55 AAAAAGGCTCCG AAAGGCUCCG CCAAACAGUC % CG = 43.5 154/155/156 ACTGTTTGGNA ACUGUUUGG GGAGCCUUU ilh1c.pk3.j7.f   4 AAAAAGCTCCAT AAAGCUCCAU UUCACCUGUA % CG = 43.5 157/158/159 ACAGGTGAACG ACAGGUGAA UGGAGCUUU  26 AAAAACAAGCAC AAACAAGCAC CCCGUCUUUG % CG = 43.5 160/161/162 AAAGACGGGTC AAAGACGGG UGCUUGUUU 669 AAGTATTTCAGT GUAUUUCAGU CAGAGGAAGA % CG = 39.1 163/164/165 CTTCCTCTGCT CUUCCUCUG CUGAAAUAC ilh1c.pk3.o1.f  36 AAGTCAGAATGT GUCAGAAUGU UUUCAGUCGA % CG = 39.1 166/167/168 CGACTGAAAAG CGACUGAAA CAUUCUGAC 267 AAGGAACGTGAG GGAACGUGAG CAGGAUCAUC % CG = 43.5 169/170/171 ATGATCCTGTA AUGAUCCUG UCACGUUCC 525 AACCCNACTTTC CCCNACUUUC UUUGUACAAG % CG = 34.8 172/173/174 TTGTACAAAGT UUGUACAAA AAAGU.GGG ilh1c.pk4.b8.f  11 AAGTTTTTGCGG GUUUUUGCGG AUUCCGACAC % CG = 43.5 175/176/177 TGTCGGAATGT UGUCGGAAU CGCAAAAAC 361 AAAANNNNTCCG AANNNNUCCG GGCGGCGUUC % CG = 43.5 178/179/180 AACGCCGCCAA AACGCCGCC GGA....UU 668 AAACTCACCTTC ACUCACCUUC GGCUUGAGAG % CG = 47.8 181/182/183 TCTCAAGCCGT UCUCAAGCC AAGGUGAGU ilh1c.pk4.d17.f  56 AATTCAACGAGA UUCAACGAGA AUUCGGUUAU % CG = 34.8 184/185/186 TAACCGAATGA UAACCGAAU CUCGUUGAA 295 AAGTCTGTGTTG GUCUGUGUUG ACUUUCAGAC % CG = 39.1 187/188/189 TCTGAAAGTAG UCUGAAAGU AACACAGAC  56 AACTCCCAGTGT CUCCCAGUGU UUGAGGACGA % CG = 52.2 190/191/192 CGTCCTCAAGA CGUCCUCAA CACUGGGAG 649 AAGTTCCATCCA GUUCCAUCCA GCGGUGCUUU % CG = 52.2 193/194/195 AAGCACCGCAG AAGCACCGC GGAUGGAAC ilh1c.pk4.k13.f   8 AAGGAAGTATCG GGAAGUAUCG AAUGUGGUGC % CG = 43.5 196/197/198 CACCACATTCT CACCACAUU GAUACUUCC 445 AAATCAAGGACA AUCAAGGACA CUACCACAUU % CG = 39.1 199/200/201 ATGTGGTAGCT AUGUGGUAG GUCCUUGAU 698 AAAGTGAAGGTG AGUGAAGGUG CGCAAUCUUC % CG = 43.5 202/203/204 AAGATTGCGAG AAGAUUGCG ACCUUCACU ilh1c.pk11.a8.f  14 AAGATGTTGTGT GAUGUUGUGU GUAAACCUAA % CG = 39.1 205/206/207 TAGGTTTACCG UAGGUUUAC CACAACAUC 394 AACAAAGTCGAT CAAAGUCGAU CUAGGUGGAA % CG = 43.5 208/209/210 TCCACCTAGAG UCCACCUAG UCGACUUUG 515 AACTTTGGTCCT CUUUGGUCCU AUCCAAACCA % CG = 43.5 211/212/213 GGTTTGGATAG GGUUUGGAU GGACCAAAG ilh1c.pk11.d1.f  42 AAGCTACAGGAA GCUACAGGAA UU.UCCGGAU % CG = 39.1 214/215/216 TCCGGANAATT UCCGGANAA UCCUGUAGC 136 AAGGCGTGTAAT GGCGUGUAAU GCUUGAGAGA % CG = 43.5 217/218/219 CTCTCAAGCAA CUCUCAAGC UUACACGCC 182 AATTCGCGGTCA UUCGCGGUCA AGAUAAAGUU % CG = 39.1 220/221/222 ACTTTATCTCT ACUUUAUCU GACCGCGAA (Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 4 were generated to have 2 thymine residues at the 3′ end.)

Example 2 Lygus hesperus Assay Methodology

Lygus hesperus egg packs are received from the University of Missouri and placed in Fluon® AD-1 (AG Fluoropolymers)-treated containers in a 18° C. incubator, RH˜40 to 60%, and no light. Eggs generally hatch after 6 days and then are transferred to a 25° incubator, RH˜40 to 60%, 22 hours Day:2 hours Night. Neonates are fed artificial diet (Bio-Serv F9644B) in parafilm packets. 1 day old 2^(nd) instar nymphs are used for bioassay.

Liquid samples (20 ul) are dispensed to 96 well microtiter plates (Falcon Assay Plate 353910) and mixed with 75 ul of artificial diet (Bio-Serv F9644B). Assays typically include 4 to 5 observations for each sample. The plate is then covered with slightly stretched parafilm. Several (3 to 8) 1 day old 2^(nd) instar nymphs are placed in each well of a 96 well filter plate (Millipore MABVN1250). The diet/sample plate is flipped on top of the nymph-infested filter plate so that the wells line up and the nymphs can feed on the diet/sample mixture through the parafilm. The filter plate and the diet plate are clamped together using rubber bands. The plates are placed in a 25° incubator, RH˜40 to 60%, and no light, and the assay is scored after 4 days. Each well is scored individually and given a rating of either 0, 1, or 2 based on the following system:

-   -   0=Normal development—molting to third instar nymphs     -   1=Stunted growth—same size as 1 day old 2^(nd) instars or         slightly larger     -   2=Dead         The score is based on the least affected nymph in the well. For         example, if all but one nymph is dead, and that nymph is         stunted, the well would be scored as a 1. If 4 nymphs are         stunted and 2 are normal, the well would be scored as 0. Several         repetitions are run using the same sample and dose. The well         values for all observations are added together and a % effect is         calculated using the following formula:

${\frac{\begin{matrix} {{{Rep}\mspace{14mu} 1\mspace{14mu} \left( {{well}\mspace{14mu} {value}} \right)} + {{Rep}\mspace{14mu} 2\mspace{14mu} \left( {{well}\mspace{14mu} {value}} \right)} +} \\ {{{Rep}\mspace{14mu} 3\mspace{14mu} \left( {{well}\mspace{14mu} {value}} \right)\mspace{14mu} \ldots} + {{Rep}\mspace{14mu} N\mspace{14mu} \left( {{well}\mspace{14mu} {value}} \right)}} \end{matrix}}{\left( {{Total}\mspace{14mu} {number}\mspace{14mu} {of}\mspace{14mu} {reps}\mspace{14mu} N} \right)*(2)} \times 100} = {\% \mspace{14mu} {effect}}$

Where N is the number of observations run for that sample and dose

Using the % effect numbers and the corresponding doses, an Effective Concentration (EC) 50 can be calculated using a probit analysis program (LdP Line).

Results:

62 synthetic dsRNA samples (Sigm-Genosys, The Woodlands, Tex.) were tested at the following concentrations: 35, 17.5, 8.25, and 4.125 ppm. Of the samples tested, 47 were inactive, while 15 demonstrated varying degrees of activity including stunting and mortality (highlighted in table 5).

TABLE 5 Sam- ple id Targeted region sense strand antisense strand SEQ ID NO A1 ilh1c.pk005.o10.f AAGAGGTACAAATGTCTTTCCTG GAGGUACAAAUGUCUUUCC GGAAAGACAUUUGUACCUC 223/224/225 B1 ilh1c.pk005.o10.f AAGTCAGTCCTACACGTGTCCTC GUCAGUCCUACACGUGUCC GGACACGUGUAGGACUGAC 226/227/228 C1 ilh1c.pk005.o10.f AACAACGTTCGCCAGGATTTTTT CAACGUUCGCCAGGAUUUU AAAAUCCUGGCGAACGUUG 229/230/231 D1 ilh1c.pk004.e6.f AAGACTGCTGACGGAATAACGAA GACUGCUGACGGAAUAACG CGUUAUUCCGUCAGCAGUC 232/233/234 E1 ilh1c.pk004.e6.f AACCCCGACGGCACCGTCGCTGA CCCCGACGGCACCGUCGCU AGCGACGGUGCCGUCGGGG 235/236/237 F1 ilh1c.pk004.e6.f AAGATCTCCAAAGCTCGTGGAAT GAUCUCCAAAGCUCGUGGA UCCACGAGCUUUGGAGAUC 238/239/240 G1 ilh1c.pk001.e23.f AAATTACCCGCGGAGGATACTCA AUUACCCGCGGAGGAUACU AGUAUCCUCCGCGGGUAAU 241/242/243 H1 ilh1c.pk001.e23.f AATTGTGGCTTCAGCTCCCGTAT UUGUGGCUUCAGCUCCCGU ACGGGAGCUGAAGCCACAA 244/245/246 A2 ilh1c.pk010.f11.f AAGTCTTTAAGGACGGATTTACG GUCUUUAAGGACGGAUUUA UAAAUCCGUCCUUAAAGAC 247/248/249 B2 ilh1c.pk010.f11.f AATGCGTGTTGGCTCATCTGTCA UGCGUGUUGGCUCAUCUGU ACAGAUGAGCCAACACGCA 250/251/252 C2 ilh1c.pk010.f11.f AAGCTGGTGGTCGTCTGAAGGAT GCUGGUGGUCGUCUGAAGG CCUUCAGACGACCACCAGC 253/254/255 D2 ilh1c.pk010.f11.f AACACTCGGATGAAATCACTGTG CACUCGGAUGAAAUCACUG CAGUGAUUUCAUCCGAGUG 256/257/258 E2 ilh1c.pk011.m15.f AATCAGTATCACGCTCAGGATGT UCAGUAUCACGCUCAGGAU AUCCUGAGCGUGAUACUGA 259/260/261 F2 ilh1c.pk011.m15.f AACACCCATGAAGTCGCTGTCGC CACCCAUGAAGUCGCUGUC GACAGCGACUUCAUGGGUG 262/263/264 G2 ilh1c.pk011.m15.f AAGATCTCCAAAGCTCGTGGAAT GAUCUCCAAAGCUCGUGGA UCCACGAGCUUUGGAGAUC 265/266/267 H2 ilh1c.pk005.d21.f AACTACAAGTATCCTGTGGAGGG CUACAAGUAUCCUGUGGAG CUCCACAGGAUACUUGUAG 268/269/270 A3 ilh1c.pk005.d21.f AAATTGGAGTGTGACTGGTGCTG AUUGGAGUGUGACUGGUGC GCACCAGUCACACUCCAAU 271/272/273 B3 ilh1c.pk005.d21.f AACATCAGACGCCCTCTACTGGA CAUCAGACGCCCUCUACUG CAGUAGAGGGCGUCUGAUG 274/275/276 C3 ilh1c.pk011.f4.f AAACGGTTCTTTCCGAAACGACG ACGGUUCUUUCCGAAACGA UCGUUUCGGAAAGAACCGU 277/278/279 D3 ilh1c.pk011.f4.f AACCATCGTTCCTGGTGATGCAT CCAUCGUUCCUGGUGAUGC GCAUCACCAGGAACGAUGG 280/281/282

283/284/285 F3 ilh1c.pk004.l22.f AAGATGTTCCATGGAGAGGCACA GAUGUUCCAUGGAGAGGCA UGCCUCUCCAUGGAACAUC 286/287/288

289/290/291

292/293/294 A4 ilh1c.pk004.l22.f AAGCTGCACTGGGATTCATTCCT GCUGCACUGGGAUUCAUUC GAAUGAAUCCCAGUGCAGC 295/296/297 B4 ilh1c.pk003.d10.f AATACAAAAGTCGCGTCTTCCGG UACAAAAGUCGCGUCUUCC GGAAGACGCGACUUUUGUA 298/299/300 C4 ilh1c.pk003.d10.f AAGATCTTTCGACTCTTGACGTG GAUCUUUCGACUCUUGACG CGUCAAGAGUCGAAAGAUC 301/302/303

304/305/306 E4 ilh1c.pk010.d2.f AATTTCGACGTGGAAGTGTTAAG UUUCGACGUGGAAGUGUUA UAACACUUCCACGUCGAAA 307/308/309 F4 ilh1c.pk010.d2.f AATGTTGCATCTCGAAGGTGCAA UGUUGCAUCUCGAAGGUGC GCACCUUCGAGAUGCAACA 310/311/312 G4 ilh1c.pk010.d2.f AACACTGGGTAAAGATGTAGGAC CACUGGGUAAAGAUGUAGG CCUACAUCUUUACCCAGUG 313/314/315

316/317/318

319/320/321

322/323/324

325/326/327

328/329/330

331/332/333

334/335/336

337/338/339

340/341/342

343/344/345

346/347/348 C6 ilh1c.pk002.d9.f AAAAAGGCTCCGACTGTTTGGNA AAAGGCUCCGACUGUUUGG CCAAACAGUCGGAGCCUUU 349/350/351 D6 ilh1c.pk003.j7.f AAAAAGCTCCATACAGGTGAACG AAAGCUCCAUACAGGUGAA UUCACCUGUAUGGAGCUUU 352/353/354 E6 ilh1c.pk003.j7.f AAAAACAAGCACAAAGACGGGTC AAACAAGCACAAAGACGGG CCCGUCUUUGUGCUUGUUU 355/356/357 F6 ilh1c.pk003.j7.f AAGTATTTCAGTCTTCCTCTGCT GUAUUUCAGUCUUCCUCUG CAGAGGAAGACUGAAAUAC 358/359/360 G6 ilh1c.pk003.o10.f AAGTCAGAATGTCGACTGAAAAG GUCAGAAUGUCGACUGAAA UUUCAGUCGACAUUCUGAC 361/362/363 H6 ilh1c.pk003.o10.f AAGGAACGTGAGATGATCCTGTA GGAACGUGAGAUGAUCCUG CAGGAUCAUCUCACGUUCC 364/365/366 A7 ilh1c.pk004.b8.f AAGTTTTTGCGGTGTCGGAATGT GUUUUUGCGGUGUCGGAAU AUUCCGACACCGCAAAAACd 367/368/369 B7 ilh1c.pk004.b8.f AAACTCACCTTCTCTCAAGCCGT ACUCACCUUCUCUCAAGCC GGCUUGAGAGAAGGUGAGU 370/371/372 C7 ilh1c.pk004.d17.f AATTCAACGAGATAACCGAATGA UUCAACGAGAUAACCGAAU AUUCGGUUAUCUCGUUGAA 373/374/375 D7 ilh1c.pk004.d17.f AAGTCTGTGTTGTCTGAAAGTAG GUCUGUGUUGUCUGAAAGU ACUUUCAGACAACACAGAC 376/377/378 E7 ilh1c.pk004.d17.f AACTCCCAGTGTCGTCCTCAAGA CUCCCAGUGUCGUCCUCAA UUGAGGACGACACUGGGAG 379/380/381 F7 ilh1c.pk004.d17.f AAGTTCCATCCAAAGCACCGCAG GUUCCAUCCAAAGCACCGC GCGGUGCUUUGGAUGGAAC 382/383/384 G7 ilh1c.pk004.k13.f AAGGAAGTATCGCACCACATTCT GGAAGUAUCGCACCACAUU AAUGUGGUGCGAUACUUCC 385/386/387 H7 ilh1c.pk004.k13.f AAATCAAGGACAATGTGGTAGCT AUCAAGGACAAUGUGGUAG CUACCACAUUGUCCUUGAU 388/389/390 A8 ilh1c.pk004.k13.f AAAGTGAAGGTGAAGATTGCGAG AGUGAAGGUGAAGAUUGCG CGCAAUCUUCACCUUCACU 391/392/393 B8 ilh1c.pk011.a8.f AAGATGTTGTGTTAGGTTTACCG GAUGUUGUGUUAGGUUUAC GUAAACCUAACACAACAUC 394/395/396 C8 ilh1c.pk011.a8.f AACAAAGTCGATTCCACCTAGAG CAAAGUCGAUUCCACCUAG CUAGGUGGAAUCGACUUUG 397/398/399 D8 ilh1c.pk011.a8.f AACTTTGGTCCTGGTTTGGATAG CUUUGGUCCUGGUUUGGAU AUCCAAACCAGGACCAAAG 400/401/402 E8 ilh1c.pk011.d10.f AAGGCGTGTAATCTCTCAAGCAA GGCGUGUAAUCUCUCAAGC GCUUGAGAGAUUACACGCC 403/404/405 F8 ilh1c.pk011.d10.f AATTCGCGGTCAACTTTATCTCT UUCGCGGUCAACUUUAUCU AGAUAAAGUUGACCGCGAA 406/407/408 (Note: the sense RNA primer sequence and the antisense RNA primer sequences shown in table 5 were generated to have 2 thymine residues at the 3′ end.)

TABLE 6 % Response (4 reps) Sample 35 ppm 17.5 ppm 8.25 ppm 4.125 ppm A1 37.5 0 0 25 B1 25 0 0 0 C1 0 0 0 0 D1 12.5 0 0 0 E1 0 0 0 0 F1 12.5 0 25 0 G1 0 0 0 0 H1 0 0 0 0 A2 12.5 0 0 25 B2 25 0 0 0 C2 0 0 0 0 D2 0 25 25 0 E2 0 0 25 0 F2 0 0 0 0 G2 0 0 0 0 H2 0 0 0 25 A3 0 0 0 0 B3 0 0 0 0 C3 12.5 0 0 0 D3 0 0 25 25 E3 75 62.5 12.5 0 F3 0 0 0 0 G3 87.5 25 0 0 H3 100 50 12.5 0 A4 25 12.5 0 0 B4 12.5 0 0 0 C4 12.5 0 0 0 D4 62.5 0 0 0 E4 37.5 25 0 0 F4 0 25 0 0 G4 25 0 0 0 H4 100 37.5 0 0 A5 62.5 37.5 0 0 B5 100 75 12.5 0 C5 100 100 50 37.5 D5 100 100 37.5 12.5 E5 100 87.5 50 12.5 F5 100 50 0 0 G5 100 100 50 0 H5 87.5 50 0 25 A6 100 50 25 0 B6 100 37.5 0 0 C6 0 0 0 0 D6 0 0 0 0 E6 0 12.5 0 0 F6 0 0 0 0 G6 0 0 25 25 H6 0 0 0 0 A7 0 0 0 0 B7 0 0 0 0 C7 0 0 0 25 D7 0 0 0 0 E7 0 0 0 0 F7 0 0 0 0 G7 0 0 0 0 H7 0 0 0 0 A8 0 0 0 0 B8 0 0 0 0 C8 12.5 0 0 0 D8 0 0 25 0 E8 0 0 0 0 F8 0 0 0 0 A confirmation test was run with the 14 most active samples. The activity was confirmed. See, Table 7.

TABLE 7 % Activity (5 reps) 37.5 ppm 17.5 ppm 8.25 ppm 4.125 ppm 3E 100 50 30 0 3G 90 40 10 0 3H 90 60 10 0 4H 100 40 10 0 5A 90 40 10 0 5B 100 80 50 0 5C 100 90 50 20 5D 100 90 40 10 5E 100 80 40 0 5F 90 40 0 0 5G 100 70 40 10 5H 90 40 10 0 6A 100 40 0 0 6B 90 40 10 0

New samples were made of 7 of the most active samples. These were de-salted or were HPLC purified dsRNAs from the same vender (Sigma-Genosys, the Woodlands, Tex.). The samples tested were 5C, 5D, 5E, 5F, 5G, 5H, and 6A. Only one of the samples, 5C, showed activity at the doses tested, and only minor stunting was evident. See, Table 8. Similarly, the desalted primers also had limited activity.

TABLE 8 % Effect HPLC De-Salted 35 ppm 50 30 17.5 20 0 8.75 0 10 4.375 0 0 No Mortality, only minor stunting at 35 ppm The samples were retested at a higher dose (70 ppm) and again, sample 5C was found to be the only sample active. See, Table 9. Mortality occurred with the two top doses (35 and 70 ppm).

TABLE 9 5C % effect HPLC purified De-Salted   70 ppm 100 70   35 ppm 70 30 17.5 ppm 10 0 8.75 ppm 0 0 Dosages were increased again for the HPLC-purified samples and activity became evident with all the samples tested. Mortality and stunting occurred at the top three doses. See, Table 10.

TABLE 10 % Effected ppm 5C 5D 5E 5F 5G 5H 6A 100 100 75 75 75 100 87.5 37.5 50 50 62.5 37.5 25 50 25 25 25 12.5 12.5 12.5 12.5 12.5 12.5 12.5 12.5 0 0 12.5 0 0 0 0

Example 3 Transformation of Maize

Immature maize embryos from greenhouse donor plants are bombarded with a plasmid containing the a silencing element of the invention is operably linked to a maize Ubi1-5UTR-Ubi1 intron and the selectable marker gene PAT (Wohlleben et al. (1988) Gene 70:25-37), which confers resistance to the herbicide Bialaphos. In one embodiment, the construct comprises two identical 2 to 300 bp segments of a target gene in opposite orientations with an intron segment between them acting as a hairpin loop. In further embodiments, the construct is driven off of the dMMV promoter. Alternatively, the selectable marker gene is provided on a separate plasmid. Transformation is performed as follows. Media recipes follow below.

Preparation of Target Tissue

The ears are husked and surface sterilized in 30% Clorox bleach plus 0.5% Micro detergent for 20 minutes, and rinsed two times with sterile water. The immature embryos are excised and placed embryo axis side down (scutellum side up), 25 embryos per plate, on 560Y medium for 4 hours and then aligned within the 2.5 cm target zone in preparation for bombardment.

A plasmid vector comprising the silencing element of interest operably linked to a maize Ubi1-5UTR-Ubi1 intron is made. This plasmid DNA plus plasmid DNA containing a PAT selectable marker is precipitated onto 1.1 μm (average diameter) tungsten pellets using a CaCl₂ precipitation procedure as follows: 100 μl prepared tungsten particles in water; 10 μl (1 μg) DNA in Tris EDTA buffer (1 μg total DNA); 100 μl 2.5 M CaCl₂; and, 10 μl 0.1 M spermidine.

Each reagent is added sequentially to the tungsten particle suspension, while maintained on the multitube vortexer. The final mixture is sonicated briefly and allowed to incubate under constant vortexing for 10 minutes. After the precipitation period, the tubes are centrifuged briefly, liquid removed, washed with 500 ml 100% ethanol, and centrifuged for 30 seconds. Again the liquid is removed, and 105 μl 100% ethanol is added to the final tungsten particle pellet. For particle gun bombardment, the tungsten/DNA particles are briefly sonicated and 10 μl spotted onto the center of each macrocarrier and allowed to dry about 2 minutes before bombardment.

The sample plates are bombarded at level #4 in a particle gun. All samples receive a single shot at 650 PSI, with a total of ten aliquots taken from each tube of prepared particles/DNA.

Following bombardment, the embryos are kept on 560Y medium for 2 days, then transferred to 560R selection medium containing 3 mg/liter Bialaphos, and subcultured every 2 weeks. After approximately 10 weeks of selection, selection-resistant callus clones are transferred to 288J medium to initiate plant regeneration. Following somatic embryo maturation (2-4 weeks), well-developed somatic embryos are transferred to medium for germination and transferred to the lighted culture room. Approximately 7-10 days later, developing plantlets are transferred to 272V hormone-free medium in tubes for 7-10 days until plantlets are well established. Plants are then transferred to inserts in flats (equivalent to 2.5″ pot) containing potting soil and grown for 1 week in a growth chamber, subsequently grown an additional 1-2 weeks in the greenhouse, then transferred to classic 600 pots (1.6 gallon) and grown to maturity. Plants are monitored and scored for the appropriate marker.

Bombardment medium (560Y) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000× SIGMA-1511), 0.5 mg/l thiamine HCl, 120.0 g/l sucrose, 1.0 mg/l 2,4-D, and 2.88 g/l L-proline (brought to volume with D-I H₂O following adjustment to pH 5.8 with KOH); 2.0 g/l Gelrite (added after bringing to volume with D-I H₂O); and 8.5 mg/l silver nitrate (added after sterilizing the medium and cooling to room temperature). Selection medium (560R) comprises 4.0 g/l N6 basal salts (SIGMA C-1416), 1.0 ml/l Eriksson's Vitamin Mix (1000× SIGMA-1511), 0.5 mg/l thiamine HCl, 30.0 g/l sucrose, and 2.0 mg/l 2,4-D (brought to volume with D-I H₂O following adjustment to pH 5.8 with KOH); 3.0 g/l Gelrite (added after bringing to volume with D-I H₂O); and 0.85 mg/l silver nitrate and 3.0 mg/l bialaphos (both added after sterilizing the medium and cooling to room temperature).

Plant regeneration medium (288J) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/l glycine brought to volume with polished D-I H₂O) (Murashige and Skoog (1962) Physiol. Plant. 15:473), 100 mg/l myo-inositol, 0.5 mg/l zeatin, 60 g/l sucrose, and 1.0 ml/l of 0.1 mM abscisic acid (brought to volume with polished D-I H₂O after adjusting to pH 5.6); 3.0 g/l Gelrite (added after bringing to volume with D-I H₂O); and 1.0 mg/l indoleacetic acid and 3.0 mg/l bialaphos (added after sterilizing the medium and cooling to 60° C.). Hormone-free medium (272V) comprises 4.3 g/l MS salts (GIBCO 11117-074), 5.0 ml/l MS vitamins stock solution (0.100 g/l nicotinic acid, 0.02 g/l thiamine HCL, 0.10 g/l pyridoxine HCL, and 0.40 g/l glycine brought to volume with polished D-I H₂O), 0.1 g/l myo-inositol, and 40.0 g/l sucrose (brought to volume with polished D-I H₂O after adjusting pH to 5.6); and 6 g/l bacto-agar (added after bringing to volume with polished D-I H₂O), sterilized and cooled to 60° C.

To assay for insecticidal activity, a FAW feeding assay can be performed. Briefly, leaf discs from the transgenic plant are excised using a 1 cm cork borer or leaf punch. Six leaf discs are prepared for each plant. The leaves are placed in a 24 well microtiter plate on top of 500 ul of 0.8% agar. Each leaf disc is infested with 2 neonate Fall armyworm and the plate is then sealed with mylar. A small ventilation hole is made for each well and the plates are then stored in a 28C growth chamber. The assay is scored for mortality, stunting, and leaf consumption at 96 hours.

Example 4 Agrobacterium-Mediated Transformation of Maize

For Agrobacterium-mediated transformation of maize with a silencing element of the invention, the method of Zhao is employed (U.S. Pat. No. 5,981,840, and PCT patent publication WO98/32326; the contents of which are hereby incorporated by reference). Briefly, immature embryos are isolated from maize and the embryos contacted with a suspension of Agrobacterium, where the bacteria are capable of transferring the polynucleotide comprising the silencing element to at least one cell of at least one of the immature embryos (step 1: the infection step). In this step the immature embryos are immersed in an Agrobacterium suspension for the initiation of inoculation. The embryos are co-cultured for a time with the Agrobacterium (step 2: the co-cultivation step). The immature embryos are cultured on solid medium following the infection step. Following this co-cultivation period an optional “resting” step is contemplated. In this resting step, the embryos are incubated in the presence of at least one antibiotic known to inhibit the growth of Agrobacterium without the addition of a selective agent for plant transformants (step 3: resting step). The immature embryos are cultured on solid medium with antibiotic, but without a selecting agent, for elimination of Agrobacterium and for a resting phase for the infected cells. Next, inoculated embryos are cultured on medium containing a selective agent and growing transformed callus is recovered (step 4: the selection step). The immature embryos are cultured on solid medium with a selective agent resulting in the selective growth of transformed cells. The callus is then regenerated into plants (step 5: the regeneration step), and calli grown on selective medium are cultured on solid medium to regenerate the plants.

Example 5 Soybean Embryo Transformation Culture Conditions

Soybean embryogenic suspension cultures (cv. Jack) are maintained in 35 ml liquid medium SB196 (see recipes below) on rotary shaker, 150 rpm, 26° C. with cool white fluorescent lights on 16:8 hr day/night photoperiod at light intensity of 60-85 μE/m2/s. Cultures are subcultured every 7 days to two weeks by inoculating approximately 35 mg of tissue into 35 ml of fresh liquid SB196 (the preferred subculture interval is every 7 days).

Soybean embryogenic suspension cultures are transformed with the plasmids and DNA fragments described in the following examples by the method of particle gun bombardment (Klein et al. (1987) Nature, 327:70).

Soybean Embryogenic Suspension Culture Initiation

Soybean cultures are initiated twice each month with 5-7 days between each initiation.

Pods with immature seeds from available soybean plants 45-55 days after planting are picked, removed from their shells and placed into a sterilized magenta box. The soybean seeds are sterilized by shaking them for 15 minutes in a 5% Clorox solution with 1 drop of ivory soap (95 ml of autoclaved distilled water plus 5 ml Clorox and 1 drop of soap). Mix well. Seeds are rinsed using 2 1-liter bottles of sterile distilled water and those less than 4 mm are placed on individual microscope slides. The small end of the seed are cut and the cotyledons pressed out of the seed coat. Cotyledons are transferred to plates containing SB1 medium (25-30 cotyledons per plate). Plates are wrapped with fiber tape and stored for 8 weeks. After this time secondary embryos are cut and placed into SB 196 liquid media for 7 days.

Preparation of DNA for Bombardment

Either an intact plasmid or a DNA plasmid fragment containing the silencing element, such as those described in Example 3, and the selectable marker gene are used for bombardment. Plasmid DNA for bombardment are routinely prepared and purified using the method described in the Promega™ Protocols and Applications Guide, Second Edition (page 106). Fragments of the plasmids carrying the silencing element of interest are obtained by gel isolation of double digested plasmids. In each case, 100 ug of plasmid DNA is digested in 0.5 ml of the specific enzyme mix that is appropriate for the plasmid of interest. The resulting DNA fragments are separated by gel electrophoresis on 1% SeaPlaque GTG agarose (BioWhitaker Molecular Applications) and the DNA fragments containing silencing element of interest are cut from the agarose gel. DNA is purified from the agarose using the GELase digesting enzyme following the manufacturer's protocol.

A 50 μl aliquot of sterile distilled water containing 3 mg of gold particles (3 mg gold) is added to 5 μl of a 1 μg/μl DNA solution (either intact plasmid or DNA fragment prepared as described above), 50 μl 2.5M CaCl₂ and 20 μl of 0.1 M spermidine. The mixture is shaken 3 min on level 3 of a vortex shaker and spun for 10 sec in a bench microfuge. After a wash with 400 μl 100% ethanol the pellet is suspended by sonication in 40 μl of 100% ethanol. Five μl of DNA suspension is dispensed to each flying disk of the Biolistic PDS1000/HE instrument disk. Each 5 μl aliquot contains approximately 0.375 mg gold per bombardment (i.e. per disk).

Tissue Preparation and Bombardment with DNA

Approximately 150-200 mg of 7 day old embryonic suspension cultures are placed in an empty, sterile 60×15 mm petri dish and the dish covered with plastic mesh. Tissue is bombarded 1 or 2 shots per plate with membrane rupture pressure set at 1100 PSI and the chamber evacuated to a vacuum of 27-28 inches of mercury. Tissue is placed approximately 3.5 inches from the retaining/stopping screen.

Selection of Transformed Embryos

Transformed embryos were selected either using hygromycin (when the hygromycin phosphotransferase, HPT, gene was used as the selectable marker) or chlorsulfuron (when the acetolactate synthase, ALS, gene was used as the selectable marker).

Hygromycin (HPT) Selection

Following bombardment, the tissue is placed into fresh SB196 media and cultured as described above. Six days post-bombardment, the SB196 is exchanged with fresh SB196 containing a selection agent of 30 mg/L hygromycin. The selection media is refreshed weekly. Four to six weeks post selection, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated, green tissue is removed and inoculated into multiwell plates to generate new, clonally propagated, transformed embryogenic suspension cultures.

Chlorsulfuron (ALS) Selection

Following bombardment, the tissue is divided between 2 flasks with fresh SB196 media and cultured as described above. Six to seven days post-bombardment, the SB196 is exchanged with fresh SB196 containing selection agent of 100 ng/ml Chlorsulfuron. The selection media is refreshed weekly. Four to six weeks post selection, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated, green tissue is removed and inoculated into multiwell plates containing SB196 to generate new, clonally propagated, transformed embryogenic suspension cultures.

Regeneration of Soybean Somatic Embryos into Plants

In order to obtain whole plants from embryogenic suspension cultures, the tissue must be regenerated.

Embryo Maturation

Embryos are cultured for 4-6 weeks at 26° C. in SB196 under cool white fluorescent (Phillips cool white Econowatt F40/CW/RS/EW) and Agro (Phillips F40 Agro) bulbs (40 watt) on a 16:8 hr photoperiod with light intensity of 90-120 uE/m2s. After this time embryo clusters are removed to a solid agar media, SB 166, for 1-2 weeks. Clusters are then subcultured to medium SB103 for 3 weeks. During this period, individual embryos can be removed from the clusters and screened for the appropriate marker or the ability of the plant, when ingested by Lygus, to control the Lygus.

Embryo Desiccation and Germination

Matured individual embryos are desiccated by placing them into an empty, small petri dish (35×10 mm) for approximately 4-7 days. The plates are sealed with fiber tape (creating a small humidity chamber). Desiccated embryos are planted into SB71-4 medium where they were left to germinate under the same culture conditions described above. Germinated plantlets are removed from germination medium and rinsed thoroughly with water and then planted in Redi-Earth in 24-cell pack tray, covered with clear plastic dome. After 2 weeks the dome is removed and plants hardened off for a further week. If plantlets looked hardy they are transplanted to 10″ pot of Redi-Earth with up to 3 plantlets per pot. After 10 to 16 weeks, mature seeds are harvested, chipped and analyzed for proteins

Media Recipes

SB 196 - FN Lite liquid proliferation medium (per liter) - MS FeEDTA - 100x Stock 1 10 ml MS Sulfate - 100x Stock 2 10 ml FN Lite Halides - 100x Stock 3 10 ml FN Lite P, B, Mo - 100x Stock 4 10 ml B5 vitamins (1 ml/L) 1.0 ml 2,4-D (10 mg/L final concentration) 1.0 ml KNO3 2.83 gm (NH4)2SO4 0.463 gm Asparagine 1.0 gm Sucrose (1%) 10 gm pH 5.8

FN Lite Stock Solutions

Stock # 1000 ml 500 ml 1 MS Fe EDTA 100x Stock Na₂ EDTA* 3.724 g 1.862 g FeSO₄—7H₂O 2.784 g 1.392 g 2 MS Sulfate 100x stock MgSO₄—7H₂O 37.0 g 18.5 g MnSO₄—H₂O 1.69 g 0.845 g ZnSO₄—7H₂O 0.86 g 0.43 g CuSO₄—5H₂O 0.0025 g 0.00125 g 3 FN Lite Halides 100x Stock CaCl₂—2H₂O 30.0 g 15.0 g KI 0.083 g 0.0715 g CoCl₂—6H₂O 0.0025 g 0.00125 g 4 FN Lite P, B, Mo 100x Stock KH₂PO₄ 18. g 9.25 g H₃BO₃ 0.62 g 0.31 g Na₂MoO₄—2H₂O 0.025 g 0.0125 g *Add first, dissolve in dark bottle while stirring

SB1 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 31.5 g sucrose; 2 ml 2,4-D (20 mg/L final concentration); pH 5.7; and, 8 g TC agar.

SB 166 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 60 g maltose; 750 mg MgCl2 hexahydrate; 5 g activated charcoal; pH 5.7; and, 2 g gelrite.

SB 103 solid medium (per liter) comprises: 1 pkg. MS salts (Gibco/BRL—Cat#11117-066); 1 ml B5 vitamins 1000× stock; 60 g maltose; 750 mg MgCl2 hexahydrate; pH 5.7; and, 2 g gelrite.

SB 71-4 solid medium (per liter) comprises: 1 bottle Gamborg's B5 salts w/sucrose (Gibco/BRL—Cat#21153-036); pH 5.7; and, 5 g TC agar.

2,4-D stock is obtained premade from Phytotech cat# D 295—concentration is 1 mg/ml.

B5 Vitamins Stock (per 100 ml) which is stored in aliquots at −20 C comprises: 10 g myo-inositol; 100 mg nicotinic acid; 100 mg pyridoxine HCl; and, 1 g thiamine. If the solution does not dissolve quickly enough, apply a low level of heat via the hot stir plate. Chlorsulfuron Stock comprises 1 mg/ml in 0.01 N Ammonium Hydroxide

The article “a” and “an” are used herein to refer to one or more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one or more element.

All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced within the scope of the appended claims. 

That which is claimed:
 1. A plant cell having stably incorporated into its genome a heterologous polynucleotide comprising a silencing element, wherein said silencing element when ingested by a pest from the Lygus genus, reduces the level of a target sequence in said pest, and thereby controls the pest from the Lygus family, and said silencing element is selected from the group consisting of: a) a polynucleotide comprising the sense or antisense sequence of the sequence set forth in SEQ ID NO:283, 289, 292, 304, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343 or 346; b) a polynucleotide comprising the sense or antisense sequence of a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 283, 289, 292, 304, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343 or 346; c) a polynucleotide comprising the sequence set forth in SEQ ID NO:284, 285, 290, 291, 293, 294, 305, 306, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347 or 348; and d) a polynucleotide comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NO:284, 285, 290, 291, 293, 294, 305, 306, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347 or
 348. 2. The plant cell of claim 1, wherein said pest comprises Lygus hesperus.
 3. The plant cell of claim 1, wherein said silencing element comprises a hairpin RNA.
 4. The plant cell of claim 1, wherein said silencing element is operably linked to a heterologous promoter.
 5. The plant cell of claim 1, wherein said plant cell is from a monocot.
 6. The plant cell of claim 5, wherein said monocot is maize, barley, millet, wheat or rice.
 7. The plant cell of claim 1, wherein said plant cell is from a dicot.
 8. The plant cell of claim 7, wherein said plant cell is soybean, canola, alfalfa, sunflower, safflower, tobacco, Arabidopsis, or cotton.
 9. The plant cell of claim 1, wherein said plant cell has stably incorporated into its genome a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof, wherein the combined expression of the silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNAi specific for the pest target sequence in said plant cell.
 10. A plant or plant part comprising the plant cell of claim
 1. 11. The plant or plant part of claim 9, wherein the combined expression of said silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNA specific for the pest target sequence in the phloem of said plant or plant part.
 12. A transgenic seed from the plant of claim
 10. 13. A method for controlling Lygus comprising feeding to a Lygus a composition comprising a silencing element, wherein said silencing element, when ingested by said Lygus, reduces the level of a target Lygus sequence and thereby controls the Lygus and said silencing element comprises: a) a polynucleotide comprising the sense or antisense sequence of the sequence set forth in SEQ ID NO: 283, 289, 292, 304, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343 or 346; and, b) a polynucleotide comprising the sense or antisense sequence of a sequence having at least 95% sequence identity to the sequence set forth in SEQ ID NO: 283, 289, 292, 304, 316, 319, 322, 325, 328, 331, 334, 337, 340, 343 or
 346. c) a polynucleotide comprising the sequence set forth in SEQ ID NO: 284, 285, 290, 291, 293, 294, 305, 306, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347 or 348; and d) a polynucleotide comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NO:284, 285, 290, 291, 293, 294, 305, 306, 317, 318, 320, 321, 323, 324, 326, 327, 329, 330, 332, 333, 335, 336, 338, 339, 341, 342, 344, 345, 347 or
 348. 14. The method of claim 13, wherein said composition comprises a plant or plant part having stably incorporated into its genome a polynucleotide comprising said silencing element.
 15. The method of claim 13, wherein said pest comprises Lygus hesperus.
 16. The method of claim 13, wherein said silencing element comprises a hairpin RNA.
 17. The method of claim 13, wherein said silencing element is operably linked to a heterologous promoter.
 18. The method of claim 13, wherein said plant or plant part has stably incorporated into its genome a second polynucleotide comprising a suppressor enhancer element comprising the target pest sequence or an active variant or fragment thereof, wherein the combined expression of the silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNAi specific for the pest target sequence in said plant.
 19. The method claim 18, wherein the combined expression of said silencing element and the suppressor enhancer element increases the concentration of an inhibitory RNA specific for the pest target sequence in the phloem of said plant or plant part.
 20. The method of claim 13, wherein said plant is a monocot.
 21. The method of claim 20, wherein said monocot is maize, barley, millet, wheat or rice.
 22. The method of claim 13, wherein said plant is a dicot.
 23. The method of claim 22, wherein said plant is soybean, canola, alfalfa, sunflower, safflower, tobacco, Arabidopsis, or cotton. 